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ABSTRACT 
The aim of this project was to explore the formation of multicomponent crystals of some known, as well 
as some novel, antiplasmodial agents and investigate and compare structures and properties of the 
antiplasmodials and the multicomponent crystals that they form.  
A series of five known 4-aminoquinoline antiplasmodial agents were chosen and the formation of 
multicomponent crystals with these compounds was investigated. The use of molecular electrostatic 
potential surfaces (MEPS) to calculate molecular complementarity with a specific coformer allowed us 
to rank a list of coformers according to the probability of forming multicomponent crystals with each 4-
aminoquinoline. A total of nineteen multicomponent forms were obtained by liquid-assisted grinding, 
and these were characterised by PXRD, IR, TGA and DSC. Possible reasons are given for why two of 
the five 4-aminoquinolines yielded only amorphous multicomponent products, while three yielded 
crystalline products. Additionally, a brief discussion is given for the reasonably low success rate (38%) 
of the MEPS method for coformer selection.  
Attempts were then made to synthesise a series of novel aminoferrocene-containing lapatinib analogues 
so that the abovementioned knowledge could be applied to a novel system. While, we successfully 
achieved the synthesis of the precursor fragments, the key reaction that coupled the aminoferrocene 
fragment to the lapatinib core – the Suzuki-Miyaura reaction – proved more challenging than expected. 
After substantial effort, the desired product was obtained (as detected by LC-MS), however it could not 
be isolated, most likely due to low yields. The use of an amine or amide linker (instead of a direct 
carbon-carbon bond) was also investigated, however these attempts were also unsuccessful.  
A series of 6-substituted quinazolin-4(3H)-ones, formed serendipitously during the synthesis of the 
lapatinib analogues, were also studied for their ability to form multicomponent crystals. The MEPS 
method to select coformers was applied and liquid-assisted grinding was used to form eight novel 
multicomponent crystals. Interestingly, only one of the quinazolinone derivatives formed 
multicomponent crystals with the chosen coformers, while the remaining three yielded only mixtures of 
starting materials. Possible explanations for this were explored and it is clear that there are additional 
factors that play a larger role than initially thought.  
This study shows that quinoline- and quinazolinone-based antiplasmodial agents warrant further 
attention for the formation of multicomponent crystals. The work described in this thesis provides a 
greater understanding of the ability of these molecules to form multicomponent crystals. Together with 
similar studies, this knowledge could be applied to related systems, which would one day allow for 
accurate predictions and the formation of multicomponent crystals of antiplasmodial agents with tailored 
properties.  
  
Stellenbosch University  https://scholar.sun.ac.za
 iii | P a g e  
 
UITTREKSEL 
Die doel van hierdie projek was om die vorming van multikomponent kristalle van sommige bekende 
sowel as sommige nuwe, antiplasmodiese middels te ondersoek en om die strukure en eienskappe van 
die antiplasmodiese en die multikomponentkristalle wat hulle vorm, te odersoek en vergelyk. 
'n Reeks van vyf bekende 4-aminokwinolien-antiplasmodiese middels is gekies en die vorming van 
multikomponent kristalle met hierdie verbindings is ondersoek. Die gebruik van molekulêre 
elektrostatiese potensiaal oppervlaktes (MEPS) om molekulêre komplementariteit met 'n spesifieke 
kovormer te bereken, het ons toegelaat om 'n lys van kovormers te rangskik volgens hul waarskynlikheid 
om multikomponent kristalle met elke 4-aminokwinolien te vorm. In totaal in negentien 
multikomponent vorms verkry deur middel van vloiestof-vergemaklikde meganiese chemie, en is 
beskryf deur PXRD, IR, TGA en DSC. Moontlike redes word gegee waarom twee van die vyf 4-
aminokwinolien molekules slegs amorfiese multikomponent produkte opgelewer het, terwyl drie 
kristallyne produkte opgelewer het. Daarbenewens word 'n kort bespreking gegee oor die redelike lae 
suksessyfer (38%) van die MEPS-metode vir die keuse van kovormers. 
Pogings is dan aangewend om 'n reeks nuwe aminoferroseen-bevattende lapatinib-analoë te sintetiseer 
sodat die bogenoemde kennis op 'n nuwe stelsel toegepas kan word. Ons het die sintese van die 
voorloperfragmente suksesvol voltooi, maar die sleutelreaksie wat die aminoferoseenfragment aan die 
lapatinib-kern koppel – die Suzuki-Miyaura-reaksie – was meer uitdagend as verwag. Na aansienlike 
moeite is die verlangde produk verkry (soos aangetoon deur LC-MS), maar dit kon nie geïsoleer word 
nie, waarskynlik as gevolg van lae opbrengste. Die gebruik van 'n amien- of amiedskakelaar (in plaas 
van 'n direkte koolstof-koolstofbinding) is ook ondersoek, maar hierdie pogings was ook onsuksesvol. 
ŉ Reeks 6-gesubstitueerde kwinazolinoon wat gevorm is tydens die sintese van die lapatinib analoge, is 
ook bestudeer vir hul vermoë om multikomponent kristalle te vorm. Die MEPS-metode om koformers 
te kies is toegepas en vloiestof-vergemaklikde meganies chemie is gebruik om agt nuwe 
multikomponent kristalle te vorm. Slegs een van die kwinazolinoon analoge multikomponent kristalle 
gevorm met die gekose koformers, terwyl die oorblywende drie slegs mengsels van die 
uitgangsmateriaal opgelewer het. Moontlike verduidelikings hiervoor is ondersoek en dit is duidelik 
data daar addisionele faktore is wat ŉ groter rol speel as aanvanklik gedink. 
Hierdie studie toon dat kwinolien- en kwinazolinoon-gebaseerde antiplasmodiese middels verdere 
aandag verdien rakende die vorming van multikomponent kristalle. Die werk wat in hierdie tesis beskryf 
word, bied 'n groter begrip oor die vermoë van hierdie molekules om multikomponent kristalle te vorm. 
Saam met soortgelyke studies kan hierdie kennis toegepas word op verwante stelsels, wat eendag kan 
toelaat vir akkurate voorspellings en die vorming van multikomponent kristalle met antiplasmodiese 
middels. 
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CHAPTER 1 
Introduction 
 
 
1.1 MALARIA  
 
Malaria is a mosquito-borne infectious disease that has been prevalent for millenia.1 Predominately 
found in tropical climates and especially third world countries, malaria is a burden to 97 countries and 
over 3.2 billion people are at risk worldwide.2 Although the number of cases of malaria has decreased 
globally (216 million in 2016 in comparison to 237 million in 2010), the rate of decline has plateaued 
and even reversed in some areas since 2014.3 Even with current treatment options, over 1200 deaths of 
children under five years old are reported every day, making up a vast majority of the total annual death 
toll in Africa.4 Therefore, the African continent, and more specifically sub-Saharan Africa, continues to 
account for the majority of malaria cases and deaths worldwide.3  
Numerous organisations, such as the Medicines for Malaria Venture, the Bill and Melinda Gates 
Foundation and the Roll Back Malaria Partnership, the United Nations and World Health Organisation, 
have developed an updated global strategy for malaria that focuses on reducing global malaria incidents 
by 90% by 2030.2 The impact that this will have on the global poverty rate as well as standard of living 
worldwide, is undeniable. In many of the poorer countries (especially in Africa), direct costs such as 
medication and health care, drain a country’s economic growth. In addition, sectors such as tourism, 
foreign investment and trade have also been negatively affected, which in turn influences the economic 
status of a country.5 Currently, increased financial support is being provided by a number of 
organisations not only for the distribution of preventative measures (such as bed nets) but also for 
research into new initiatives to combat the disease. Furthermore, increased education in rural areas to 
promote the correct use of medications and preventative measures is being carried out, however this is 
no simple task.6 Researchers have also been studying multiple aspects of the malaria parasite, including 
its life cycle and potential drug targets, as a way to one day be able to eradicate this disease.  
Malaria is caused by members of the Plasmodium genus and are commonly transmitted to a human host 
by approximately 40 species of the female Anopheles mosquito.7 There are five species of the 
Plasmodium parasite that are known to infect humans – P. falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi. Of these five Plasmodium species, P. falciparum is most prevalent and deadly, with 
roughly 90% of worldwide infections occurring in sub-Saharan Africa.7 The manifestation of the disease 
within the human host is dependent on the species of Plasmodium as well as the life cycle of the parasite, 
amongst other reasons. 
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1.2 THE LIFE CYCLE OF THE MALARIA PARASITE 
 
The malaria parasite is spread through the infection of two hosts – mosquitoes and humans (Figure 1.1).8 
The life cycle of the parasite can be divided into three stages: one sexual stage (in the mosquito) and 
two asexual stages that occur in the human host (one in liver cells and one in red blood cells). When the 
female Anopheles mosquito feeds on human blood, she injects sporozoites into the human host’s blood 
stream that are rapidly taken up by the liver cells. These then further develop within the liver to form 
merozoites. In two of the five Plasmodium species, namely P. ovale and P. vivax, a portion of these 
parasites stay dormant in the liver for months or even years that could lead to a relapse in malaria 
symptoms even after treatment. Once the liver cells lyse, the merozoites enter the bloodstream and red 
blood cells. At this stage, the parasites replicate asexually and can consume the contents of the 
erythrocytes (red blood cells).9 The red blood cells eventually lyse, releasing the merozoites back into 
the blood stream. This asexual cycle repeats every 48 hours and gives rise to the clinical symptoms 
associated with malaria, such as periodic fever and chills. After several asexual cycles, some of the 
merozoites further develop into gametocytes within the human’s blood stream. When a mosquito takes 
another blood meal, these gametocytes enter the mosquitoes blood stream, where they undergo fusion 
to develop zygotes. These zygotes further develop to form sporozoites, which begins the cycle afresh.1,7 
Understanding the life cycle of the parasite is critical to developing new antiplasmodial agents as it 
allows researchers to target specific stages of the life cycle and therefore treat the patient at various 
stages of infection. 
 
Figure 1.1: Life cycle of the Plasmodium parasite. Taken from Medicines for Malaria Venture online resources.8  
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1.3 MODES OF ACTION OF ANTIMALARIAL DRUGS 
 
Antimalarial agents can be classified into three broad categories based on their mode of action – the 
antifolates (that target dihydrofolate reductase, DHFR), the endoperoxides (formation of radical species) 
and the quinolines (β-hematin inhibitors).10  
 
1.3.1 The antifolates 
 
Humans are incapable of synthesising folate derivatives and therefore require dietary sources in the form 
of essential nutrients. However, protozoa, such as Plasmodium, make use of pteridine, p-aminobenzoic 
acid and mono-L-glutamate as precursors in the biosynthesis of folate derivatives, rather than dietary 
sources. This pathway is therefore an attractive target for antiplasmodial drug development. Therefore, 
the antifolate class of antimalarial drugs target one of two folate pathways in the malaria parasite – either 
folate salvage (inhibition of dihydrofolate reductase) or de novo folate synthesis (inhibition of 
dihydropteroate synthase, DHPS). It is however, important to note that these two classes are synergistic 
and are therefore often used in combination to treat malaria.11  
Both DHFR and DHPS catalyse the synthesis of tetrahydrofolate – a co-factor in the synthesis of 
pyrimidines, which are responsible for deoxyribonucleic acid (DNA) synthesis.12,13 In the case of the 
DHFR class, it is thought that the drug molecule (such as pyrimethamine or proguanil, Figure 1.2a and 
1.2b) competes with dihydrofolate by mimicking its pteridine structure. The “sulfa drugs” (such as 
sulphadoxine, Figure 1.2c) that target the inhibition of DHPS act by mimicking p-aminobenzoic acid 
that targets the active site of DHPS. In this way, folate formation is inhibited, thereby depriving the 
parasite of essential folate co-factors required for growth and proliferation.14  
 
 
 
 
 
 
 
Figure 1.2: Structure of (a) pyrimethamine, (b) proguanil and (c) sulphadoxine. 
 
One of the major drawbacks of the antifolate class of antimalarial agents is that resistance to these 
compounds is widespread. In addition, these compounds often have negative side effects, low 
bioavailability and high toxicity. For these reasons, they are currently only used in combination with 
other classes of antimalarial agents as alternative treatment options.15,16 
(a) (b) (c) 
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1.3.2 The endoperoxides 
 
Today the endoperoxide class of antimalarial agents, and more specifically artemisinin and its semi-
synthetic derivatives (Figure 1.3), are the World Health Organisation’s recommended choice in the 
treatment of malaria caused by P. falciparum, including multi-drug resistant infections.17 This class of 
drugs target different membrane structures within infected cells, such as the digestive vacuole 
membrane, the plasma membrane and the nuclear envelope.18 
 
 
 
 
 
 
Figure 1.3: Structure of (a) artemisinin, (b) dihydroartemisinin and (c) artesunate. 
 
While this class is considered to be the most effective for malaria treatment, the exact mode of action is 
still under debate.19 It is hypothesised that the free heme or iron within infected cells interacts with the 
endoperoxide bridge of the drug molecule and in doing so, releases free radicals that disrupt parasitic 
cell membranes.20,21 An alternative suggestion is that these free radical species interact with free heme 
to form a more lethal form of heme thereby causing parasite death.22 It is this mode of action that results 
in a drug that is efficient, fast-acting and has few side effects.23 Unfortunately, some countries have 
reported that strains of P. falciparum are showing signs of resistance to these drugs too.24,25 
 
1.3.3 β-hematin inhibitors 
 
Once the sporozoites enter the red blood cell, they feed on host hemoglobin, where it is broken down in 
the digestive vacuole of the parasite to provide the amino acids that are necessary for growth.26 It is at 
this stage that the iron centre of hemoglobin is oxidised, whereupon free heme is released. This heme 
(ferriprotoporphyrin IX) is toxic to the parasite and is therefore crystallised into a non-toxic form (called 
hemozoin) by the parasite. Hemozoin has a distinctive brown pigmentation that is characteristic of 
malaria-infected red blood cells and is the tell-tale sign of infection.27  
The quinoline-based antimalarial agents, such as quinine and chloroquine, target this conversion of free 
heme to hemozoin. It is well-known that the quinoline moiety is essential for the efficacy of this class 
of compounds.27–29 It is postulated that because of the weak basicity of the nitrogen atom in the quinoline 
ring, the drug enters the acidic food vacuole of the parasite, where it is protonated and subsequently 
cannot be removed by efflux pumps out of the vacuole. This method, known as pH-trapping, allows a 
high concentration of the drug molecule to accumulate within the vacuole, where it can then inhibit the 
(a) (b) (c) 
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formation of hemozoin (or the synthetic derivative, β-hematin). The amino side chains of many 
antimalarial agents also aid in this pH trapping mechanism.30 It is also suggested that the quinoline drug, 
once inside the digestive vacuole, adsorbs onto the hemozoin crystal surface, which hinders further 
crystal growth, thereby killing the parasite through a build-up of toxic heme in the digestive 
vacuole.27,31,32 However, there are still gaps in the understanding of the exact mechanism of action of 
how these antimalarial compounds interfere with the crystallisation process within the parasite and is 
therefore still currently being explored.31–34  
While still being studied, the current β-hematin class of antiplasmodials are widely inactive in most 
parts of Sub-Saharan Africa for the treatment of malaria caused by P. falciparum as the parasite has 
developed resistance them, especially chloroquine (Figure 1.4b).35 A mutant protein called Plasmodium 
falciparum chloroquine resistance transporter (PfCRT) increases the efflux of chloroquine across the 
digestive vacuole and as a result leads to a diminished accumulation of the drug to inhibit the formation 
of hemozoin.36,37 Having said this, new compounds are currently being developed that can overcome 
this resistance.38,39  
 
1.4 CURRENT ANTIPLASMODIAL AGENTS 
 
Over the last century, many natural and synthetic compounds have been used to treat malaria. The first 
antimalarial agent on the market was quinine (Figure 1.4a) – a quinoline-based drug that was isolated 
from the bark of the cinchona tree and initially used to treat fever from as early as the 1600s.40 Perhaps 
one of the most well-known and most effective antimalarial agents to date is chloroquine (Figure 1.4b), 
which was developed by Bayer Pharmaceuticals in 1934.41 During World War II, chloroquine (under 
the brand name Resochin) was primarily used as a prophylaxis and treatment option for malarial 
infections caused by P. falciparum. Over twenty generic brands of chloroquine are currently on the 
market and the World Health Organisation still recommends that chloroquine remain on the List of 
Essential Medicines. These days, however, it is mainly used for the prevention and treatment of malaria 
caused by P. vivax, P. ovale and P. malariae due to the widespread resistance to P. falciparum.17  
Various antiplasmodial and antimalarial drugs have thus been developed to compensate for the 
widespread resistance. It is at this point that it is important to note that there is a distinction between 
antimalarial and antiplasmodial drugs. Antimalarial refers to a marketed drug that treats or prevents 
malarial infections, such as the quinoline-based agents described above and artemisinin combination 
therapies, while antiplasmodial describes a broad class of compounds that are efficacious against the 
Plasmodium parasite.  
Over the last decade, a flurry of research into quinoline-based agents was carried out in an attempt to 
overcome this resistance.28,39,42,43 Quinoline-methanols, 4-aminoquinolines and acridines, which are all 
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potent against P. falciparum, were developed as a result. Most notable is amodiaquine (Figure 1.4c) and 
mefloquine (Figure 1.4d), which are currently available in some combination therapies. 
 
 
 
 
 
 
Figure 1.4: Structure of (a) quinine, (b) chloroquine, (c) amodiaquine and (d) mefloquine. 
 
Aminoquinolines have been successful because they generally have low toxicity and reasonable efficacy 
values. They are also relatively simple and cheap to synthesise and so the cost per treatment is 
affordable.44 Even though resistance is becoming more prevalent with this class, they remain a target for 
novel antiplasmodial therapies.10,18,45 There are currently thirteen compounds in clinical trials, with a 
number of compounds in pre-clinical stages that look promising.46 These include Tafenoquine (an 8-
aminoquinoline), AQ-13 (a simple derivative of chloroquine), and MMV30048 (a 2-aminopyridine). 
Most promising, however, is artefenomel-ferroquine and lumafantrine-KAF156, both of which are 
currently in phase 2b clinical trials.46  
Due to the rapid development of resistance of Plasmodium to quinoline-based agents, the World Health 
Organisation recommends the use of artemisinin combination therapies (ACTs) to treat patients.17 By 
combining the fast-acting and highly efficacious artemisinin-type compounds with slower-acting 
quinoline-type compounds, a three-day dosage can be administered that will improve the cure rate and 
also lower resistance development.47 Currently, the most used combinations include artemether-
lumafantrine (Coartem®), dihydroartemisinin-piperaquine (DuoCotecxin®) and artesunate-amodiaquine 
(Camoquin®).25 
In July 2015, the world’s first malaria vaccine (MosquirixTM) was approved by the European Medicines 
Agency, following 30 years of development by GlaxoSmithKline.48 However, the vaccine is to be 
cautiously recommended, according to the World Health Organisation advisory committee.49 They 
report that in trials of over 15 000 children, a series of four shots only reduced the number of malaria 
cases by 36% in young children. The vaccine has, however, still been recommended for pilot 
programmes in Africa where it will be assessed as a complementary tool that could be added to the 
current arsenal of preventative and treatment measures.50 In May 2018, the African Vaccine Regulatory 
Forum in conjunction with Ghanaian, Kenyan and Malawian regulatory authorities authorised the 
vaccine for pilot immunisation programmes for young children. This programme is set to begin in 2019 
in these three countries.51 
(b) (c) (d) (a) 
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While the vaccine may not be as effective as initially anticipated, the hope is that a more potent vaccine 
will be developed in time. Until then, we rely on treatment options such as the ACTs described above. 
But with the development of resistance to even these treatments,25 the need for new antimalarial drugs 
becomes ever more apparent. 
 
1.4.1 Synthesising novel compounds 
 
By studying structure-activity relationships, we can gain knowledge on the types and positions of 
moieties on scaffolds that could either improve or diminish various properties of the compound such as 
efficacy, solubility and toxicity. By understanding these relationships, specific fragments can be 
combined in an attempt to synthesise molecules with desirable properties. In fact, the majority of 
compounds available on the market today are available as a result of extensive structure-activity 
relationship studies on previously reported candidates. Compounds such as AQ-13, primaquine and 
amodiaquine (Figure 1.5) all stem from chemical modifications of quinine.10 
 
 
 
 
 
 
 
Figure 1.5: Structure of (a) AQ-13, (b) primaquine and (c) amodiaquine. 
 
By far the most widely studied antiplasmodial structure-activity relationships are with the quinoline (β-
hematin inhibitor) class.45 This is most likely because these compounds are simpler and cheaper to 
synthesise, usually have low toxicity and have a known target (inhibition of β-hematin).52 The 
4-aminoquinoline class (Figure 1.6) has been extensively studied. It was found that the 7-position is 
optimal for substituents, and halogens (especially chlorine) at this position outperform other functional 
groups when comparing efficacies.30 It was also determined that the secondary amine at the 4-position 
is important. Replacing this group with a tertiary amine, or other linkers, has a detrimental effect on the 
efficacy of the drug.53 The amino side chain has been shown to assist in the mode of action of the drug, 
but changes in the linker between this amino group and the 4-aminoquinoline scaffold are more 
tolerable. Linkers such as phenyl rings,54 branched and unbranched alkyl chains,55,56 5-membered 
heterocycles such as oxazoles57 or triazoles58 and even metallocenes59,60 have all be investigated and 
some are showing promising results.  
(a) (b) (c) 
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Figure 1.6: The 4-aminoquinoline class of antiplasmodial agents. 
 
Ferroquine, an antiplasmodial agent currently in clinical trials, was also developed as a result of 
extensive structure-activity relationship studies and continuation with further studies has shown a mix 
of results. Jacobs et al. synthesised a series of ferroquine analogues with varying alkyl chain lengths as 
well as oxalamide linkers between the 4-aminoquinoline and ferrocene moieties.61 Some compounds 
displayed efficacies superior to that of chloroquine, the standard used for testing. Amino alcohol side 
chains62 have also been studied, as well as the use of other metallocenes such as ruthenocene.60 In 
addition, for these aminoquinoline-type compounds, the location of the ferrocene moiety is important. 
Work by Biot et al. indicates that the ferrocene moiety should be flanked by the aminoquinoline and an 
alkyl amino side chain.63  
A more recently investigated route is the use of molecular hybridisation. This involves the design of 
compounds by combining two or more different pharmacophores into one molecule using covalent 
linkers.10,64 This approach is thought to improve efficacy and reduce the onset of resistance because two 
modes of action are targeted simultaneously. In some cases, such as the artemisinin-quinine hybrid 
shown in Figure 1.7, the efficacy of the new compound is far superior to that of the individual 
pharmacophores, as well as a 1:1 physical mixture of artemisinin and quinine.65 It should be noted that 
hybridisation is different to the combination therapies described in the previous section. In the latter, the 
drug compounds are merely combined as a physical mixture into a specific formulation, while for 
hybridisation, a new molecule is synthesised through covalent linkage of two compounds (or parts of 
compounds).  
 
 
 
 
 
 
 
 
 
Figure 1.7: Hybrid compound formed by linking quinine and artemisinin pharmacophores with an ester linkage. 
Artemisinin 
pharmacophore 
Quinine 
pharmacophore Linker 
Amino side chain 
4-Aminoquinoline 
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Structure-activity relationships and the synthetic derivatives produced from these studies are imperative 
in the search for antiplasmodial agents that can overcome the current resistance issues, whilst 
maintaining efficacy. However, these studies can be time-consuming, costly and less than one percent 
of the compounds synthesised in these studies, and deemed as possible clinical candidaates, make it onto 
the market.  
It is clear that a delicate balance of functional groups and their positions on the molecule is required to 
achieve optimal efficacy and physicochemical properties and that, while scientists are gaining 
knowledge in this field, we are far from being able to apply a standard recipe for novel clinical candidates 
from a pantry of pharmacophores and functional groups.  
 
1.5 PROBLEMS ASSOCIATED WITH ANTIMALARIAL DRUG DEVELOPMENT 
Despite substantial progress made toward fundamental knowledge used during the drug discovery and 
development pipeline, tropical infectious diseases (such as malaria) continue to plague the developing 
world. Socio-economic issues have also played a role in the lack of progress in eliminating the disease. 
Malaria is prevalent in underdeveloped and poorer regions where education lacks. In many cases, 
patients have little to no access to hospital environments or clinics. As a result, drug candidates need to 
be well tolerated in humans, have very few side effects and ideally be offered as a single dose in tablet 
form.46,66,67 
The development of drug candidates to treat malaria was initially driven by the Western world during 
the first part of the 20th century, but as their interests drifted away from these regions, so did the 
development of novel treatment strategies.68 Given how long the drug discovery process takes, as well 
as the financial input required, it is not surprising that the pharmaceutical industry is hesitant to engage 
in these research endeavours simply because it is not profitable for them.69 Having said that, new 
partnerships with the private sector (in particular the Bill and Melinda Gates Foundation) and academia 
have seen an increase in research aimed towards malaria and other neglected tropical diseases. Open 
Source Malaria Project, led by Matthew Todd of the University of Sydney, is an online platform for 
antimalarial drug discovery based on contributions from a number of researchers. This project, in 
collaboration with Medicines for Malaria Venture and other funding agencies, is an open access project 
that focuses on phenotypic hit-to-lead phase drug discovery and is making significant contributions to 
the fight against malaria.70,71 There are, however, other issues that plague the advancement of drug 
candidates to the marketplace.68 Some of these are discussed below, along with some of the current 
methods to at least partially overcome these challenges.  
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: Introduction 
 
10 | P a g e  
 
 
1.5.1 The lengthy drug discovery and development timeline 
For a drug candidate to reach the market, numerous testing phases need to be passed. The early drug 
discovery pipeline (Figure 1.8) includes initial in vitro testing against the parasite to determine 
efficacies. Compounds that display superior efficacies (usually comparable to those currently on the 
market) are chosen for further evaluation and development, which includes additional in vitro and in 
vivo testing to determine its pharmacokinetic profile. Once the compound passes these tests, it moves 
from being a “hit” compound to a “lead” compound. At this point, a lead optimisation phase and 
preclinical trials take place that determine safety and toxicity. A further three phases of clinical trials 
that evaluate the drug candidate in humans must be carried out before the drug can be approved for the 
market. In the majority of cases, compounds do not pass the pre-clinical trial phase and are discarded 
due to a variety of reasons including low efficacy, poor solubility and bioavailability, high toxicity or 
negative side effects.72  
 
Figure 1.8: Illustration of the drug discovery and development process. Taken from Pierce et al.73 
 
Because the majority of the discovery and development process for malaria drug candidates is performed 
in academic environments (without the financial and technical resources of large pharmaceutical 
companies), some researchers have turned to “drug repurposing” to overcome some of these hurdles.74–
76 Klug et al. propose four main categories that fall under repurposing – drug repurposing, target 
repurposing, target class repurposing and lead repurposing.77 A brief description of each category, as 
well as the associated advantages and disadvantages, are described below.  
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Drug repurposing is characterised by the lack of additional optimisation needed for the repurposed 
chemical entity. As a result, Food and Drug Administration (FDA) approved compounds initially 
intended for a certain purpose are used for a second indication without structural modification. One of 
the advantages is that because it has already gone through safety testing and pharmacokinetic profiling, 
the cost and development time to the drug is considerably reduced. It should be noted, though, that 
dosing and formulation studies still need to be carried out, as well as modified clinical trials for the new 
purpose.  
Target repurposing involves a compound that is approved (or a clinical candidate) for one use, but is 
then used as a starting point to develop compounds that target the parasite. This differs from drug 
repurposing as the initial compound is often modified synthetically to optimise the selectivity and 
efficacy against the target parasite.  
Target class repurposing differentiates from target repurposing in the sense that the target (and therefore 
the mode of action) of the compound is not known. Instead, a phenotypic assay (often parasite cell death) 
is used to determine efficacy. While this approach has the disadvantage of hindering the ‘rational design’ 
optimisation process, it does provide a more robust approach to discovering novel modes of action and 
finding targets that are distinctive to that parasite.  
Lead repurposing focuses on early-stage drug candidates, rather than approved or clinical candidates. 
The process begins with a high-throughput screen of a class of lead molecules (for example, kinase 
inhibitors) that are screened for a specific target parasite, often making use of phenotypic assays to 
assess the efficacy of the compounds. The advantage of this strategy is that it is more likely to give a 
variety of chemotypes that can be further pursued and is more unbiased in comparison to the other three 
repurposing strategies. 
To date, there are no compounds that have been approved as a repurposed drug for the treatment of 
malaria; however, there are some candidates that have potential.75 One such compound is lapatinib – an 
anticancer drug that was identified as a potent antiplasmodial agent (Figure 1.9).78 Currently the Pollastri 
laboratory (Northeastern University), amongst others, are investigating derivatives of lapatinib for 
neglected tropical diseases, including malaria.79  
 
 
 
 
Figure 1.9: Structure of lapatinib. 
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This approach has the advantage of reduced financial costs associated with drug discovery, as well as a 
decrease in time from bench to clinic for these compounds.80 Therefore, this approach is attractive for 
finding alternative compounds to combat malaria. Given the widespread use of antimalarial agents for 
the treatment or prevention of infections in children, repurposing becomes challenging, as stringent 
safety requirements are needed. Another challenge contributing to this includes ineffective therapeutic 
concentrations due to poor bioavailability.81  
 
1.5.2 Poor physicochemical properties 
 
The second, and arguably the largest problem associated with the development of drug candidates is the 
achievement of appropriate physicochemical properties. It is well-known that less than one percent of 
potential drug candidates make it onto the market.82,83 While poor efficacy and toxicity is sometimes to 
blame, many candidates are discarded due to poor aqueous solubility and low bioavailability.84 
While the synthesis of analogues is important to obtain structure-property relationships, it can also be 
worthwhile to investigate improving these undesirable physicochemical properties without redesigning 
the molecule (and risking a loss in efficacy). Due to the cost associated with the discovery and 
development process, reviving candidates that displayed adequate efficacies, but were discarded due to 
solubility and bioavailability issues could be a worthwhile endeavour.  
Various methods to improve some of the physicochemical and pharmacokinetic properties of potential 
drug candidates are currently being investigated, including nanotechnology,85 emulsifications86 and 
polymer drug delivery systems.87 Other methods that are being studied include incorporating the drug 
molecule into porous materials such as metal-organic frameworks88,89 or cyclodextrins.90,91 Another 
method that has become popular is the inclusion of the drug molecule in multicomponent crystals (such 
as salts and cocrystals).92–94 This method is advantageous because it allows for a change in some of the 
physicochemical properties of the drug molecule, without changing the drug’s structure. In this way, the 
drug’s efficacy can be retained while properties such as solubility, bioavailability, stability and other 
mechanical properties can be improved.83,95,96 In addition, drug-drug multicomponent crystals could be 
formed that have the ability to target two pathways simultaneously; however, factors such as therapeutic 
dosages and synergistic or antagonistic effects would need to be studied first.97 
It should be noted that inclusion of a drug molecule in multicomponent crystals will not overcome drug 
resistance by the disease that the drug candidate is targeting. In addition, the formation of 
multicomponent crystals with a specific coformer to give certain physicochemical properties is still 
unpredictable.98 As a result, research is currently being conducted to increase the knowledge in this field. 
However, there is little knowledge on the formation of multicomponent crystals of antiplasmodial 
agents, despite the potential these molecules may have.99  
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1.6 MULTICOMPONENT CRYSTALS 
 
The field of multicomponent crystals (pharmaceutical and otherwise) falls under the term 
“supramolecular chemistry” which focuses on interactions between molecules and how they assemble 
on a molecular level.84 While it should be noted that supramolecular chemistry certainly takes place in 
solution as well, only the solid-state supramolecular chemistry will be discussed here, as it is the focus 
of this thesis. Under the umbrella of supramolecular chemistry, lies the field of crystal engineering, 
which involves the design of new materials with a specific property (or purpose) through the application 
of knowledge obtained from known systems. We attempt to rationalise how molecules interact in the 
solid state by studying patterns in known structures (and also how this effects the properties of the 
system) and then apply this knowledge to deduce patterns and ‘rules’.100 In this way, we are working 
towards one day being able to tailor-make multicomponent crystals and other materials with specific 
properties.  
A multicomponent crystal is defined as a crystal that contains more than one type of chemical entity in 
the crystal lattice.101 Each entity can be classified as an ion, solvent or coformer and the combination of 
these in the crystal lattice gives rise to the types of multicomponent crystals discussed below. In the 
context of pharmaceutical multicomponent crystals, the coformer, ion or solvent needs to be safe for 
human consumption.93 These coformers can be chosen from EAFUS (Everything Added to Food in the 
United States) and GRAS (Generally Regarded As Safe) databases.102,103  
 
1.6.1 Types of multicomponent crystals  
 
In a broad sense, the term ‘multicomponent crystal’ encompasses three categories – cocrystals, salts and 
solvates; however, other intermediary categories have also been suggested in an attempt to be more 
specific in the description. These other categories include salt solvates, cocrystal solvates, cocrystal salts 
and cocrystal salt solvates (Figure 1.10). The definition of many of these terms (especially cocrystals) 
is currently still under debate.104 It is important to note that while there may be slightly different 
definitions for these terms, the ones given below are most commonly used in the literature,93,101,105 and 
will be used throughout this thesis. 
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Figure 1.10: Multicomponent forms and how they overlap. Taken from Aitipamila et al.105 
 
The formation of simple salts of drug molecules is a common practice in the pharmaceutical industry as 
a way to improve solubility. It is estimated that about half of all marketed drugs are sold in salt form.106 
The main reason for this is the relative ease of synthesis and the reliability of the product that forms. 
The definition of a salt, according to the International Union of Pure and Applied Chemistry (IUPAC), 
is a “chemical compound consisting of an assembly of cations and anions”.107 Reviews are available that 
focus on the use of counter ions such as chloride and sodium ions, as well as the administration routes 
and daily dosages.108,109 The use of organic molecules as coformers could also result in the formation of 
salts (such as carboxylic acid coformers with basic drug molecules). In some cases, however, it is 
difficult to predict whether proton transfer will take place or not. The use of the ∆pKa rule is often used 
to assist in this regard, where a salt is expected to form when ∆pKa >3 and a cocrystal when ∆pKa < 0. 
When the ∆pKa is between 0 and 3, there is uncertainty as to whether a salt or cocrystal will form or 
even a product in which partial proton transfer may occur.110 In some cases, however, drug molecules 
are not ionisable and as a result, exploration into the formation of cocrystals becomes valid.111  
The definition of a cocrystal has had much debate over the last decade, but in 2018 the FDA released a 
document on pharmaceutical cocrystals in which they make use of the following definition: 
“pharmaceutical cocrystals are crystalline materials composed of two or more different molecules, one 
of which is the API (active pharmaceutical ingredient), in a defined stoichiometric ratio within the same 
crystal lattice that are associated by non-ionic and noncovalent bonds.”112 This definition, however, 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: Introduction 
 
15 | P a g e  
 
could include solvates or hydrates. Another definition previously proposed by Vioglio et al. is more 
specific, stating that, in addition to the above criteria, all components must be in the solid state (in other 
words no solvent molecules in the lattice).113 
In some cases, solvent molecules can be included into the crystal lattice. For these multicomponent 
crystals, if there is only one other molecule present, they would be considered solvates (or hydrates if 
the solvent is water). It is also possible to form a cocrystal solvate (or hydrate), a salt solvate, or even a 
cocrystal salt solvate (or hydrate).114 These forms are illustrated in Figure 1.11 along with simpler 
cocrystals and salts.  
For clarity and simplicity within this thesis, when the multicomponent crystal contains neutral drug and 
coformer molecules only, it will be termed a cocrystal. When there is charge transfer between the two 
(or more) molecules or atoms, it will be termed a salt and in cases where solvent is included, the 
multicomponent crystal will be termed a solvate (or hydrate when the solvent is water). 
While not classified as a multicomponent crystal, it is also important to define amorphous materials as 
they are frequently seen in the literature, as well as in the pharmaceutical industry.115–118 An amorphous 
material differs from a crystalline material in that there is no long-range order of the packing of 
molecules in the solid state.119 There is still, however, short-range ordering and intermolecular 
interactions between the molecules, but in no uniform fashion that would form a crystal lattice.119 
Advantages of amorphous materials include improved solubility, dissolution rates and occasionally 
improved compression characteristics in comparison to crystalline forms.120 Conversely, the physical 
and chemical stability of amorphous material is often poor in comparison to crystalline forms.120  
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Figure 1.11: Types of multicomponent crystals. Image adapted from Voiglio et al.113 and Duggirala et al.93 
 
1.6.2 Multicomponent crystals as intellectual property 
 
In addition to their physicochemical advantages, multicomponent crystals have been a hot topic in terms 
of intellectual property over the past decade.121,122 In 2007, Trask reviewed the then-current position of 
pharmaceutical cocrystals as intellectual property.122 He suggests that cocrystals satisfy the criteria for 
patent approval – namely novelty, utility and non-obviousness. This has been more recently reviewed 
by Braga et al. in relation to crystal engineering in the patent and regulatory literature.123 There are a 
number of patents that describe multicomponent forms of drug molecules, as well as their preparation.124  
Regulatory approval, however, is the challenging step in drug development.82 In 2013, the FDA stated 
that cocrystals should be regarded as “drug product intermediates” rather than new active 
pharmaceutical ingredients.125 In early 2018, however, they released more detailed guidelines on the 
topic. The FDA now requires that applications that claim new cocrystal forms of APIs submit evidence 
for this in the form of three points: evidence that the API and coformer are present in the unit cell, that 
they are both neutral species and interact non-ionically and that there is significant dissociation of the 
API from the cocrystal before it reaches its target site. They also state that APIs that satisfy these points 
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are analogous to a polymorphic form of the API, rather than a new API. In addition, drug-drug cocrystals 
should be thought of as fixed-dose combination products, rather than new single APIs.112  
In 2015, the European Medicines Agency (EMA) also released their reflection paper on the topic of 
pharmaceutical cocrystals, however their stance on the matter is slightly different.112 They state that 
cocrystals would not be classed as ‘New Active Substances’ unless they demonstrate different safety or 
efficacy data in comparison to the API itself. They consider cocrystals to be similar to polymorphic 
forms, salts, hydrates or solvates and should be treated as such, unless they differ in their safety or 
efficacy data. Cocrystals are therefore considered eligible for drug product applications in a similar 
manner to that of other multicomponent crystals (salts, hydrates etc.). 
Although the FDA and EMA differ slightly on their position of pharmaceutical cocrystals, the fact that 
there are now more detailed guidelines for industry means that the advancement of cocrystal drug 
development is warranted. Furthermore, it will promote the application of cocrystal drug products to 
regulatory bodies and as a result, more drug molecules could be available on the market in their 
multicomponent forms.126,127 
 
1.6.3 Designing multicomponent crystals 
 
In order to obtained new multicomponent crystals, some knowledge of the individual components is 
first required, as well as an understanding of the types of interactions that could form when trying to 
combine the components to form a multicomponent crystal.128 
1.6.3.1 Intermolecular interactions 
Intermolecular interactions are those forces that are present between atoms that are not directly bonded 
to each other and are reversible.84 For this reason they are also referred to as non-covalent interactions. 
They play a large role in the way molecules assemble in the solid state and can also influence properties 
such as solubility, thermal stability and density. There are numerous intermolecular interactions that 
have been observed and described in the literature, including dispersion interactions, electrostatic 
interactions, π-π interactions as well as hydrogen- and halogen-bonding interactions.84 In the solid state, 
these interactions can be present in varying proportions and need not be strong interactions – many weak 
interactions could have a larger effect than one strong interaction.129 As this thesis focuses primarily on 
multicomponent crystals that are formed through hydrogen bonding and π-π interactions, these two 
interactions will be the focus of this section. In addition, halogen bonding is becoming increasingly 
popular in crystal engineering and the pharmaceutical industry and will therefore also be briefly 
discussed.130 
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The hydrogen bond is considered one of the most common non-covalent interactions found in the 
literature and certainly the most widely-studied, especially in the pharmaceutical industry.131–133 In 2011, 
IUPAC defined the hydrogen bond104 as “an attractive interaction between a hydrogen atom from a 
molecule or molecular fragment D–H in which D is more electronegative than H, and an atom or group 
of atoms in the same or different molecule, in which there is evident of bond formation.” The hydrogen 
bond (shown in Figure 1.12) therefore comprises a hydrogen bond donor (D–H) and an acceptor (A–Y) 
and is described by the distance (d) between A and H and the angle (θ) DĤA. When there is proton 
transfer between the donor and acceptor, it is known as a charge-assisted hydrogen bond. The hydrogen 
bond is considered to be the strongest of the intermolecular interactions and has been shown to have 
directionality and a distinct effect on the packing of molecules in the solid state.134 In addition, the 
hydrogen bond is important in many biological systems with the most common interaction being C–
H⋯O (or N).135 
 
 
 
Figure 1.12: (a) Hydrogen bond and (b) charge-assisted hydrogen bond (salt formation). 
 
A second type of interaction, known as the π-π interaction, occurs between aromatic molecules (as 
shown in Figure 1.13). The delocalised π electrons of the aromatic ring can form dispersion interactions 
due to their polarisability.136 Because the C–H bond is slightly polarised, the centre of the aromatic ring 
has a slight negative charge, while the rim of the ring (σ-framework) has a slight positive charge. These 
interactions are common, however not as strong or directional as hydrogen bonds.137 In cases where 
hydrogen bonding between molecules is absent or very weak, π-π interactions can play a large role in 
the packing of the molecules.138  
 
 
 
 
Figure 1.13: Types of π-π interactions. 
 
D 
H A 
Y 
θ 
d 
δ
+
 
δ
-
 D
-
 H A
+
 
Y 
θ 
d 
(a) (b) 
Edge-to-face Face-to-face Off-set parallel 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 1: Introduction 
 
19 | P a g e  
 
The halogen bond (Figure 1.14) is considerably less-studied than the previous two forms of 
intermolecular interactions, however it is becoming progressively more common not only in the crystal 
engineering field but in medicinal chemistry too.130,139–141 IUPAC defines the halogen bond, R–X⋯Y–
Z, as “a net attractive interaction between an electrophilic region on a halogen atom X belonging to a 
molecule or molecular fragment, R–X and a nucleophilic region of a molecule or molecular fragment, 
Y–Z.”142 The halogen bond is considered to be highly directional and often the distance between the 
donor and acceptor atoms is much shorter than the sum of their van der Waals radii. The halogen-
bonding ability of the halogen is dependent on its polarisability (F << Cl << Br << I).121 Unfortunately, 
the use of halogen bonding to form multicomponent crystals in the pharmaceutical industry has been 
scarcely explored because the halogen donor molecules that act as coformers are often considered toxic 
and not safe for human consumption.140  
 
 
 
Figure 1.14: A scheme of the halogen bond where X is the halogen, R is the rest of the molecule, Y is the 
nucleophile of a second molecule and Z is the rest of that molecule.  
 
A summary of these intermolecular interactions as well as acceptable distances between the relevant 
atoms is given in Table 1.1 below.  
 
Table 1.1: Types of intermolecular interactions with ranges of acceptable distances between relevant atoms 
 
Type of interaction Relevant atoms 
Distance (between relevant atoms 
or centroid to centroid) 
Hydrogen bond  D–H⋯A 2.2 – 3.0 84 
Halogen bond R–X⋯Y 2.6 – 3.3 143 
π-π interaction (face-to-face and  
offset face-to-face) 
Centroid to centroid 3.3 – 3.8 144 
π-π interaction (edge-to-face) Centroid to centroid Up to 5 144 
D = donor atom; A = acceptor atom; R = rest of molecule, X = halogen, Y = nucleophile  
 
1.6.3.2 The synthon approach to selecting coformers 
One of the most common methods of forming multicomponent crystals is using the synthon approach, 
which relies on the abovementioned intermolecular interactions that are present between functional 
R 
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Z 
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groups.145 A synthon can be described as “the repeating structural unit that directs how molecules 
interact with each other in the solid state.”146 Figure 1.15 shows selected synthons used in crystal 
engineering. The use of carboxylic acids and amides are popular for forming multicomponent crystals 
as they form strong hydrogen bonds. The acid-amide interaction is said to be the most common on the 
Cambridge Structural Database (CSD), followed by the amide-amide and acid-acid interaction.147  
 
Figure 1.15: Selected synthons in crystal engineering strategies.  
 
1.6.3.3 Using computational tools to aid in coformer selection 
One of the main disadvantages of the use of multicomponent crystals to improve physicochemical 
properties of drug molecules is the lack of predictability in forming them in the first place. In this sense, 
the most challenging aspect is accurately choosing a coformer that will result in the formation of the 
correct multicomponent crystal. While some focus on the synthon approach to choose coformers, others 
turn to computational methods to assist in the selection process.148 Some focus on modified crystal 
structure prediction methods149 that investigate lattice energies and stable packing arrangements of 
cocrystals in comparison to the individual components.150–152 It is generally thought that a 
multicomponent crystal is the thermodynamically favoured product and therefore would only form if it 
is more stable than the crystals of the individual components.152 Using this assumption, density 
functional theory is used to determine lattice energies of each component and the multicomponent 
crystal. The comparison of component and cocrystal stability is used to determine whether or not the 
coformer is a suitable choice. These methods, however, can be computationally expensive as they 
require new calculations for each set of potential components. 
The use of hydrogen bond propensity calculations have also been carried out as a way to predict the 
likelihood of successful cocrystallisations by statistically analysing the occurrence of hydrogen bonds 
between particular fragments in the CSD.153,154 The software used searches the CSD for structures that 
have similar functional groups to that of the input molecule and quantifies the probability of the 
occurrence of hydrogen bonds between the components. If the hydrogen bonds of highest propensity are 
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found to occur between functional groups found on the coformer and the drug molecule, then the 
possibility of the formation of multicomponent forms is high. It should be noted that the software does 
not take into consideration factors such as aromaticity, steric hindrance between functional groups or 
the chemical environment of the donor-acceptor groups.110  
Fluid-phase thermodynamics theory conductor-like screening model for real solvents (COSMO-RS 
theory)155,156 has also become popular for the screening of coformers. It has been used to calculate the 
difference in excess enthalpies between the multicomponent form and the individual components. 
COSMO-RS assumes that the interactions between components in the solid phase are equivalent to that 
of a super-cooled liquid phase.157 
Another method is to calculate gas-phase molecular electrostatic potential surfaces (MEPS) for each 
molecule (API and coformer) to evaluate molecular complementarity. This method employs an 
electrostatic model to identify a set of surface site interaction points (SSIPs), which can be described as 
H-bond donor and H-bond acceptor parameters.158,159 Using the MEPS approach, the probability of the 
formation of multicomponent forms are estimated through the comparison of the calculated energy of 
the multicomponent form and that of the pure components. This difference in energy between the pure 
and multicomponent forms provides a measure of the thermodynamic driving force for multicomponent 
crystal formation.157,160  
The COSMO-RS and MEPS approach have been compared by Grecu et al. and found to yield similar 
results when used as a virtual cocrystal screening tool.160 While these methods may seem crude and have 
major approximations, the advantage is that they are simple, fast and do not require crystal structure 
data. For these reasons, these methods are suitable for screening of large libraries of potential coformers, 
but have the disadvantage of reliability in the predictions.160  
The effectiveness of prediction methods is directly related to the complexity of the system 
(conformational flexibility, number of molecules in the asymmetric unit and the presence of heavy 
elements). As a result, current computational methods do not always take into account long-order 
packing contributions that could be playing an important role in the stabilisation of the system.161 These 
aspects, together with other assumptions described above that are needed for the various computational 
methods, could provide an explanation for why we are not yet at the point where we can accurately 
predict the formation of multicomponent crystals. Possibly a combined approach of experimentally-
obtained data and computational calculations is the key for more accurate predictions in the future.  
1.6.3.4 Methods used to form multicomponent crystals 
The most commonly used method for the preparation of multicomponent crystals is the solvent 
evaporation method.162 In a typical solution cocrystallisation, the individual components are dissolved 
in a minimum amount of a common solvent, often with gentle heating and stirring. The vial is then 
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placed in an area with little vibration or movement and the solvent is allowed to slowly evaporate. This 
method allows for the formation of single crystals that can be studied using single crystal X-ray 
diffraction. In some cases, however, one or more of the components can crystallise out separately and 
the multicomponent form is not obtained. This could be due to the solubility, or that the formation of 
the multicomponent product is not favourable over the individual components.  
Another solution-based method is a layering technique that could overcome the differences in solubility 
of the individual components. In this method, one of the components is dissolved in one solvent, and 
the other in a second solvent. The one is gently pipetted over the first so that a two-layer system is 
obtained. By slow diffusion of the solvents, the components interact and can form multicomponent 
crystals. Alternatively, a solvent in which neither component is soluble can be layered over the solution 
of components in a similar two-layer system. In this way, it is hoped that crystals will grow at the 
interface between the layers.  
The use of mechanochemistry has also been reported for the formation of multicomponent crystals. In 
this method, mechanical force is applied through grinding or milling to induce interactions between 
components.163 The use of a mortar and pestle is often used; however, ball mills are becoming more 
popular as they are more reliable. Liquid-assisted grinding – where catalytic amounts of solvent are used 
to accelerate the reaction – is a more popular choice for the formation of multicomponent crystals, 
especially as a screening tool, as it is fast and efficient and overcomes solubility differences between 
components.164 One of the disadvantages of this method is that it does not allow for the formation of 
single crystals and therefore other methods are required to obtain single crystal data.  
A less-studied method is the co-sublimation of components. This method relies on the ability of the 
components to enter the gas phase where they can interact and potentially form as a new solid material. 
The advantage of this method is that it is solvent-free and allows for the formation of single crystals. 
However, not all compounds are able to sublime directly to vapour on heating and the temperature at 
which the components sublime could be very different. This could influence the formation of 
multicomponent crystals.165  
Alternative methods for the preparation of multicomponent crystals include melt crystallisation,166 twin 
screw extrusion,167 spray drying,168 freeze-drying169 and slurry methods;170 however, these are not as 
widely used.  
1.6.3.5 Other factors to consider 
While synthons and their ability to form intermolecular interactions are known to drive the formation of 
multicomponent crystals, other factors such as molecular shape and the affinity of molecules to close 
pack can play a role in crystal packing and the ability to form multicomponent crystals.171 In general, 
organic molecules will typically pack in such a way as to fill the space as efficiently as possible. This is 
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due to van der Waals interactions present between molecules that have a stabilising effect according to 
the contact area.104,172 
It is also important to consider the physicochemical properties of the components in relation to the 
experimental method that will be used to obtain the multicomponent crystals.173 Solution methods are 
popular, but issues such as solubility of the component in solvents can result in one of the components 
‘crashing out’ instead of forming the intended multicomponent crystal. Mechanochemical methods 
could prove problematic for compounds that have stability issues – where the force from milling or 
grinding could decompose one of the components. It should also be noted that the use of various 
cocrystallisation methods could potentially give rise to polymorphs, or even different types of 
multicomponent crystals (for example salts or cocrystals) depending on the method used.174,175 
 
1.6.4 Current pharmaceutical multicomponent crystals 
 
The formation of multicomponent crystals has been well-documented for the improvement of certain 
physicochemical properties, but because of uncertainty in their classification until recently, it has not 
been well taken up by the pharmaceutical industry in terms of marketing drugs as their multicomponent 
forms. In addition, the lack of suitable production methods on large scale, as well as predictability issues 
has dampened full-scale research efforts by pharmaceutical companies.119  
Excluding simple salts (such as chloride or sodium salts), there are currently only three multicomponent 
forms of drug molecules that are on the market.176 The first is escitalopram oxalate, which was approved 
by the FDA in 2009 for the treatment of anxiety and depression and is marketed as Lexapro®. It is 
classified as a cocrystal salt hydrate as it comprises two escitalopram cations, charge-balancing oxalate 
anions, as well as a neutral molecule of oxalic acid and one molecule of water per asymmetric unit.177 
The second is a valproate sodium cocrystal with valproic acid, licensed in 2012 and marketed as 
Depakote®. It is marketed by Novartis to treat disorders such as seizures and manic depression. It 
comprises a 1:1 molar ratio of the sodium valproate salt and valproic acid, resulting in a crystalline, non-
hygroscopic solid form.178 The third is Entresto® (sacubitril-valsartan), a 1:1 molar ratio of sacubitril 
and valsartan, both present as the anionic form stabilised by three sodium cations and water molecules. 
It is currently used for the treatment of chronic heart failure.179 In addition, the cocrystal of the anti-
diabetic drug, Ertugliflozin and coformer 5-oxo-proline, is currently in clinical trials. This drug has also 
been cocrystallised with other coformers, including pyroglutamic acid and L-proline.180 
Investigation into improving physicochemical properties of drug molecules through the formation of 
multicomponent crystals has increased substantially over the past decade.82 Some of these drug 
molecules include ibuprofen that exhibits an 8-fold improvement in the dissolution rate when 
cocrystallised with nicotinamide.181 Carbamazepine has been cocrystallised with saccharin182,183 and a 
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number of carboxylic acid coformers,184 and many of these cocrystals showed improvements to the 
solubility and bioavailability of the drug molecule. Smith et al. investigated the formation of the 
multicomponent crystal of quercetin with isonicotinamide, caffeine and theobromine, all of which 
displayed improved solubility and absorption of the drug in vivo.185 Lapatinib, an anticancer drug, has 
also been cocrystallised with caproic acid, caprylic acid and adipic acid to form salts in each case.186  
While multicomponent forms of drug molecules have received considerable attention, there has been a 
neglect with antiplasmodial drug molecules, despite the urgent need to improve the physicochemical 
properties of some of them.99 Having said this, there are a few reported cases of multicomponent forms 
of some known antiplasmodial agents. Some of these are described below.  
Pyrimethamine, an antifolate antiplasmodial agent, has been well studied by a number of 
researchers.110,187,188 Delori et al. made use of the ∆pKa rule and hydrogen bond propensity calculations 
to screen for potential coformers. Multicomponent forms of pyrimethamine were obtained with 
theophylline, aspirin, α-ketoglutaric acid, saccharin, p-coumaric acid, succinimide and L-leucine.110 
Stanley et al. reported two salts formed from pyrimethamine and glutaric acid (Figure 1.16a) or formic 
acid (both in a 1:1 ratio of API to coformer).188 Sethuraman et al. reported a further four salts formed 
from pyrimethamine with maleic acid, succinic acid, phthalic acid or fumaric acid (Figure 1.16b).189 In 
the majority of these cases where carboxylic acid coformers are used, the acid-aminopyridine 
heterosynthon is observed to be the driving force behind cocrystallisation.  
 
  
 
 
 
 
 
 
 
 
 
Figure 1.16: Structure of the salt of pyrimethamine formed with (a) glutaric acid (CSD ref: UHAYEH) and (b) 
fumaric acid (CSD ref: ULAXIO). Circled in green is the acid-aminopyridine heterosynthon and in black is the 
aminopyridine homosynthon. 
 
A second antifolate drug that was developed but discarded before clinical use is MMP – a methyl 
suphonyl aminopyridine antiplasmodial agent developed by Chibale and coworkers.190 This compound 
showed excellent potency against P. falciparum, but exhibited poor aqueous solubility (10 µg/mL at pH 
= 7.4). Investigation into the formation of multicomponent forms of this compound led to the formation 
of five salts and one cocrystal with various coformers, including salicylic acid, oxalic acid and adipic 
(a) (b) 
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acid (Figure 1.17). These multicomponent forms showed similar hydrogen-bonding motifs to those of 
pyrimethamine described above. The acid-aminopyridine heterosynthon is highlighted in green in 
Figure 1.17. For three of the salts obtained, improved solubility of up to 200 µg/mL at pH = 7.4 was 
observed.  
 
 
 
 
 
 
Figure 1.17: Structure of the cocrystal formed from MMP and adipic acid (CSD ref: PIWWEZ). Cirlcled in 
green is the acid-aminopyridine heterosynthon. 
 
Two multicomponent forms of artemisinin have been reported by Karki et al.191 The use of orcinol and 
resorcinol as coformers yielded two cocrystals with artemisinin. In both cases, O–H⋯O hydrogen 
bonding is observed (as seen in Figure 1.18) between the API and coformer, but the packing arrangement 
is different. In addition, a co-amorphous solid of curcumin-artemisinin has recently been reported by 
Mannava et al., which showed improved solubility and bioavailability in comparison to artemisinin.192  
Figure 1.18: Structure of the cocrystal of artemisinin formed with (a) resorcinol (CSD ref: TALCOA) and (b) 
orcinol (CSD ref: TALCUG). 
 
The quinoline-containing class of antiplasmodial agents has received more attention in the literature and 
has been shown to form multicomponent crystals with a number of coformers.193–195 In most of these 
cases, linear and aromatic carboxylic acids were used as coformers. However, in some instances 
saccharin and certain binaphthyl derivatives were able to form multicomponent crystals. For the 
(a) (b) 
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multicomponent crystals obtained with mefloquine and amodiaquine, an improvement in the solubility 
and in vitro dissolution rates were observed in comparison to the parent API. Unfortunately, the authors 
did not obtain crystal structures of these forms. 
While there have been many more reports of multicomponent forms of quinine,196–199 the 
physicochemical properties of these forms have not yet been investigated. In these cases, crystal 
structures show hydrogen bonding between the nitrogen atom in the amino side chain of the API and 
the coformer, as shown in Figure 1.19.  
 
 
 
 
 
 
Figure 1.19: Structure of the salt of quinine formed from (a) 2-chlorobutyrate (CSD ref: VAZCUZ) and (b) 
saccharin (CSD ref: YANNIL). 
 
Previously, we have reported salts of 1,2,3-triazole-containing quinolines and aromatic acids such as 
salicylic acid and pamoic acid (Figure 1.20).200 Hydrogen bonding takes place between the carboxylic 
acid and the nitrogen in the amino side chain, as well as with the quinoline nitrogen atom. Interestingly, 
here the choice of coformer seems to influence the efficacy of the compound. However, further work 
needs to be conducted before any definitive claims can be made.  
 
 
 
 
 
 
 
Figure 1.20: Structure of the salt of 7-chloro-4-(4-(pyrrolidin-1-ylmethyl)-1H-1,2,3-triazole-1-yl)quinoline 
formed with (a) salicylic acid and (b) pamoic acid, showing the proton transfer between the salicylate and amino 
groups. Solvent molecules (DMSO and H2O) from (b) have been removed for clarity. 
(a) (b) 
(a) (b) 
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While these cases seem to promote the fact that antiplasmodial agents have the potential to form 
multicomponent crystals as a way of improving physicochemical properties, it is unfortunate that there 
is possibly a bias in the literature toward positive results. It may well be that there are many cases where 
the use of multicomponent crystals has a detrimental effect on the physicochemical properties of the 
parent drug molecule, but these results may not have been published. In addition, the majority of the 
negative cocrystallisation attempts do not make it into peer-reviewed journals and so the bias toward the 
potential that some molecules have to forming multicomponent crystals is skewed. It was therefore our 
goal to explore this further and to gain insight into this field. 
 
1.7 INTRODUCING OUR STRATEGY 
 
In an ideal situation, a chemist should be able to use the knowledge available to assess the molecule at 
hand, select the appropriate coformer that will improve the specific property required and to form the 
multicomponent form of the API with the desired properties. Unfortunately, the present knowledge on 
forming multicomponent crystals is simply not sufficient to allow for accurate prediction. In addition, 
there is a lack of knowledge on the structure-property relationship between the chosen coformer and the 
newly-formed multicomponent crystal. These two factors are currently hindering the ability to tailor-
make multicomponent crystals with specific properties.  
 
1.7.1 The aims and objectives of this study 
 
The aim of this work was to investigate the formation of multicomponent crystals of known and novel 
antiplasmodial agents. By doing so, we aimed to contribute to the current knowledge that will one day 
allow for accurate predictions for tailor-made properties. In order to achieve this, some objectives were 
set for this project.  
Our initial strategy was to make use of a combined theoretical and experimental approach to investigate 
the formation of multicomponent crystals of known antiplasmodial agents. For this, five compounds 
were selected, namely ferroquine, phenylequine, amodiaquine, N-(7-chloroquinolin-4-yl)ethane-1,2-
diamine and N-(7-chloroquinolin-4-yl)propane-1,3-diamine (Figure 1.21). These molecules were 
chosen because they have been shown to have reasonably poor solubility, are simple to synthesise or 
purchase and are similar in structure so that comparisons can be made about the types of intermolecular 
interactions that form.  
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Figure 1.21: Structure of (a) ferroquine, (b) phenylequine, (c) amodiaquine, (d) N-(7-chloroquinolin-4-
yl)ethane-1,2-diamine and (e) N-(7-chloroquinolin-4-yl)propane-1,3-diamine. 
 
While we are able to make or purchase these compounds on gram-quantity scale, the application of the 
multicomponent crystal method to the drug discovery process would need to be carried out on much 
smaller sample sizes – sometimes only up to 50 mg of sample. Therefore, complete screening methods 
for finding multicomponent crystals from a wide range of coformers is challenging. For this reason, we 
sought to determine whether the use of computational methods could assist us in the selection of 
coformers that would likely yield multicomponent crystals with our chosen APIs. We thus decided to 
make use of molecular electrostatic potential surface calculations as carried out by Grecu et al.160 Once 
a ranked list of coformers is obtained, experimental screening could be carried out using a variety of 
methods to determine the reliability of the computational calculations, as well as to determine if there 
are trends in the types of coformers used that form multicomponent crystals, as well as the types of 
interactions formed.  
Provided this method gives multicomponent products, we would apply it to other compounds that are 
not as easily obtained in large quantities. For this we turned to lapatinib derivatives as they have been 
shown to display good efficacies against P. falciparum, but suffer from low solubility.201 The advantage 
of this approach is that the majority of the synthetic methodology is already established.202 In addition, 
inspired by Ferroquine, we sought to introduce substituted ferrocene moieties into the lapatinib 
compound, as shown in Figure 1.22.  
 
 
 
(a) (b) (c) 
(d) (e) 
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Figure 1.22: Structure of lapatinib (left) and the incorporation of an aminoferrocene moiety (right), where the R-
group is a tertiary amine (dimethyl, pyrrolidyl, morpholinyl etc.). 
 
At this point, the mode of action of the lapatinib analogues against P. falciparum is unknown. It is 
suggested that it could be targeting one or more kinases within the parasite, but could also be acting as 
a β-hematin inhibitor.79 The efficacy results that have been obtained are based on phenotypic assays that 
assess the ability of the drug molecule to inhibit the growth of the parasite. Further studies would 
therefore need to be conducted to confirm the mode of action, but this is beyond the scope of this project.  
By incorporating a synthetic approach into the project we expected to contribute to the structure-activity 
relationship studies on these compounds. We were also interested to see what effect small modifications 
to the structure would have on its ability to form multicomponent crystals. Initially, the R-groups 
described above would be investigated, and then including linkers such as amides between the 
quinazoline scaffold and the ferrocene tail group. In this way, a greater knowledge on structure-property 
relationships could be obtained. 
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CHAPTER 2 
Forming multicomponent crystals of known 
antiplasmodial agents 
 
 
2.1 INTRODUCTION 
 
One of the most challenging aspects of crystal engineering (in a pharmaceutical field and otherwise) is 
choosing the right coformer that would result in the formation of a multicomponent crystal with specific 
properties. In order to do this, studying the individual components is first required to understand what 
intra-and inter-molecular interactions are present and how these can be used to form multicomponent 
crystals. For the purpose of this study, we selected five 4-aminoquinoline derivatives, structures of 
which are shown in Figure 2.1 below. These five compounds have previously been reported in the 
literature1–4 and are therefore relatively simple to synthesise and require starting materials that are 
reasonably inexpensive.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Chemical structures of the five 4-aminoquinoline antiplasmodial agents (1 – 5) used in this study.  
 
Compound 1 (amodiaquine) is commercially available as the dihydrochloride dihydrate salt and is used 
in some combination therapies to treat malaria.5 Compound 2 (ferroquine) is the first metallocene-
containing antiplasmodial to reach clinical trials and is currently in phase II clinical trials for the 
treatment of malaria.6 Compound 3 (phenylequine), the phenyl analogue of 2, has been shown to have 
a similar efficacy to 2 against P. falciparum.3 While possessing reasonable in vitro efficacies, 
compounds 4 and 5 were discarded as drug candidates due to poor physicochemical properties. We 
therefore thought that this series of five 4-aminoquinolines would be interesting to study in terms of the 
ability of these compounds to form multicomponent crystals, as well as what effect changes to the 
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structure would have on this ability. In addition to these reasons, these compounds all possess suitable 
functional groups to allow for intramolecular interactions with small organic coformers.  
The first of these functional groups is the 4-amino moiety in each compound that can act as a hydrogen-
bond donor or acceptor. Each compound also contains a quinoline ring that is known to form π-π 
interactions in the solid state.7,8 Furthermore, the nitrogen atom in this ring can act as a hydrogen-bond 
acceptor. The tertiary nitrogen atom in the side chain of compounds 1 – 3 can act as a hydrogen-bond 
acceptor. Compound 1 contains an additional phenolic OH moiety that can form intermolecular 
interactions with a hydrogen-bond donor or acceptor. Finally, compounds 4 and 5 contain a primary 
amine, rather than a tertiary amine tail, that can act as a hydrogen-bond donor or acceptor. 
Compounds 2 and 3 were chosen because we were interested in seeing what effect the ferrocene linker 
(in 2) has on the ability to form multicomponent crystals in comparison to the phenyl linker (in 3). 
Compounds 4 and 5 were chosen because they have a short alkyl chain as a linker instead of the phenyl 
or ferrocene moiety. We also wanted to see whether the length of the alkyl chain (and therefore the 
increased rotation in that chain) would influence the ability to form multicomponent crystals with these 
compounds. 
With this series of compounds, we were confident that we would be able to obtain some insight into 
their ability to form multicomponent crystals and hopefully observe trends in which coformers resulted 
in the formation of these multicomponent crystals. Our first goal was to synthesise the desired 
compounds before choosing coformers to form multicomponent crystals. 
 
2.2 SYNTHESIS OF THE ANTIPLASMODIAL AGENTS 
 
Each of the five antiplasmodial agents have been synthesised previously and therefore the literature 
procedures were followed for each synthesis as discussed in the relevant sections below. In some cases, 
yields were lower than those obtained in the literature, but as sufficient amounts of the desired product 
was obtained in each case, no optimisation was attempted for any of the steps. Only a brief discussion 
of the synthesis of each compound is given below. Detailed synthetic procedures and characterisation 
data can be found in Chapter 6 (pages 123 – 131).  
 
2.2.1 Synthesis of amodiaquine free base (1) 
 
Amodiaquine dihydrochloride dihydrate was bought from Sigma-Aldrich (now Merck) and converted 
into the free base by stirring the salt in ammonia solution (25%) for 2 hours, followed by extraction into 
ethyl acetate. The solvent was removed under reduced pressure before the product was dissolved in a 
minimum amount of methanol (MeOH). After placing the vial in the fridge overnight, a pale yellow 
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precipitate was obtained, which was filtered and dried under high vacuum (88% yield).9 1H nuclear 
magnetic resonance (NMR) spectroscopy confirmed that the desired product was obtained. Powder X-
ray diffraction (PXRD), thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) 
were used to characterise the free base and results were compared to that of the hydrochloride salt (see 
Chapter 6, page 123) to prove that the product was no longer the salt. The crystal structure of the 
dihydrochloride dihydrate salt (CSD ref code: GIWLII01), as well as a propanol solvate of the free base 
(CSD ref code: SENJIF01) is available in the CSD. We attempted to form suitable single crystals of the 
free base using a variety of methods, but were unfortunately unable to obtain a crystal structure. 
 
2.2.2 Synthesis of ferroquine (2) 
 
The synthesis of ferroquine was carried out according to literature procedures as shown in Scheme 
2.1.10,11  
 
Scheme 2.1: Synthesis of 2.  
 
Commercially available N,N-dimethylaminomethyl ferrocene (6) was ortho-lithiated with 
1.0 equivalent of freshly-titrated tert-butyllithium (t-BuLi) under a nitrogen atmosphere. It should be 
noted that while the use of n-butyllithium (n-BuLi) has been reported in the literature for these 
reactions,11 the use of t-BuLi significantly reduces reaction times.12 Because aldehyde product 7 can 
degrade over time, especially in solution,12 minimising the reaction time results in an improvement of 
the yield of this reaction. Two hours after the ortho-lithiation of 6, the bright orange suspension was 
quenched with anhydrous dimethyl formamide (DMF) forming the desired product in quantitative yield. 
The conversion of the aldehyde moiety into primary amine 9 was carried out via the formation of oxime 
8, without purification of the oxime intermediate. Finally, ferrocenyl amine 9 was coupled to 
commercially available 4,7-dichloroquinoline (10) to give ferroquine in a 54% yield after purification 
by flash column chromatography and subsequent recrystallisation from dichloromethane 
(DCM)/Hexane.  
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The 1H NMR spectrum of 2 shows the characteristic singlet at 4.15 ppm 
integrating for 5H that corresponds to the unsubstituted cyclopentadiene ring of 
ferrocene. The characteristic splitting of the CH2 protons in the 1H NMR 
spectrum due to chirality, is also noted. The singlet integrating for 6H at 2.23 
ppm corresponds to the two N-methyl groups. Five peaks were observed in the 
aromatic region, each integrating for 1H, which corresponds to the protons on 
the quinoline ring. All other protons were accounted for. It should be noted that the data correlated well 
with that reported in the literature.11  
It is worth noting that 1,2-disubstituted metallocenes such as ferroquine (2) exhibit planar chirality and 
are therefore subject to a variation of the (R,S) nomenclature.13 In Figure 2.3 below, the R and S 
configurations are shown for ferroquine. The synthesis described above results in the formation of the 
racemate, which can be resolved using L-tartaric acid.12 It has, however, been shown that the racemate 
has slightly improved in vitro efficacy against P. falciparum in comparison to either enantiomer.14 
Because in vivo testing and clinical trials has made use of the racemate,2 it was decided to continue with 
the formation of multicomponent forms of 2 without first resolving the racemate. 
 
 
 
 
 
 
Figure 2.3: Enantiomers of 2.  
 
Single crystals of 2 were also obtained and the unit cell parameters of these crystals correlated well with 
the crystal structure of the racemate of ferroquine in the CSD. A powder X-ray diffraction (PXRD) 
pattern of the bulk material also correlated well with that of the predicted pattern obtained from single 
crystal data. While this structure is known, it is useful to study its inter- and intra-molecular interactions 
and packing in the solid state. Figure 2.2 shows the asymmetric unit of 2 (with the intramolecular 
hydrogen bond shown in black) as well as the packing of 2 viewed down the a axis.   
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Figure 2.2: (a) The asymmetric unit of 2 showing the intramolecular hydrogen bond; (b) packing of 2 viewed 
down the a axis. CSD ref code: LEZNIO. 
 
The dominant hydrogen bond present in the crystal structure of 2 is the intramolecular N–H⋯N 
interaction between the secondary amine (4-amino moiety) and the side chain nitrogen atom of the 
molecule. Other weaker interactions are present and contribute to the overall packing and stability of 
molecules in the solid state. 
 
2.2.3 Synthesis of phenylequine (3) 
 
The synthesis of 3 follows similar procedures as for ferroquine, which can be seen in Scheme 2.2, but 
begins with commercially available N,N-dimethylaminomethyl benzene (11).12 The final product was 
obtained as a white crystalline powder in 48% yield over the last three steps after purification by flash 
column chromatography and subsequent recrystallisation from DCM/Hexane.  
 
 
Scheme 2.2: Synthesis of 3.  
 
(a) (b) 
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The 1H NMR spectrum of 3 shows a singlet integrating for 6H corresponding 
to the methyl protons as well as the five peaks, each integrating for 1H, in the 
aromatic region that corresponds to the protons on the quinoline ring. Here, the 
splitting of the CH2 protons is not observed (as for 2) as there is no chirality. 
Instead the two singlets, each integrating for 2H, at 4.47 ppm and 2.29 ppm, 
correspond to the two CH2 groups on 3. All other protons are accounted for 
and the data compared well with the values found in the literature.3  
 
A crystal structure was obtained from crystals that grew from the NMR spectroscopy sample of 3. 
Compound 3 packs in the tetragonal space group P21/c. An N–H⋯N hydrogen bond (2.900 ) between 
the NH-moiety of one molecule and the quinoline nitrogen atom of a second molecule results in the 
formation of chains of molecules that extend parallel to the crystallographic c axis (Figure 2.4). These 
chains of molecules then pack in three dimensions, resulting in the solid-state structure. Selected 
crystallographic data can be found in Table 2.1. Hydrogen-bonding geometries can be found in Chapter 
6, page 130.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: (a) The asymmetric unit of 3; (b) packing of 3 viewed down the c axis and (c) hydrogen-bonded 
chains of 3 viewed down the a axis. 
 
 
 
 
 
(a) (b) 
(c) 
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Surprisingly, the hydrogen-bonding interactions within the solid-state structure of 2 (CSD ref code: 
LEZNIO) are remarkably different to those of 3. While it was expected that the ferrocene moiety would 
influence the packing of the molecules in the solid state, it seemed likely that a similar intramolecular 
hydrogen-bonding motif between the secondary amine (4-amino moiety) and the amino side chain 
(Figure 2.5a) would be observed in 3. This, however, is not the case. Rather, the dominant interaction 
in 3 is the intermolecular hydrogen bond between the 4-amino moiety and the quinoline nitrogen atom 
of two molecules (Figure 2.5b).  
 
 
 
 
 
 
 
Figure 2.5: The structure of (a) 2 (CSD ref code: LEZNIO) and (b) 3 obtained from single crystal X-ray 
diffraction data. Circled in green is the dominant hydrogen-bonding interaction for each molecule.  
Table 2.1: Selected crystallographic 
details for 3. 
 3 
Molecular formula C19H20N3Cl 
Formula weight 
(g/mol) 
325.83 
Crystal system Tetragonal 
Space group P21/c 
Z 8 
a (Å) 15.932(2) 
b (Å) 15.932(2) 
c (Å) 13.334(1) 
α (°) 90 
 (°) 90 
 (°) 90 
Volume (Å 3) 3377.0(5) 
Temperature (K) 100(2) 
Rint 0.054 
R1 [I>2(I)] 0.025 
wR2 0.065 
GoF 1.08 
(a) (b) 
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This intramolecular hydrogen bond in 2 has been observed in solution as well as in the solid state.15 
While the intermolecular interactions found in 3 may well be seen in solution too, these assumptions 
cannot be made with only this data. The differences in the efficacy of these two compounds could be 
related to the intra- or intermolecular bonding; however, it would be inaccurate to infer this solely based 
on the crystal structure of each compound. While this would be interesting to study further, it would 
require extensive pharmaceutical investigation, which is beyond the scope of this study. Rather, we 
chose to focus on what difference these interactions have on the ability of these compounds to form 
multicomponent crystals. 
 
2.2.4 Synthesis of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4) 
 
The synthesis of 4 follows a one-step procedure (Scheme 2.3) where 4,7-dichloroquinoline (10) was 
added to an excess of 1,2-diaminoethane and, after neutralising with a saturated solution of sodium 
carbonate, afforded the desired product as a pale yellow crystalline solid in 58% yield.  
 
 
 
 
Scheme 2.3: Synthesis of 4.  
 
The 1H NMR spectrum of 4 confirmed that the desired product was obtained. 
Two triplets at 3.31 ppm and 2.68 ppm, each integrating for 2H, corresponded 
to the two methylene protons in the side chain. The five peaks in the aromatic 
region, each integrating for 1H, correlated to the protons on the quinoline ring. 
The infrared spectrum shows a primary amine stretch at 3247 cm-1. Finally, the spectroscopic data 
correlates well with that obtained from the literature.4,16  
 
2.2.5 Synthesis of N1-(7-chloroquinolin-4-yl)propane-1,2-diamine (5) 
 
The synthesis of 5 follows the same procedure described for 4 above, but uses 1,3-diaminopropane as 
the nucleophile in the coupling reaction. As a result, the desired product was obtained as a pale yellow 
powder in 71% yield.  
 
 
Scheme 2.4: Synthesis of 5.  
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The 1H NMR spectrum of 5 showed three peaks corresponding to the protons 
on the alkyl chain – one multiplet (1.77 – 1.68 ppm) and two triplets (at 3.32 
ppm and 2.68 ppm) – each integrating for 2H. The five peaks in the aromatic 
region, each integrating for 1H, correspond to the protons on the quinoline 
ring. The primary amine stretch in the infrared spectrum was observed at 3350 cm-1. These data 
corresponded well with the literature values.4,16  
As the crystal structures of 4 and 5 are not available on the CSD, attempts were made to obtain 
diffraction-quality single crystals for each of them using a variety of solvents as well as sublimation 
techniques; however, all attempts so far have been unsuccessful. Despite this lack of crystal data, we set 
out to form multicomponent crystals of each of the five antiplasmodial compounds, using a variety of 
coformers.  
 
2.3 SELECTION OF COFORMERS 
 
Having synthesised the five antiplasmodial agents, our next step was to form multicomponent crystals 
with each of them. Before this could be done however, we would need to select appropriate small organic 
molecules (coformers), which would be used to form the multicomponent crystals.  
In the field of pharmaceuticals, only certain coformers are allowed to be used that are known to be safe 
for human consumption. There are two main databases available – GRAS (generally regarded as safe) 
and EAFUS (everything added to food in the United States) that provide a list of tested compounds that 
can be used in food and medication, amongst other things.17,18 Many of the potential drug molecules 
(including antiplasmodial agents) that are synthesised require a multistep synthesis and therefore a full 
experimental screen with many coformers is simply not feasible as it requires large quantities of the 
drug molecule. This can thus be an expensive endeavour. While the use of only ‘safe’ molecules limits 
the number of coformers that could be used to form multicomponent crystals of our molecules, there are 
still far too many compounds on these lists and therefore an additional method would be needed to 
further refine our list. 
The most widely used method of choosing coformers is the synthon approach that involves molecular 
complementarity between functional groups on each molecule.19 By identifying the types of functional 
groups on our molecules (as discussed in the beginning of this chapter), coformers with complementary 
functional groups can be identified. In our molecules, the aromatic rings can form π-π interactions with 
aromatic coformers. The quinoline nitrogen atom, the 4-amino moiety and the side chain nitrogen atom 
can form intermolecular interactions with alcohols, amides or carboxylic acids, with carboxylic acids 
being most prevalent in the literature.20 Based on this logic, coformers containing either a carboxylic 
acid moiety, or aromatic ring (or both), would be likely to yield multicomponent crystals; however, there 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2: Forming multicomponent crystals of known antiplasmodial agents 
 
51 | P a g e  
 
is no guarantee of this. In addition to favoured intermolecular interactions, the shape of both the 
antiplasmodial compound and the coformer can have a large influence on the outcome of 
cocrystallisation.21 The compromise between a number of variables dictates, in each case, the outcome 
of the attempted cocrystallisation. Essentially, this means that the multicomponent crystal will only form 
if it is more favourable than the crystallisation of the single components.  
Despite narrowing down the list of coformers to choose from, there is still a great deal of uncertainty in 
which might be successful. Hence, being able to at least somewhat predict the likelihood of whether a 
multicomponent form of the drug can be obtained with a specific coformer would be valuable. 
Unfortunately, the current knowledge on crystal structure prediction does not allow for accurate 
predictions in a high throughput fashion.22 
Nonetheless, in pursuit of marginal gains of predictability, and to further narrow our choice of 
coformers, we decided to investigate the use of a “virtual” screening method based on computational 
calculations to provide a list of coformers that are more likely to form multicomponent forms of each of 
the five molecules discussed above. A method described by Hunter and coworkers makes use of 
molecular electrostatic potential surfaces (MEPS) to calculate surface site interaction points on each 
molecule that, after some simple calculations, provides a ranked list of coformers that would be more 
likely to form multicomponent crystals.23,24 This method has been used successfully in obtaining 
multicomponent forms of some drug molecules, including caffeine, carbamazepine, nalidixic acid and 
spironolactone.25–28 
A key advantage of this method is that prior knowledge of the crystal structure and intra- and inter-
molecular interactions of the components is not required. While this does not necessarily give the most 
accurate depiction of the solid-state geometries, it does provide a robust method that can be applied to 
any drug molecule and coformer of choice. A second advantage of this approach is that both 
conventional hydrogen-bonding interactions, as well as weaker electrostatic interactions are taken into 
account through the identification of the surface site interaction points on each molecule. This gives a 
reasonable mathematical description of the surface properties of the molecule that can then be used to 
calculate the total interaction of the molecule with its surrounding environment.  
Because this approach makes use of gas-phase calculations, there is some degree of inaccuracy since 
the experimental screening would most likely take place in the solid or solution state. This approach 
also assumes that all possible interactions that can be made, are made and the molecular shape and 
packing within a crystal lattice is of lesser importance than the interactions between donor and acceptor 
sites. However, the advantage of efficiency and straight forward calculations makes this method viable 
for use with larger libraries of potential coformers. We therefore decided to make use of this method in 
our attempt to narrow down the list of potential coformers, so that experimental screening could be 
limited to the most likely candidates. 
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To this end, each antiplasmodial agent and potential coformer was drawn in ChemCraft and a geometry 
optimisation was performed in Gaussian 09 at the B3LYP/6-31+G* level of theory.25,29 This level of 
theory is limited to the first 36 elements of the periodic table (H – Kr) and therefore there is a limitation 
in the types of molecules that can be investigated. Alternative basis sets are available that accommodate 
heavier atoms, but the geometry optimisations for all molecules (drug and coformers) would need to be 
carried out with this basis set in order to accurately complete the calculations. Once optimised, the 
molecular electrostatic potential was mapped onto the 0.002 Bohr -3 isodensity surface using AIMAll 
software.30 Figure 2.6 gives an example of the MEPS of 1 and oxalic acid (set to the same colour scale 
for comparative purposes). 
 
 
 
 
 
 
 
 
 
Figure 2.6: (a) Molecular electrostatic potential surface of (a) 1 and (b) oxalic acid indicating the local maxima 
and minima (blue +315 kJ mol-1 to red -207 kJ mol-1) used to determine the hydrogen-bond interaction sites, α 
and β.  
 
Local minima and maxima were located for each molecule on the MEPS surface and equations (1) and 
(2) were used to calculate the hydrogen-bond interaction sites, α and β, at each minimum and maximum.  
 
α = 0.0000162 MEPmax2 + 0.00962 MEPmax (1) 
β = 0.000146 MEPmin2 – 0.00930 MEPmin (2) 
where MEPmax and MEPmin are local maxima and minima on the MEPS in kJ mol-1. 
The highest α value corresponds to the best donor site, while the highest β value corresponds to the best 
acceptor site. Assuming that the highest α value will interact with the highest β value and so forth, the 
list of α and β values for each molecule were arranged in descending order. This allowed us to calculate 
the total interaction site pairing energy of each solid, E, using equation (3).  
The likelihood of a multicomponent crystal forming between the two components (∆E) can be calculated 
by simply subtracting the energy of each component from that of the multicomponent form using 
equation (4).  
(b) (a) 
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𝐸 =  − ∑ 𝛼𝑖𝛽𝑗
𝑖𝑗
 
 ∆E = Ecc – nE1 – mE2      (4) 
where E1 is the interaction site pairing energy of the pure form of the antiplasmodial agent (component 1) 
and E2 is the interaction site pairing energy of the pure form of the coformer (component 2). The 
interaction site pairing energy of the multicomponent product of component 1 and is given by Ecc. 
Stoichiometry can be included by varying the n and m values. 
The ∆E values for each combination of antiplasmodial agent and coformer in a 1:1 ratio were then 
calculated. The more negative the ∆E value, the more likely it is to form a multicomponent product with 
those two components. Therefore, these values were arranged in descending order to provide a ranked 
list of potential coformers that would most likely form multicomponent crystals with each 
antiplasmodial compound. The top ten coformers are reported in Table 2.2 for each compound, along 
with the ∆E values associated with them. The full list of 32 potential coformers and their corresponding 
∆E values can be found in Chapter 6 (page 132). 
 
Table 2.2: Ranked list of top ten coformers for each antiplasmodial compound and their corresponding ∆E 
values (kJ mol-1).  
1 2 3 4 5 
coformer -∆E coformer -∆E coformer -∆E coformer -∆E coformer -∆E 
OXA 12.1 OXA 24.5 OXA 14.6 OXA 15.5 FUM 22.5 
DHBA 9.0 DHBA 19.0 DHBA 10.7 PAM 10.3 OXA 18.4 
TRIM 8.4 FUM 18.4 FUM 9.1 TRIM 10.0 TRIM 13.5 
FUM 7.6 TRIM 17.0 IND 8.5 BIPY 9.0 DHBA 13.2 
PAM 6.9 MAL 16.8 PAM 8.2 PYZ 8.2 PAM 12.9 
RES 6.7 PAM 16.8 TRIM 8.1 DHBA 8.1 RES 10.9 
IND 6.4 IND 16.2 RES 7.7 FUM 7.7 IND 9.9 
MAL 4.9 RES 16.1 MAL 7.3 IND 7.5 MAL 9.2 
TERE 4.9 TERE 15.7 TERE 6.6 RES 7.2 TERE 8.7 
SAL 4.3 SUC 15.2 pABA 6.1 VAN 6.8 SUC 7.7 
Coformer codes: OXA – oxalic acid, DHBA – 3,5-dihydroxybenzoic acid, TRIM – trimesic acid, 
FUM – fumaric acid, PAM – pamoic acid, RES – resorcinol, IND – indole, MAL – malonic acid, 
TERE – terephthalic acid; SAL – salicylic acid, SUC – succinic acid, pABA – p-aminobenzoic acid, 
BIPY – 4,4-bipyridine, PYZ – pyrazine, VAN – vanillin. 
 
 
 
 
(3) 
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Looking at the outcome of the virtual screening methods, it is noted that there is a large degree of overlap 
in the types of coformers that are likely to form multicomponent crystals with each antiplasmodial agent. 
It is evident that carboxylic acids, in most cases, dicarboxylic acids, are most favourable in terms of 
forming multicomponent crystals with 1 to 5. This is not surprising, given that each antiplasmodial 
compound contains at least one nitrogen atom that can act as a hydrogen-bond acceptor for the OH 
moiety on the carboxylic acid coformer. Having said this, there are still a large number of possible 
carboxylic acid coformers that could have been used. This method, then, provided a starting point for 
which carboxylic acid coformers to try first. What is somewhat unexpected, however, is the inclusion 
of coformers such as indole, 4,4-bipyridine and pyrazine. As most of the functional groups on our 
molecules are hydrogen-bond acceptors, pairing them with other hydrogen-bond acceptors such as 
pyrazine does not seem likely to result in a multicomponent product. Here, however, it is likely that π-
π interactions would play a more dominant role if multicomponent products are obtained with these 
coformers. With our list in hand, we set out to validate this computational screening method by carrying 
out experimental cocrystallisations with these coformers to form multicomponent crystals.  
 
2.4 FORMATION OF MULTICOMPONENT CRYSTALS 
 
There are a number of methods that can be used to form multicomponent crystals.31 Two of the more 
popular methods are solvent evaporation or mechanochemistry. The antiplasmodial compounds in this 
study (especially 1, 4 and 5) are not very soluble in many organic solvents (with the exception of hot 
MeOH and DMSO). Therefore, while solution cocrystallisations would be possible, it is likely that the 
antiplasmodial agent would simple “crash out” of solution in each case, as it is substantially less soluble 
than the coformers. The use of mechanochemisty – grinding the components together – avoids solubility 
issues like these and is therefore a more versatile method. In addition, mechanochemistry is faster than 
solution-based methods for forming multicomponent products.32 For these reasons, mechanochemistry 
(and specifically liquid-assisted grinding methods) was chosen for our experimental screening, together 
with PXRD to analyse the outcome.  
Mechanochemical cocrystallisation can be carried out manually (using a mortar and pestle) or using a 
ball mill. We opted to make use of manual grinding, since considerably less sample is needed in 
comparison to the ball mill. In cases where cocrystallisation is successful, upscaling to form more 
product is then possible with the ball mill.  
For the purpose of this study, the top ten coformers for each drug molecule were chosen from the virtual 
screening to perform the experimental screening. Stoichiometric amounts (1:1 ratio) of each compound 
(10 mg) and coformer were thus ground together in a mortar and pestle for 5 minutes with a few drops 
of MeOH. While other ratios are certainly possible, we chose to start with a 1:1 ratio due to simplicity. 
This could be expanded to other ratios at a later stage should it be necessary. PXRD was then used to 
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determine whether a new form had been obtained or whether only a mixture of starting materials 
remained by comparing the PXRD pattern of the new powder to that of each individual component. The 
outcomes of the experimental screening are discussed below.  
Each of the five antiplasmodial compounds, as well as the coformers, were individually ground using 
the same conditions as described above to confirm that a new product (such as a polymorph, solvate, 
hydrate etc.) is not obtained simply by grinding the individual components. Grinding could also result 
in the amorphisation of the sample and therefore this needed to be established before beginning the 
cocrystallisation screening.33 In all cases, the PXRD pattern obtained after grinding the component 
matched that of the pre-ground material, indicating that no new or amorphous product is obtained from 
individual components under these conditions.  
 
2.4.1 Outcome of liquid-assisted grinding experiments 
 
For each grinding experiment, the PXRD pattern of the product was compared to that of the individual 
components to determine whether or not a new product was obtained. The PXRD patterns of the 
successful attempts can be found in Chapter 6 (page 134 to 140). The remaining combinations only 
yielded starting material after liquid-assisted grinding, even after grinding for an additional 5 minutes.  
As an example, one of the successful attempts are discussed in this chapter in detail, and a summary of 
the remaining successful combinations given. In Figure 2.7, the PXRD patterns of 4 (blue), pamoic acid 
(green) and the new multicomponent form obtained after grinding the components for 5 minutes in a 
mortar and pestle with a few drops of methanol (maroon) are shown. It can be seen that the new pattern 
does not correspond to a physical mixture that of the two individual components. It is also evident that 
there is no remaining starting material present in the product’s PXRD pattern, indicating that a 1:1 ratio 
of each component is present in the new multicomponent product.  
 
 
 
 
 
 
 
 
 
Figure 2.7: Comparison of the PXRD patterns of the two individual components, 4 (blue) and pamoic acid 
(PAM, green), and the new multicomponent form produced from LAG (4·PAM, maroon). 
 
4·PAM 
4 
PAM 
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In total, 19 new products were obtained, 13 of which were crystalline and 6 of which were amorphous, 
as determined by PXRD. This results in a 38% success rate in forming new multicomponent forms of 
these antiplasmodial agents with the top ten coformers identified by the computational screening. A 
summary of the successful attempts can be seen in Table 2.3 (for compounds 1 – 3) and Table 2.4 (for 
compounds 4 and 5). 
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Table 2.3: Outcomes of experimental screening of the top ten coformers with 1 – 3. 
Coformer* 
-∆E
(kJ mol-1) 
LAG 
outcome** 
Coformer* 
-∆E
(kJ mol-1) 
LAG 
outcome** 
Coformer* 
-∆E
(kJ mol-1) 
LAG 
outcome** 
OXA 12.1 MCC OXA 24.5 A OXA 14.6 MCC 
DHBA 9.0 SM DHBA 19.0 SM DHBA 10.7 MCC 
TRIM 8.4 A FUM 18.4 SM FUM 9.1 SM 
FUM 7.6 MCC TRIM 17.0 A IND 8.5 MCC 
PAM 6.9 SM MAL 16.8 SM PAM 8.2 SM 
RES 6.7 SM PAM 16.8 SM TRIM 8.1 SM 
IND 6.4 SM IND 16.2 SM RES 7.7 MCC 
MAL 4.9 SM RES 16.1 SM MAL 7.3 MCC 
TERE 4.9 MCC TERE 15.7 SM TERE 6.6 SM 
SAL 4.3 SM SUC 15.2 SM pABA 6.1 SM 
*Coformer codes: OXA – oxalic acid, DHBA – 3,5-dihydroxybenzoic acid, TRIM – trimesic acid, FUM – fumaric acid, PAM – pamoic acid, RES – resorcinol,
IND − indole, MAL – malonic acid, TERE – terephthalic acid; SAL – salicylic acid, , SUC – succinic acid, pABA – p-aminobenzoic acid.
**LAG outcome: MCC = new multicomponent crystalline material, A = amorphous product and SM = only starting materials remained after grinding.
1 2 3 
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Table 2.4: Outcomes of experimental screening of the top ten coformers with 4 and 5.  
  
Coformer* 
-∆E 
(kJ mol-1) 
LAG 
outcome** 
Coformer* 
-∆E 
(kJ mol-1) 
LAG 
outcome** 
OXA 15.5 MCC FUM 22.5 SM 
PAM 10.3 MCC OXA 18.4 A 
TRIM 10.0 MCC TRIM 13.5 SM 
BIPY 9.0 SM DHBA 13.2 SM 
PYZ 8.2 SM PAM 12.9 SM 
DHBA 8.1 SM RES 10.9 SM 
FUM 7.7 MCC IND 9.9 SM 
IND 7.5 MCC MAL 9.2 A 
RES 7.2 SM TERE 8.7 SM 
VAN 6.8 SM SUC 7.7 A 
*Coformer codes: OXA – oxalic acid, PAM – pamoic acid, TRIM – trimesic acid, BIPY – 4,4-bipyridine, 
PYZ − , pyrazine, DHBA – 3,5-dihydroxybenzoic acid, FUM – fumaric acid, IND – indole, RES – resorcinol, 
VAN – vanillin; MAL – malonic acid, TERE – terephthalic acid; SUC – succinic acid.  
**LAG outcome: MCC = new multicomponent crystalline material, A = amorphous product and SM = only 
starting materials remained after grinding. 
 
 
Compound 1 yielded four new multicomponent forms, all with carboxylic acid coformers. Three of 
these forms were crystalline and only one was amorphous. Compound 2 yielded only two 
multicomponent forms, both of which were amorphous. Compound 3 yielded five multicomponent 
forms, all of which were crystalline. Three of the coformers were carboxylic acids, while one was a 
phenol and the other an indole. Compound 4 yielded five new multicomponent crystals, all of which 
were crystalline. All except for one made use of carboxylic acids as coformers. Compound 5 yielded 
three multicomponent forms, all of which were amorphous and made use of carboxylic acid coformers. 
It is interesting that compounds 2 and 5 give only amorphous products, while 3 and 4 give only 
crystalline products. Since each component remains crystalline after grinding them separately under the 
same conditions, the formation of the multicomponent product for 2 and 5 is likely inducing 
amorphisation, rather than the grinding. For compound 2, the shape of the molecule or the fact that it is 
racemic could be influencing the amorphous outcome. Compound 5 contains the extended alkyl chain 
that, due to the rotational freedom, could be causing a disruption in the packing of these molecules in a 
uniform manner when the coformer is included. 
It should be highlighted that obtaining an amorphous multicomponent product is not considered a failure 
from a pharmaceutical point of view. Amorphous materials are often prepared using mechanochemistry 
 4 
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to improve the dissolution of a drug molecule.34–36 Unfortunately, obtaining amorphous material makes 
studying the intermolecular interactions challenging as they cannot be analysed with X-ray diffraction.  
For the 7 amorphous multicomponent forms, extended grinding times were also investigated because, 
in some cases, the formation of multicomponent forms of molecules are known to go through an 
amorphous phase before crystallisation as the new multicomponent form.37,38 In our case, however this 
was not observed after an additional 10 minutes of grinding. 
When comparing the outcomes of 2 and 3, the obvious difference is that 2 only forms two 
multicomponent forms (both of which are amorphous), while 3 forms five (all of which are crystalline). 
The ferrocene moiety in 2, in comparison to the phenyl moiety in 3, is likely the reason for this outcome. 
The bulkiness of the ferrocene moiety might be playing a role as well as the intra- and inter-molecular 
interactions in each compound. In the case of 2, the quinoline nitrogen atom is inaccessible through an 
intramolecular hydrogen bond with the NH moiety at the 4-position of the quinoline. While it is possible 
that some coformers could give rise to intermolecular interactions that are more favourable than the N–
H⋯N intramolecular interaction, it seems that for the majority of the coformers that we tried, this was 
simply not the case. In compound 3, however, this intramolecular interaction is not present, leaving that 
nitrogen atom available to interact with other molecules.  
When comparing compounds 4 and 5, it seems that the shorter side chain increases the ability of the 
compound to form crystalline multicomponent products. In addition, the additional rotational freedom 
of the side chain of 5 could be hindering efficient packing of the molecules during cocrystallisation.  
 
2.4.2 Characterising the new multicomponent products 
 
Attempts were made to form single crystals of each of the newly-formed multicomponent products by 
dissolving them in hot MeOH. In many cases, the product was insoluble in MeOH and therefore DMSO 
was used; however, this was also unsuccessful in dissolving many of the products. In cases where the 
product did dissolve, allowing the solvent to slowly evaporate did not yield any single crystals. In the 
majority of the attempts, a sticky residue was obtained that could not be analysed by PXRD. For some 
attempts, a powdered product was obtained and PXRD confirmed that the same product was formed as 
obtained in the liquid-assisted grinding (LAG) experiment. 
Because we could not obtain single crystals and therefore could not characterise these new products 
using single crystal X-ray diffraction, it was necessary to make use of other spectroscopic and analytical 
techniques to provide additional insight into these systems. Fourier-transform infrared (FT-IR) 
spectroscopy was used to establish if proton transfer had taken place between the carboxylic acid 
coformer and the antiplasmodial agent during the formation of the new multicomponent product. 
Studying the carboxylic acid/carboxylate stretch in the IR spectrum of the coformer and new 
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multicomponent product, we could suggest whether proton transfer had occurred or not.31 If proton 
transfer had occurred, the multicomponent product is classified as a salt, while if no proton transfer 
occurs, it is classified as a cocrystal. It should be noted that proton transfer is not always observed 
discretely, but that rather a continuum exists between the two extremes.39 Therefore it is also possible 
to observe partial proton transfer between the two components. In these cases, it is difficult to observe 
a distict shift in the C=O stretch on the FT-IR spectrum. 
The FT-IR spectra for the multicomponent products of each antiplasmodial agent with oxalic acid is 
shown as an example below. The carbonyl stretch of the carboxylic acid has shifted in wavenumbers 
after grinding, as highlighted by the blue shaded block in Figure 2.8. This blue shift indicates that proton 
transfer has taken place between the carboxylic acid moiety and one of the nitrogen atoms on the 
antiplasmodial agent. Unfortunately, it is difficult to say with certainty which nitrogen atom is acting as 
the hydrogen-bond acceptor; however, it is likely to be the tertiary nitrogen atom in the side chain as it 
is most basic in nature. In addition, the phenolic OH stretch of the carboxylic acid is no longer seen 
(green shaded area in Figure 2.7), which further indicates that a salt has formed. The FT-IR spectra for 
all multicomponent products obtained can be found in Addendum B (electronic supplementary 
information). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Comparison of the FT-IR spectrum of oxalic acid and the multicomponent forms obtained with 
compounds 1 – 5. Highlighted in the blue shaded block is the carboxylic acid/carboxylate C=O stretch region. 
Highlighted in the green shaded block is the carboxylic acid OH stretch region. 
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Table 2.4 summarises whether each multicomponent form obtained with carboxylic acid coformers in 
particular, is a salt or cocrystal, based on the shift in the carboxylic acid C=O stretch. For the majority 
of the multicomponent forms, proton transfer was evident. For 3·MAL and 4·PAM, no significant 
change in the carbonyl stretch was noted, indicating cocrystal formation. For 4·FUM and 4·TRIM, the 
shift in the peak was not as prominent and it is likely that partial proton transfer is occurring in these 
compounds.  
 
Table 2.4: Summary of multicomponent forms of 1 – 5 obtained with carboxylic acid 
coformers – salt versus cocrystal outcomes.  
Multicomponent 
form 
C=O stretch of 
coformer (cm-1) 
C=O stretch of 
multicomponent 
form (cm-1) 
Salt / coformer 
1·OXA 
1656 
1567 Salt 
2·OXA* 1592 Salt 
3·OXA 1588 Salt 
4·OXA 1578 Salt 
5·OXA* 1541 Salt 
1·FUM 
1658 
1567 salt 
4·FUM 1617 Salt/cocrystal† 
1·TRIM* 
1691 
1607 Salt  
2·TRIM* 1607 Salt 
4·TRIM 1646 Salt/cocrystal† 
3·MAL 
1693 
1697 Cocrystal  
5·MAL* 1539 Salt 
1·TERE 1673 1547 Salt  
3·DHBA 1681 1588 Salt  
4·PAM 1647 1637 Cocrystal  
5·SUC* 1683 1537 Salt 
* amorphous products 
† Shift in the C=O stretch is not as pronounced as for the other cases and it is likely that there is only 
partial proton transfer in these cases.  
 
 
Non-acidic coformers were used in the formation of 3·IND, 3·RES and 4·IND and therefore a salt is 
not likely to have formed. For 3·RES, the phenolic OH moiety of resorcinol is most likely hydrogen 
bonding to one of the nitrogen atoms in 3, resulting in the formation of a cocrystal. The IR spectrum of 
3·RES shows an OH-stretch at 3063 cm-1, slightly lower in wavenumber to that of the OH peak in 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2: Forming multicomponent crystals of known antiplasmodial agents 
   
62 | P a g e  
 
resorcinol. For 3·IND and 4·IND, the NH stretch at 3394 cm-1 of indole can be seen in the IR spectrum 
of 3·IND at 3397 cm-1, indicating no proton transfer.  
We also investigated the thermal stability of these systems in comparison to their individual components. 
This was carried out using TGA and DSC. Figure 2.9 shows the thermal analysis for 4·OXA in 
comparison to the two individual components. Oxalic acid melts at 102.5 °C, while 4 melts at 138.3 °C. 
The multicomponent form has increased thermal stability, with the first endotherm in the DSC being 
observed at 162.9 °C. This correlates to the melt (as observed visually with a melting point machine) 
and followed soon after by decomposition of the material. The thermal analysis for the remaining 
multicomponent forms can be found in Chapter 6 (page 141 – 150).  
 
 
 
 
 
 
 
Figure 2.9: Thermal analysis of 4·OXA in comparison to its individual components. The TGA trace of 4·OXA 
is shown in black, the DSC trace of 4·OXA is shown in maroon, the DSC trace of 4 is shown in blue and the 
DSC trace of oxalic acid is shown in green. 
 
For many of the multicomponent forms, an initial mass loss on the TGA indicated that solvent is 
removed upon heating. Calculations suggest that it is most likely H2O or MeOH, or a combination of 
both. This was also observed visually using a hot-stage microscope where a small amount of the powder 
was placed under oil and heated. Bubbles were observed at temperatures corresponding to the initial 
mass loss indicated in the TGA analysis, proving that MeOH or H2O was indeed being released. After 
the release of the MeOH or H2O molecules, a melt is observed on the DSC followed, often immediately, 
by the decomposition of the product.  
 
 
 
 
102.5 °C 
138.3 °C 
162.9 °C 
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2.5 CONCLUDING REMARKS 
 
This chapter investigated the formation of multicomponent crystals of five 4-aminoquinoline 
antiplasmodial agents. The compounds were synthesised using literature methods and characterised 
using NMR, IR, TGA, DSC, PXRD and in the case of 2 and 3, SCXRD. While the crystal structure of 
2 is known, the crystal structure of 3 has not been previously reported. Obtaining this structure allowed 
us to compare the solid-state interactions of 2 and 3 that provided insight into the differences in 
intermolecular interactions and solid-state packing between the two compounds. 
A total of 19 novel multicomponent forms of the five antiplasmodial agents were obtained, of which 13 
were crystalline and 6 of which were amorphous. This resulted in a 38% success rate in the 
computational screening method. While this figure is lower than the systems described by Hunter and 
coworkers,26–28 the systems in this study do not possess as many hydrogen-bonding sites as the ones in 
their studies. It is also likely that a larger screening pool may have yielded an alternative top ten list that 
could have resulted in a higher success rate. While not as successful as hoped, the method still proved 
useful in the choice of coformers.  
As the MEPS calculations are carried out in the gas phase and the experiments are carried out in the 
solid phase, it is possible that this is influencing this success rate. While sublimation (gas-phase) 
techniques are possible, its use as a screening tool is challenging because of the time involved as well 
as the optimisation of conditions that would be required to cocrystallise the two materials. Some organic 
molecules, especially larger ones, are unable to sublime and therefore render this technique impractical 
in the formation of multicomponent crystals.  
Comparing compounds 2 and 3 reveal that the ferrocene moiety (in 2) has a large influence on its ability 
to form multicomponent crystals. It could be that the racemic nature of 2 hinders the formation of 
multicomponent crystals or that the intra-and inter-molecular interactions in 2 are simply more 
favourable than the potential interactions between 2 and a coformer and this results in no 
multicomponent product formation.  
When comparing compounds 4 and 5, it was clear that the additional carbon atom in the side chain of 5 
played a considerable role in the compound’s ability to form multicomponent crystals. This could be 
due to increased rotational freedom that does not result in efficient packing with coformers, or that the 
shape complementarity between 5 and the coformer was not favourable.  
It is unfortunate that we were unable to obtain single crystals of any of the new products that formed, 
despite many attempts. This would have provided more detail about the ratio of components and how 
they interact in the solid state. By studying the FT-IR spectrum of each new product, we were able to 
suggest that the majority of the new products were salts (i.e. that proton transfer had taken place between 
the antiplasmodial and the coformer). 
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While various solution methods were employed in an attempt to form single crystals of these 
multicomponent products, the use of melt recrystallisation techniques could still yield suitable single 
crystals. A similar heating-cooling cycle has been used to induce crystallisation in amorphous material.40 
This method could be investigated as a possible way to obtained crystalline materials from the 
amorphous products that will allow us to study their interactions and properties in more detail. Should 
suitable single crystals not be obtained for any of the multicomponent products, solving the structure 
from PXRD (provided the sample is crystalline) is possible, however it would require high quality 
PXRD patterns (possibly using synchrotron radiation). While theoretically relatively simple, in practice 
it is considerably more challenging and often requires a great deal of knowledge and experience in the 
field to accurately determine a crystal structure by PXRD. For these reasons, this was not carried out as 
part of this work, however, future collaborations with research groups that do have the required facilities 
and experience would prove useful to further understand the solid-state chemistry of these systems.  
The next step would be to investigate the subsequent change in physicochemical properties (such as 
solubility) of each multicomponent product to determine what effect each coformer has on these 
properties. In addition, studying the effect that the coformer has on the in vitro efficacy and 
pharmacokinetic profiles of the parent drug molecule would be valuable. This, however, requires exact 
knowledge of the sample composition. In many of our multicomponent products, thermal analysis 
indicates that water, methanol or a combination of both are included in the structure. Without single 
crystal data, it is difficult to ascertain exact ratios of all components.  
While it is unfortunate that we were not able to obtain crystal structures of any of the multicomponent 
products to study them in more detail, this study has nonetheless provided valuable information on the 
types of coformers that form multicomponent products with these 4-aminoquinoline-based 
antiplasmodial agents. It also provides an excellent starting point for subsequent studies on other 
quinoline-based compounds. This study also shows that these systems warrant further investigation and 
that, in combination with other studies on similar compounds, sufficient insight can be gained that allows 
us to be one small step closer to the point where prediction of multicomponent product formation may 
be possible, at least for these types of systems.  
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CHAPTER 3 
Synthesis of ferrocene-containing analogues of lapatinib 
 
 
3.1 INTRODUCTION 
 
Since the formation of multicomponent crystals of five known antiplasmodial agents was successful 
using the combined computational and experimental approach described in Chapter 2, we decided to 
synthesise five novel antiplasmodial compounds and apply the knowledge gained through the 
computational and experimental techniques to form multicomponent crystals of these novel compounds. 
In this way we could study the structures and properties, such as efficacy and solubility, of these new 
compounds, as well as investigate their ability to form multicomponent crystals, and compare the 
properties of any multicomponent crystals obtained with those of the original compounds.  
Taking inspiration from the Pollastri laboratory in Boston, USA, we set out to make use of a target class 
repurposing strategy to synthesise derivatives of lapatinib as potential antiplasmodial agents. As 
previously discussed in Chapter 1 (page 11), target class repurposing involves the use of a previously-
approved drug (used to treat a specific disease or pathogen) as a starting point to synthesise new drug 
molecules. Lapatinib has been shown to inhibit Plasmodium species and therefore a series of medicinal 
chemistry optimisations have been performed to identify similar analogues with improved in vitro 
properties.1,2 While the target class repurposing approach hinders the option for “rational design”, it does 
provide the option to explore a broader target range and gives the opportunity to identify novel modes 
of action.3  
Through a target class repurposing strategy, extensive structure-activity relationship studies have been 
carried out on lapatinib by Pollastri and coworkers, on what is known as the “head” group (4-amino 
substituent), the “tail” (furan) group as well as the core scaffold (quinazoline).2,4,5 These three regions 
are illustrated in Figure 3.1, along with some examples of substituents that have replaced each region, 
in an attempt to improve some of the physicochemical properties. It has been shown that replacing the 
quinazoline core scaffold with a thiopyrimidine or an isoquinoline moiety decreases the efficacy against 
P. falciparum, whereas switching to a quinoline retains the efficacy.5,6 This suggests that β-hematin 
inhibition is at least one of the targets of these compounds; however, no studies have yet been performed 
to determine the targets or modes of action of these compounds. It should be noted that the EC50 values 
(concentration of a compound where 50% of its maximal effect is observed) for these compounds are 
still in the low micromolar range, indicating that there is most likely more than one target. Replacing 
the head group with more polar moieties, such as pyrimidines, pyridines and thiazoles, successfully 
improves solubility of these compounds; however, results in diminished efficacies.4 The tail region, 
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however, has been shown to be more tolerable to changes and a variety of substituents have replaced 
the furan tail of lapatinib without a substantial loss in efficacy. In most cases, substituted phenyl rings 
improve efficacies, while removing the group all together decreases efficacy against P. falciparum.2  
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Structure of lapatinib (left) and various substituents that have been used to replace each region on the 
molecule in structure-activity relationship studies. 
 
While a great deal of work has been carried out in this area, the use of metallocenes as “tail” moieties 
has not yet been studied. Motivated by the literature on ferrocenes and other metallocenes in 
antiplasmodial drug discovery7–9 we sought to investigate the effect of substituting the lapatinib furan 
tail with a substituted ferrocene moiety, as shown in Figure 3.2. As our goal was to improve the solubility 
through formation of multicomponent crystals, we opted for the head group that displayed the best 
efficacy, even if it meant that the solubility would not be optimal. Therefore, the lapatinib head group 
would be retained, as it shows the best efficacy against P. falciparum. 
 
 
 
 
Figure 3.2: Structure of lapatinib (left) and the incorporation of an aminoferrocene moiety (right) into the tail 
region (purple) of the structure. 
 
 
“Tail” group 
 
Substituted 
ferrocene moiety 
Lapatinib Target molecules for this work 
Lapatinib 
Core scaffold 
“Tail” group 
“Head” group 
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It has been shown that the ferrocene moiety plays an important role in the efficacy of ferroquine and 
that its position within the molecule is crucial.10,11 Furthermore, it has been established that it needs to 
be covalently bound to the molecule for improved efficacies against P. falciparum.12 Therefore, forming 
multicomponent crystals of drug molecules with coformers, such as aminoferrocenes, is not worthwhile. 
Rather, the incorporation of the moiety into the molecule prior to the formation of multicomponent 
crystals with these molecules could be more beneficial.  
The tail moieties in the majority of the lapatinib analogues described above were introduced onto the 
core scaffold by means of a palladium-catalysed Suzuki-Miyaura coupling reaction.5 This well-known 
reaction makes use of a palladium catalyst to form a carbon-carbon bond between an aryl halide 
fragment and an organoboronic acid species.13,14 The catalytic cycle (Figure 3.3) begins with the 
oxidative addition of the aryl halide species to the Pd(0) catalyst to form a Pd(II) complex. The boronic 
acid species is activated by the base, where after the transmetallation step takes place. Lastly, reductive 
elimination takes place, which yields the coupled product and regenerates the palladium(0) catalyst.  
 
Figure 3.3: The general reaction mechanism proposed by Lennox and Lloyd-Jones for the Suzuki-Miyaura 
coupling reaction.14  
 
Our goal was therefore to synthesise the following five compounds (Figure 3.4, 15a-e) through a 
palladium-catalysed Suzuki-Miyaura coupling reaction between boronic acids 16 and aryl halide 17. 
These amines were chosen as previous work conducted by members of our research group have shown 
improved efficacies with these amines (with other linkers).15,16 While ferroquine makes use of the 
dimethyl substituent (a), work by the Pollastri group that makes use of amino-substituted phenyl linkers 
have shown that the piperidyl (d) and morpholinyl (e) substituents also result in improved efficacies.2 
We were also interested in studying a series of these compounds to determine what effect small changes, 
such as these amine substituents, would have on the solid-state properties of these compounds, in 
addition to their efficacious properties. It should be noted that compounds 15a-e, like ferroquine, are 
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chiral due to the di-substitution on the ferrocene ring, as discussed in Chapter 2 (page 45). We would 
once again work with the racemic mixture in all cases.  
 
Figure 3.4: Target compounds for this study (15a-e) shown by way of retrosynthetic disconnection. 
 
Once synthesised and fully characterised, the compounds would be sent to the Pollastri group and their 
collaborators for efficacy testing against P. falciparum and also for solubility testing. We would then 
make use of the computational screening method described in the previous chapter to identify the 
coformers that would most likely form multicomponent crystals. Experimental screening with liquid-
assisted grinding would then be carried out with 15a-e and the structures and physicochemical properties 
of any multicomponent crystals obtained would be studied in detail.  
With our synthetic strategy in hand, we set out to synthesise the precursor molecules that would then be 
coupled together.  
 
3.2 SYNTHESIS OF THE PRECURSOR FRAGMENTS 
 
While an overview of the synthesis of these compounds is described here, full experimental details for 
each compound can be found in Chapter 6 (page 150 – 160). Fragment 17 and similar derivatives of 16 
have been previously reported in the literature2,17 and as a result, the synthesis of these compounds 
proceeded without incident and with minimal optimisation of reaction conditions required. For ease of 
reading, the synthesis has been divided into three parts – synthesis of the quinazoline core scaffold 
including the lapatinib head group (aryl halide fragment 17), the tail fragment (boronic acid fragment 
16) and finally, the Suzuki-Miyaura reaction to couple the two fragments.  
 
3.2.1 The aryl halide fragment (“core scaffold and head group”) 
 
The synthesis of the aryl halide fragment follows that described in the literature for the synthesis of 
lapatinib.5,17 In some instances, the literature procedures were modified and this is described here. The 
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formation of the quinazoline core scaffold could be achieved in a three-step synthesis as shown in 
Scheme 3.1.  
 
Scheme 3.1: Three-step synthesis of 4-chloro-6-iodoquinazoline (21). 
 
In the first step, commercially available anthranillic acid (18) was treated with an iodine solution under 
buffered conditions and allowed to stir at room temperature. After neutralisation, the crude product was 
recrystallised from hot MeOH to yield a brown crystalline solid in good yield (78%). Subsequent ring-
closure with formamide and ammonium formate afforded compound 20 as a brown crystalline solid in 
moderate yields (55%) after recrystallisation from hot methanol.  
The 1H NMR and FT-IR spectroscopic analysis confirmed that the formation of the 
desired product was successful. The proton at position 2 on the quinazolinone ring was 
observed as a singlet at 8.12 ppm on the 1H NMR spectrum. Three peaks were observed 
in the aromatic region, each integrating to 1H, which correspond to the remaining 
protons on the molecule. The spectroscopic data correlated well with that reported in the literature.2  
In addition, X-ray diffraction was utilised to obtain a crystal structure of 20 and confirms the position 
of the iodine atom on the molecule, as well as that the ring-closure was successful. The asymmetric unit 
and packing diagrams are shown in Figure 3.5. This compound was studied further in a separate project 
and its crystal structure will be discussed in more detail in Chapter 4.  
 
 
 
 
 
 
 
 
 
Figure 3.5: Structure of 20: (a) asymmetric unit and (b) packing diagram viewed down the b axis. 
 
It should be noted that 20 exists as a tautomer, as can be seen in Figure 3.6. In the solid state, analysis 
of the bond length of the carbonyl moiety and the C–N bonds of the ring indicates that only tautomer 1 
is observed. In solution however, the amide peak of tautomer 2 can be seen by 1H NMR spectroscopy 
(b) (a) 
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at 12.4 ppm, when polar/protic solvents such as CD3OD or DMSO-d6 are used. While non-polar/non-
protic solvents (such as CDCl3) may give a different outcome, this could not be tested as 20 is insoluble 
in CDCl3.  
 
 
 
 
Figure 3.6: Two tautomers of 20. 
 
Finally, 20 was refluxed in thionyl chloride (with catalytic DMF) under a nitrogen atmosphere for 
2 hours to give 6-iodo-4-chloroquinazoline (21) in moderate yield (58%).  
Analysis of the 1H NMR spectrum of 21 shows four aromatic peaks, each integrating for 
1H that corresponds to the four protons on the molecule. The absence of the carbonyl 
stretch in the IR spectrum is also noted. As expected, the spectroscopic data correlates 
well with the literature.2  
The next step was to synthesise the head group that would later be added onto the core scaffold. This 
required a two-step synthesis as shown in Scheme 3.2, starting from commercially available starting 
materials, 22 and 23.  
Scheme 3.2: Two-step synthesis of the head group to be attached to the quinazoline scaffold. 
 
Compound 22 was added dropwise to a solution of 23 and potassium carbonate in acetonitrile, and after 
stirring for 3 hours at 75 °C, the product was extracted and purified to give a pale yellow crystalline 
solid in excellent yields (90%). Subsequently, the reduction of the nitro group was carried out with zinc 
powder and ammonium chloride in a mixed solvent system to aid in the solubility of the reagents and 
yielded 25 in 84% yield. The spectroscopic data corresponds well with that in the literature.2  
The final step in the synthesis of the aryl halide fragment 17 was to couple 21 and 25 via a nucleophilic 
substitution reaction as shown in Scheme 3.3. The two fragments were stirred at 30 °C in 2-propanol 
overnight to yield a bright yellow product in good yield (81%). Spectroscopic data correlates well with 
that in the literature.2  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3: Synthesis of ferrocene-containing analogues of lapatinib 
 
74 | P a g e  
 
 
Scheme 3.3: Coupling the head group (25) to the core quinazolinone scaffold (21). 
 
It should be noted that while the quinazoline scaffold has effectively two positions for substitution 
(either at the position of the chlorine or iodine atom), substitution only occurs at the 4-position in this 
reaction. Similarly to quinoline scaffolds, the 4-position is significantly more reactive toward 
nucleophilic substitution when compared to the 6- or 7-positions. This is because of the nitrogen atoms 
present in the ring that facilitate a more favourable intermediate, as shown in Figure 3.7. While 
substitution at the 6-position on 21 is possible, it would require specialised reaction conditions (for 
example palladium-catalysed aminations.)18  
  
 
Figure 3.7: Mechanism for the nucleophilic substitution at the 4-position of 21. 
 
Having successfully synthesised the aryl halide fragment, we moved onto the synthesis of the boronic 
acid fragment. 
 
3.2.2 The boronic acid fragment 
 
The synthesis of the required boronic acid fragments could be carried out in two steps, as seen in Scheme 
3.4. Initially only two fragments (16a,d) were synthesised and used in subsequent steps. Once the 
Suzuki-Miyaura reaction was optimised, the other boronic acid fragments (16b,c,e) would be 
synthesised. 
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Scheme 3.4: Two-step synthesis of the various ferrocene boronic acid fragments. 
 
N,N-dimethylaminomethyl ferrocene (27a) is commercially available and had already been purchased 
for the synthesis of ferroquine (2) in the previous chapter. Therefore, it was not necessary to synthesise 
this analogue. The synthesis of 27d was carried out using a procedure described by Wu et al.3 They 
report the use of formaldehyde, pyrrolidine and phosphoric acid in acetic acid to form an iminium 
intermediate that reacts with ferrocene (26) via electrophilic aromatic substitution to form the desired 
amine product. Although a thorough attempt at optimising the reaction was carried out, they report low 
yields (<50%) due to the formation of a by-product (dipyrrolidinylmethane). We made use of their 
optimised reaction conditions to form 27d in comparable yields (51%), using piperidine rather than 
pyrrolidine.  
Analysis of the 1H NMR spectrum for 27d showed the characteristic Cp singlet of the 
ferrocene at 4.11 ppm, integrating for 5H, as well as the methylene protons as a singlet 
at 3.37 ppm, integrating for 2H. All other protons are accounted for. This data compares 
well with that in the literature.3,4  
It is well-known that the amine group on these ferrocene analogues acts as a strong ortho-director in 
lithiation reactions.19,20 As discussed in the previous chapter, t-BuLi is the preferred choice of metalation 
reagent over n-BuLi for these reactions due to shorter reaction times, leading to higher yields.21 
Aminoferrocenes 27a and 27d were thus treated with t-BuLi in diethyl ether at 0 °C, forming a bright 
orange precipitate (Scheme 3.4). After 2 hours, the reaction was quenched with trimethyl borate. 
Following workup, the boronic acid 16a and 16d were isolated in excellent yields. The spectroscopic 
data for 16a compared well with the literature values.5,6  
The 1H NMR spectroscopic analysis of 16d showed the Cp singlet of the 
ferrocene at 4.16 ppm (integrating for 5H) as well as the methylene protons at 
3.73 ppm, integrating for 2H. All other protons were accounted for. LC-MS 
showed a product mass correlating to [M+H]+ of 287.94 m/z, which compared 
well with the calculated value of 287.96 m/z.  
Having successfully synthesised the aminoferrocene boronic acid derivatives, we were ready to attempt 
the coupling reaction to provide the target compounds.  
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3.3 COUPLING THE FRAGMENTS TOGETHER 
 
While the Suzuki-Miyaura reaction is a robust and versatile method of performing carbon-carbon 
coupling reactions, it is known to frequently require substantial optimisation before the reaction 
produces the desired product in acceptable yields.22 Suzuki-Miyaura reactions require the use of a 
palladium catalyst, a base and a thoroughly degassed solvent system. For many cases, heat is also 
required to increase reaction rates and yields. The strength and amount of the base used plays an 
important role in the transmetallation step.23 The solvent choice influences not only the dissolution of 
starting materials, but can play a role in the reaction rate and/or selectivity of the reaction. In addition, 
it has been shown that by not degassing the solvent sufficiently, the yield can decrease dramatically or 
even promote the formation of unwanted side-products.24 The choice of catalyst has also been shown to 
have an effect on the yield of the desired product.25 
While deoxygenated reaction conditions are necessary, anhydrous conditions are not, and often these 
reactions make use of water as a co-solvent to facilitate the dissolution of reagents, especially the base.26 
Our initial attempt (shown in Scheme 3.5) made use of the reaction conditions carried out by Woodring 
et al. as they make use of the same aryl halide fragment (17).27 For this reaction, a solvent system of 
dimethoxyethane (DME), dioxane and water was used, along with potassium carbonate as a base and 
palladium tetrakis(triphenylphosphine) – Pd(PPh3)4 – as a catalyst. After heating at 80 °C overnight, 
TLC analysis indicated that a new product had formed. After workup and purification, 1H NMR analysis 
confirmed that the product obtained was not the desired product, but rather the dehalogenated starting 
material (Scheme 3.5, 15-H). This was also confirmed by mass spectrometry. Unfortunately, this 
product is a common occurrence with Suzuki-Miyaura reactions and reaction conditions need to be 
optimised in order to eliminate or at least reduce the formation of this unwanted product.28,29  
 
 
Scheme 3.5: Initial attempt at the Suzuki-Miyaura reaction to couple 17 and 16a. Insert (right): dehalogenated 
starting material (15-H) obtained instead of the desired product.  
 
The literature reports that the choice of base and solvent can have a large effect on the formation of the 
dehalogenated product.28 In addition, other factors such as temperature and increased equivalents of the 
boronic acid species have also been shown to reduce the formation of side-products and to improve 
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yields of the desired product.30 We investigated a number of solvent mixtures, bases and catalysts in an 
attempt to obtain the desired product (Table 3.1). The use of a nickel catalyst was also attempted as 
recent literature has shown that these catalysts have been successfully used in some Suzuki-Miyaura 
reactions.31,32 Microwave reaction conditions are also popular in the literature as it allows for higher 
temperatures in comparison to conventional heating and faster reactions times that could lead to the 
reduction of by-product formation or degradation.33,34 We therefore also made use of this technique in 
our optimisation process. Disappointingly, we were unable to obtain any of the desired product from 
these attempts.  
At this point we were planning a three-month research visit to the Pollastri laboratory in Boston and we 
decided to make use of their expertise and knowledge of similar reactions in an attempt to understand 
what was happening in our reactions and how we could obtain the desired product. Starting materials 
were synthesised in our laboratory and couriered there. It should be noted that their laboratory makes 
use of in-house LC-MS analysis to monitor reactions (rather than TLC analysis as in our case). This 
allows us to more accurately track even trace quantities of product formation that would not be possible 
using TLC analysis. This has the advantage of quickly and reliably determining all products that are 
formed.  
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Table 3.1: Conditions for Suzuki coupling of 16 and 16a. 
 
Attempt Solvent systema 
Base 
(3 eq) 
Catalyst 
(10 mol%) 
Reaction 
conditionsb 
Outcome 
(according to 
TLC analysis) 
1 DME/dioxane/H2O K2CO3 Pd(PPh3)4 80 C, 18 h 15-H 
2 Dioxane/EtOH/H2O Cs2CO3 Pd(PPh3)4 80 C, 18 h 15-H 
3 DME/EtOH/H2O Cs2CO3 Pd(dppf)Cl2 80 C, 18 h 15-H 
4 DME/EtOH/H2O NaOH Pd(dppf)Cl2 70 C, 18 h 15-H 
5 DMF/H2O K2CO3 Pd(dppf)Cl2 100 C, 2 d 
starting material 
and 15-H 
6 Dry EtOH/ Toluene Et3N Pd(dppf)Cl2 85 C, 18 h starting material 
7 Dry EtOH/Toluene Et3N Pd(PPh3)4 85 C, 18 h starting material 
8 Dry dioxane K2CO3 Pd(dppf)Cl2 115 C, 18 h 15-H 
9 Dioxane/MeOH K3PO4 1,2-Ni(dppe)Cl2 110 C, 24 h starting material 
10c DME/dioxane/H2O K2CO3 Pd(dppf)Cl2 
MW, 110 C, 
30 min 
starting material 
11 c DMF/H2O K2CO3 Pd(dppf)Cl2 
MW, 150 C, 
2 h 
degradation – 
multiple spots 
on TLC 
12 c EtOH/H2O K2CO3 Pd(PPh3)4 
MW, 110 C, 
30 min 
dehalogenation 
and starting 
material 
a 
Solvent and reagent mixture was degassed using the freeze-pump-thaw method (4 cycles) before catalyst was 
added.  
b 
Reactions were carried out in a Schlenk tube that had been purged and refilled with nitrogen gas before use. 
c
 Reactions carried out in a microwave reactor. 
  
 
Initially, the reaction depicted by entry 1 in Table 3.1 was repeated to confirm that dehalogenation occurs 
and that it is indeed the only product that forms. Our next step was to determine which fragment (the 
aryl halide or ferrocene boronic acid) was hindering the formation of the desired product. To this regard, 
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two small-scale test reactions were performed, as shown in Scheme 3.6. In each case, the solvent system 
was degassed by bubbling nitrogen gas through the mixture for 20 minutes before adding the reagents. 
Commercially available PdCl2(dppf)·DCM adduct was used as the catalyst and potassium carbonate as 
the base. The reaction was heated to 80 °C overnight, after which LC-MS was used to analyse the 
product mixture.  
 
 
 
 
 
 
 
 
Scheme 3.6: Two test reactions performed to determine which fragment was hindering the formation of the 
desired product in the Suzuki reactions. 
 
LC-MS analysis confirmed that only starting material remained in test reaction 1. It should be noted that 
the dehalogenated product (in this case benzene) is not observable by LC-MS or TLC analysis and 
therefore we cannot say whether this product is forming or not. The conversion of 17 to 31 (test reaction 
2) has been previously carried out by the Pollastri group,27 but was performed again to confirm that the 
catalyst and reaction conditions were adequate for these types of reactions. Because the focus was on 
reaction optimisation to yield desired products, 31 was not isolated and purified; however, LC-MS 
confirmed that the dehalogenated by-product was not forming and that the desired product was obtained 
([M+H]+ = 457.0 m/z). These reactions were also performed under microwave conditions, where the 
reaction mixture was irradiated at 100 °C for 30 minutes with stirring. LC-MS analysis yielded similar 
results to that of the conventional heating method. As the microwave reactions provided the same 
outcome in substantially shorter reaction times, this method was used for future reaction optimisations. 
These two reactions seemed to indicate that the problem was not the halide fragment, but rather the 
ferrocene boronic acid that was perhaps not undergoing the transmetallation or reductive elimination 
step in the required manner to facilitate the formation of the coupling. Instead, the favoured reaction 
seems to be the incorporation of a proton instead of the ferrocene moiety. This could be due to a number 
of reasons, some of which could include electronics of the system, sterics at that site or simply 
unfavourable reaction conditions.  
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We therefore set out to perform a series of test reactions with various reaction conditions to see if this 
was possibly the culprit. Table 3.2 summarises our attempts at forming the desired product with this 
simpler system. Each of these reaction conditions were obtained from literature that reports Suzuki 
coupling with similar ferrocene systems.35–39 While the use of the more common reaction conditions 
(attempts 1 – 2) did not yield any of the desired product, the use of barium hydroxide as the base and 
palladium acetate as the ligand-free catalyst proved to be successful, with the desired product mass 
detected with LC-MS analysis of the crude product mixture ([M+H]+ = 320.14 m/z). Unfortunately, 
starting material also remained even after prolonged reaction times. A second attempt at this reaction 
using a higher temperature (140 °C instead of 100 °C) did not result in reaction completion either.  
 
Table 3.2: Conditions for Suzuki coupling of 16a and 28. 
 
Attempt Solvent system* Base Catalyst 
Outcome (according to 
LC-MS analysis) 
1 Dioxane/H2O  K2CO3 PdCl2(dppf)·DCM Starting material 
2 Dioxane/H2O  NaOH PdCl2(dppf)·DCM Starting material 
3 Dioxane/H2O  Ba(OH)2 PdCl2(dppf)·DCM Starting material 
4 EtOH/H2O  Ba(OH)2 Pd(OAc)2 
29 as well as starting 
material  
*Solvent was degassed by bubbling nitrogen gas through the mixture for 20 minutes.  
 
Satisfied that we had found reaction conditions for this system that allowed the formation of the desired 
product, albeit without reaction completion, we attempted the coupling reaction between 16a and 17 to 
form 15a, but this time using these new reaction conditions (Scheme 3.7). Unfortunately, it seems that 
this system is more complicated than initially suspected, as again none of the desired product was 
formed. Once again, dehalogenation of 17 seemed to be favoured.  
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Scheme 3.7: Repeating the coupling between 2a and 3 with new reaction conditions. 
 
With this outcome, we decided that perhaps it would be more worthwhile to modify our approach. Our 
next strategy was to switch the coupling partners to see if this would be more successful. To this end, 
we would need to synthesise an iodoferrocene derivative, as well as convert the aryl halide to the 
corresponding aryl boronic acid, before carrying out the Suzuki reaction. The same product would be 
obtained, but it was hoped that this approach favours the formation of 15, instead of the dehalogenated 
product.  
 
3.4 PLAN B - SWITCHING THE COUPLING PARTNERS 
 
The synthesis of the iodoferrocene fragment follows similar chemistry to that used to synthesise the 
boronic acid fragment, however, instead of using trimethyl borate as the electrophile, 1,2-diiodoethane 
was used (Scheme 3.8). This resulted in the formation of the desired product in quantitative yields. As 
more of 27d was available at the time, this was used for the synthesis of the iodoferrocene (32) required 
for the Suzuki-Miyaura reaction.  
 
 
 
Scheme 3.8: Synthesis of iodoferrocene 32. 
 
The 1H NMR spectroscopic analysis of 32 shows the characteristic Cp singlet of 
ferrocene at 4.17 ppm that integrates for 5H. The protons associated with the piperidyl 
ring are accounted for, along with all other protons. LC-MS [M+H]+ gives 410.07 m/z; 
calculated gives [M+H]+ = 410.09 m/z. The desired product was obtained as a dark red-
brown deliquescent solid. The material was stored under high vacuum and weighed out quickly into the 
reaction vial when needed for subsequent reactions.  
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With our iodoferrocene fragment in hand, we initially set out to perform test reactions with a simple 
system – similar to that carried out earlier – to determine whether this modification would lead to the 
preferential formation of the desired product over the dehalogenated product. To this end, 32 was reacted 
with phenyl boronic acid 30 using the reaction conditions outlined in Scheme 3.9 and the reaction 
monitored using LC-MS. The reaction yielded roughly a 1:1 ratio of desired product to dehalogenated 
product as determined by the areas under each peak on the LC-MS. While the dehalogenated product 
still forms, it is in lower amounts in comparison to previous reactions and therefore this route seemed 
to at least partially solve some of our initial challenges.  
 
 
 
Scheme 3.9: Suzuki-Miyaura reaction with 32 and phenyl boronic acid (30). 
 
With this reaction proving more successful than previous ones, we continued on to the next step of 
synthesising the aryl boronic acid fragment. While synthesising this fragment has been carried out 
before, the Pollastri group recommended a one-pot borylation and Suzuki coupling instead, as the 
isolation and purification of the boronic acid can be challenging.27 This involved synthesising boronic 
ester 34 and then performing the Suzuki-Miyaura coupling with 32 without first purifying 34, as shown 
in Scheme 3.10.  
  
 
 
 
 
 
 
Scheme 3.10: One-pot borylation and Suzuki-Miyaura coupling reaction to form 15d. 
 
Bis(pinacolato)diboron was used as the borylating agent because it has been shown to be one of the 
more stable boronate species.40 The borylation was carried out under inert microwave conditions using 
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dry dioxane, potassium acetate and PdCl2(dppf)·DCM. After heating for 1 hour, LC-MS confirmed that 
the reaction had gone to completion and that the desired product was obtained. The reaction mixture 
was then filtered through Celite, concentrated under reduced pressure and the second step of the reaction 
was carried out. After heating for 30 minutes, the reaction was cooled and LC-MS analysis revealed 
that, while the reaction had not yet gone to completion, the desired product mass was detected (Figure 
3.8). Unfortunately, the dehalogenated product was also obtained. Despite some optimisation attempts, 
including longer reaction times and increased catalyst loading, the reaction never went to completion.  
While we were disappointed that we were unable to further optimise the reaction, we were nonetheless 
happy that we were finally able to detect the desired product. Our next step was to isolate and purify the 
product. Unfortunately, we were unable to isolate the product by flash column chromatography. It is 
suspected that either the product degraded on the column (many peaks were observed on the 
chromatogram) or that the product yield was simply too low to isolate using this method. Upscaling the 
reaction to 500 mg-scale did not improve the outcome. Attempts were also made to purify the product 
by means of preparative HPLC, but again the product could not be isolated.  
 
Figure 3.8: Mass spectrum of the peak corresponding to product formation. Peaks identified include that of 15d 
([M+H]+ = 662.22 m/z), hydrolysed boronic acid starting material ([M+H]+ = 424.16 m/z) and the [M+2]/2 
fragment associated with 15d. The peak at 567.13 m/z does not correspond to the fragmentation of any of the 
reagents or the desired product. 
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Having been unable to isolate 15d, and having to leave the Pollastri laboratory, it was decided to 
abandon further attempts at the synthesis of these compounds. Given that we had only been able to 
confirm the product formation through LC-MS analysis, any optimisation of these reactions without 
easy and frequent access to an LC-MS instrument would be challenging.  
Other methods to obtain the desired product include the use of a Negishi reaction that makes use of a 
zinc chloride intermediate instead of the boronic acid fragment in a similar palladium-catalysed coupling 
reaction.41,42 Furthermore, the use of mechanochemistry – the use of mechanical force to perform 
reactions – has also become popular in organic synthesis as a faster and greener way of synthesising 
compounds.43,44 In addition, it has been shown that the use of mechanochemistry has led to the formation 
of desired products when conventional solution methods fail.45,46 While both these methods were also 
investigated in our attempt to synthesise 15d, neither yielded any fruitful outcome; therefore they are 
not discussed further in this thesis. It was therefore decided to modify our target compounds slightly to 
include a linker between the quinazoline scaffold and aminoferrocene in the hope that it would aid in 
the coupling of the two fragments.  
 
3.5 MODIFYING OUR TARGET COMPOUNDS 
 
Instead of a direct carbon-carbon bond linking the two fragments, it was thought that making use of an 
amine (35) or amide (36) linker could be worthwhile. Looking at the retrosynthesis of these compounds 
(Figure 3.9), it can be seen that in both cases, an amine moiety on the quinazoline scaffold would be 
necessary. For the synthesis of 35, an aldehyde would be needed to perform the reductive amination 
reaction to yield the amine-linked product, while in the case of 36, a carboxylic acid would be needed 
in the amidation reaction to give the amide-linked product. While the coupling partners could also be 
switched (having the amine moiety on the ferrocene fragment and the carbonyl moiety on the 
quinazoline scaffold), the proposed approach has the benefit of only requiring the synthesis of three 
fragments instead of four. In addition, the ferrocene chemistry performed in reactions described 
previously (Schemes 3.4 and 3.8) could also be applied to the synthesis of 37 and 39. Lastly, the 
formation of the carbonyl group at the 6-position of the quinazoline ring would be far more challenging 
than incorporating an amine into this position.  
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Figure 3.9: Retrosynthetic strategy to form 35 and 36 where a-e are the derivatives with each of the amines 
discussed previously. 
 
With our new targets and synthetic strategy in mind, we set off to synthesise the two new fragments. 
The synthesis of ferrocene carboxaldehyde 37a had already been carried out and ferrocene carboxylic 
acid 39a has been previously reported in the literature.21  
While the synthesis of 38 follows a similar procedure to aryl halide fragment 17, slightly different 
procedures were initially followed to introduce a nitro moiety that would later be reduced to the amine 
derivative. In this case, the quinazolinone ring scaffold was first formed by reacting 18 with formamide 
and ammonium formate before carrying out the electrophilic aromatic substitution reaction to 
incorporate the nitro group (Scheme 3.11). Spectroscopic data for 40 and 41 correspond well with that 
obtained in the literature.47  
Scheme 3.11: Three-step synthesis of 42 starting from commercially available anthranilic acid (18). 
 
The chlorination of 41 to yield 42 using thionyl chloride and catalytic DMF initially gave poor yields 
(<40%); however, first recrystallising 41 from MeOH resulted in a substantial improvement of the yield 
to above 70%. During one of these recrystallisation attempts, it was noticed that two differently-shaped 
crystals grew in the same vial (Figure 3.10). Analysis of the 1H NMR spectrum of this sample confirmed 
that there was no contaminant, with a small amount of methanol solvent present. Single crystal X-ray 
diffraction of the block and needle-shaped crystals revealed that a close-packed (41) and solvated form 
(41·MeOH) had grown from the same solution. The asymmetric unit and packing diagram for each form 
can be seen in Figure 3.10, but these structures will only be discussed in more detail in Chapter 4.  
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Figure 3.10: (a) Photograph of the crystallisation vial containing the two forms of 41, (b) asymmetric unit of 41, 
(c) packing diagram of 41 viewed down the a axis, (d) asymmetric unit of 41·MeOH, (e) packing diagram of 
41·MeOH viewed down the a axis with MeOH molecules shown in green for clarity. 
 
Because the solvent within 41·MeOH would influence the yield of the chlorination reaction, attempts 
were made to obtain only the close-packed form in order to continue our synthetic strategy. It was found 
that by dissolving crude 41 in hot MeOH and placing the vial in the fridge overnight, only the close-
packed form was obtained. Further discussion on this, as well as attempts in obtaining only the solvated 
form can be found in Chapter 4.  
As shown in Scheme 3.12, once 42 had been synthesised and purified, the head group could be attached 
in a similar procedure described previously (Scheme 3.3). This afforded 43 in good yields of 86%. 
Finally, the reduction of the nitro group would yield the desired amine fragment. For this we made use 
of the same procedure as described in Scheme 3.4. Unfortunately, this was unsuccessful and only starting 
material remained after 24 hours. Increasing the temperature from 40 °C to 60 °C also did not result in 
the formation of any product. The use of the more standard combination of Pd/C and H2 (or hydrazine) 
as a reducing agent could not be used in this case as the fluorobenzyl moiety would be cleaved from the 
head group in a benzyl deprotection-type reaction.48  
 
 
 
Scheme 3.12: Coupling head group 24 to 42.  
  
We therefore decided to attempt the reduction before adding the head group (Scheme 3.9). Initially we 
attempted the reduction on 41 using zinc and ammonium chloride, but again only starting material 
Needle-shaped crystals Block-shaped crystals 
(c) (e) 
(a) 
(b) (d) 
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remained, even at elevated temperatures (60 °C). Using Pd/C and hydrazine as the reducing agent also 
did not result in the formation of the desired product 42. 
 
 
 
 
 
Scheme 3.13: Two methods for the reduction of 42.  
 
Carrying out the reduction on 41 to give 4-amino-quinazolinone 45 using Pd/C and hydrazine was 
somewhat successful (23% yield), however the remaining steps in the synthesis (especially the 
chlorination step) could not be performed with the amine present and therefore this route was not useful 
for obtaining the required aminoquinazoline fragment.  
 
 
 
Scheme 3.14: Two methods for the reduction of 41. 
 
3.6 CONCLUDING REMARKS 
 
This chapter describes our attempts toward the synthesis of novel lapatinib analogues that contain an 
aminoferrocene substituent. Our initial strategy employed a Suzuki-Miyaura reaction to couple the 
aminoferrocene boronic acid fragment to the 6-iodoquinazoline scaffold using a palladium catalyst. 
After numerous attempts at modifying the reaction conditions, including the use of various solvent 
systems, bases and catalysts, the desired product could not be obtained. Instead, only the dehalogenated 
quinazoline by-product or a mixture of starting materials was obtained.  
Our next approach was to switch the coupling partners where the iodo-aminoferrocene fragment was 
reacted with the pincolboronate quinazoline scaffold. After a number of attempts, we were finally able 
to detect the desired product mass using LC-MS, when Pd(OAc)2 was used as a catalyst together with 
Ba(OH)2 as a base and EtOH/H2O (3:1) as the solvent system. However, even after additional 
optimisation of the reaction conditions as well as simply upscaling the reaction, the desired product 
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could not be isolated. This is most likely because the amount of product produced was in trace amounts 
and the purification techniques used were just not sensitive enough to detect (and isolate) the desired 
product. It is currently unclear as to why this reaction does not produce higher yields. While it would be 
interesting to study this system further to pinpoint where the problem lies, it was not within the 
objectives of this work to spend time on this. As the focus was on the formation of multicomponent 
crystals, we rather turned our focus to similar analogues that could provide us with sufficient amounts 
of product to carry out cocrystallisations.  
We therefore set out to synthesise an amine-linked analogue that made use of reductive amination to 
couple the aminoferrocene carboxaldehyde to the 6-aminoquinazoline scaffold. Again problems were 
faced, but this time in the synthesis of the aminoquinazoline scaffold. After several attempts at 
performing the reduction reaction to convert the nitro group into the required amine, we were once again 
forced to abandon this strategy.  
There are multiple other methods that could potentially be used to synthesise some of the desired 
compounds or analogues thereof, but we were not hopeful that they would prove successful. Many of 
these other methods such as Sonigashira coupling (using an aryl halide and an alkyne) or Stille coupling 
(using an aryl halide and an alkyl tin reagent) all make use of palladium chemistry in a similar manner 
to that of the Suzuki-Miyaura reaction. While we cannot say for certain that these reactions wouldn’t 
work, we felt that our resources could be better spent elsewhere.  
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CHAPTER 4 
Forming multicomponent crystals of quinazolinones 
 
 
4.1 INTRODUCTION 
 
To remind the reader, one of the synthetic strategies carried out in the previous chapter is shown in 
Scheme 4.1 below. During the synthesis of the precursor analogues described in the previous chapter, 
an interesting observation was noted. In an attempt to purify 41, the crude material was dissolved in hot 
methanol and allowed to stand overnight to recrystallise. Upon returning, two differently-shaped crystals 
were observed in the same vial and, after using single crystal X-ray diffraction to obtain their structures, 
it was confirmed that two different forms of 41 grew concomitantly from the solution (see Figure 3.10 
on page 86). The two forms (Figure 4.1) were the close-packed structure of 41 (needle-shaped crystals) 
and a methanol solvate of 41 (block-shaped crystals). 
 
 
 
 
 
Scheme 4.1: Two-step synthesis of 41 starting from commercially available anthranilic acid (18). 
 
  
 
 
Figure 4.1: Structure of (a) 41 and (b) 41·MeOH obtained from single crystal data. 
 
As mentioned in the previous chapter, other derivatives of this quinazolinone have been synthesised as 
part of this thesis. We were able to obtain single crystal data for two other derivatives, namely the 
6-iodoquinazolinone (20) and 6-aminoquinazolinone (45). The unsubstituted quinazolinone (40) was 
also synthesised, however single crystals could not be obtained, despite numerous attempts. This 
included using various solvents (and layering techniques) as well as the use of sublimation. In each case, 
no crystals suitable for single crystal X-ray diffraction were obtained.  
   
(a) (b) 
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We therefore have a series of 6-substituted quinazolinones (Figure 4.2) that we can use in order to study 
what effect small changes to the molecule has on its ability to form multicomponent crystals. Before 
beginning this study, we searched the Cambridge Structural Database (CSD) to see whether these 
compounds’ crystal structures have been reported before, and whether they have been used to form 
multicomponent crystals with small organic coformers. In addition, we searched for similar derivatives 
that have been studied to potentially compare to any results we obtain. 
 
 
 
Figure 4.2: Structures of the four quinazolinones used in this study. 
 
Compound 40 forms three multicomponent crystals with terephthalic acid (CSD refcode: AYIWIQ), 
picric acid (CSD refcode: OWIXAU) and 5-aminoisophthalic acid (CSD refcode: WEFKID). In each of 
the three multicomponent crystals, there is a hydrogen-bond between the carboxylic acid moiety of the 
coformer and the tertiary nitrogen atom of the quinazolinone. In the case of picric acid, proton transfer 
has occurred, resulting in a charge-assisted hydrogen bond. Figure 4.3 shows the main hydrogen-
bonding interactions linking each molecule in the structure. No crystal structures were found for any of 
the quinazolinones by themselves or for any multicomponent crystals with 20, 41, and 45.  
  
 
 
 
 
 
 
 
 
Figure 4.3: Main hydrogen-bonding interactions in (a) AYIWIQ, (b) OWIXAU and (c) WEFKID. 
 
(a) (b) 
(c) 
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While these specific quinazolinone derivatives have not been tested for their efficacy against 
P. falciparum, various substituted quinazolin-4-(3H)-ones have been reported in the literature to have 
moderate to good efficacies.1,2 Therefore studying the solid-state properties of compounds such as the 
ones described above, as well as their ability to form multicomponent crystals, are warranted and would 
be valuable. Investigating the types of intermolecular interactions formed by these quinazolinones will 
contribute to the current knowledge in the crystal engineering field that will one day allow for accurate 
predictions and tailored multicomponent crystals.  
 
4.2 THE 6-SUBSTITUTED QUINAZOLINONES 
 
4.2.1 6-Nitroquinazolinone – 41 and 41·MeOH 
The close-packed form of 41 grew as needles in the triclinic space group P. An amide-amide hydrogen 
bond links two molecules to form a dimer with a N–H⋯O bond distance of 2.789 . These dimers then 
pack alongside each other to form a sheet, and these sheets stack to form the three dimensional structure. 
(Figure 4.4). Weaker interactions, such as the two C–H⋯O hydrogen bonds (3.416  and 3.530 ) 
between the oxygen atoms of the nitro moiety and the C–H moiety of a second molecule of 41. In 
addition, offset π-π interactions (centroid to centroid distance of 3.906 ) between two molecules 
contribute to the overall packing of this molecule in the solid state. Additional hydrogen-bonding 
interactions can be found in Chapter 6, page 160. Selected crystallographic details for this structure can 
be found in Table 4.1. 
 
Figure 4.4: (a) Hydrogen-bonded dimer of 41 and (b) packing diagram of 41 viewed down the a axis. 
 
The methanol solvate, 41·MeOH, packs in the monoclinic space group P21/c with one molecule of 41 
and one molecule of MeOH per asymmetric unit (Figure 4.5). Instead of the amide-amide hydrogen 
bond (as in the close-packed form), an N–H⋯O hydrogen bond (2.773 ) links 41 to the methanol 
molecule, which, in turn, hydrogen bonds to a second molecule of 41 (via the tertiary quinazolinone 
nitrogen atom) to form chains of molecules. There is also an additional hydrogen bond between the 
(a) (b) 
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carbonyl oxygen atom of one molecule of 41 and the C–H between the two quinazolinone nitrogen 
atoms of a second molecule. These chains pack alongside each other to form layers, which is held 
together by face-to-face π-π interactions (with centroid to centroid distances of 3.984 ). Additional 
hydrogen-bonding interactions can be found in Chapter 6, on page 168. Selected crystallographic 
information can be found in Table 4.1.  
The quinazolinone molecules pack in such a way as to incorporate the methanol molecules in channels 
that run down the a axis. By deleting these methanol molecules in Mercury3–5 and mapping the contact 
surface using a probe radius of 1.2  and a grid spacing of 0.7 , it can be seen that the molecules 
indeed do form channels (volume of 194 3), as shown in Figure 4.5c.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: (a) Hydrogen-bonded chain of 41 and MeOH molecules; (b) packing diagram of 41·MeOH viewed 
down the a axis, with MeOH molecules shown in green for clarity; (c) packing diagram of 41·MeOH viewed 
down the a axis that shows the contact surface (in yellow) of the channels calculated in Mercury using a probe 
radius of 1.2.  
 
Initially we investigated whether we could obtain the two forms separately. To this end, we dissolved 
20 mg of the crude powder in hot methanol and placed the vial in the fridge (4 °C) overnight. The next 
morning, only needle-shaped crystals were obtained (as confirmed by unit cell and PXRD analysis). 
Attempts were then made to obtain only the methanol solvate. Because the close-packed form appears 
to be the kinetically favoured product, we opted for a slower cooling period. The nitroquinazolinone 
(a) 
(b) (c) 
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powder was dissolved in methanol at 60 °C in an oil bath. Once 41 was completely dissolved, the heat 
was turned off, but the vial was left in the oil bath to slowly cool to room temperature. This unfortunately 
resulted in the formation of a mixture of the forms, even when recrystallised 41 was used instead of the 
crude powder. It was later found that by eliminating water from the solution (by using dry methanol and 
a Schlenk tube filled with nitrogen) as well as by seeding the solution with crystals of the solvate, we 
were able to increase the amount of the solvate produced, but never form it exclusively, even when using 
the slow-cooling method described above.  
Despite the methanol being hydrogen bonded to the framework, the solvent appears to readily escape, 
as the crystals become opaque after a few hours after removing them from the mother liquor. This was 
confirmed by thermogravimetric analysis (TGA), where a mass loss roughly correlating to one methanol 
molecule per asymmetric unit is observed (see Chapter 6, page 170) Once the methanol is removed, the 
framework reverts to the close-packed form, as confirmed by PXRD.  
 
4.2.2 6-Aminoquinazolinone – 45 
Compound 45 (Figure 4.6) packs in the orthorhombic space group Pca21 with two molecules per 
asymmetric unit. A similar hydrogen-bonding pattern between the amide moieties can be seen for 45 as 
was seen for 41 (Figure 4.4 and Figure 4.5), with a N–H⋯O hydrogen bond distance of 2.814  and 
2.828 . The dimers are linked via an N–H⋯N hydrogen bond between the amino moiety of one 
molecule and one of the quinazoline nitrogen atoms of a second molecule. Pairs of hydrogen-bonded 
molecules stack to form columns, held together by offset π-π interactions (with centroid to centroid 
distance of 3.564 ). Alternating columns are at 90° to each other. The columns are linked by the N–
H⋯N hydrogen bonds.  
 
 
 
 
 
 
Figure 4.6: (a) Packing of 45 viewed down b axis and (b) hydrogen-bonded sheet of molecules of 45 
viewed down the c axis. 
 
 
(b) (a) 
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4.2.3 6-Iodoquinazolinone – 20 
Compound 20 packs in the monoclinic space group P21/n with one molecule in the asymmetric unit. 
Similar hydrogen bonding between the amide moieties can be seen for 20 as in 41 (Figure 4.7), with a 
N–H⋯O hydrogen bond distance of 2.778 . Similarly to 45, the dimers π-stack (centroid to centroid 
distance of 3.493 ) in alternating columns down the a axis, but here are linked together by halogen 
bonds between the iodine atom of a molecule in one column and one of the nitrogen atoms of a molecule 
in a neighbouring column (N⋯I bond distance of 3.057 ) (Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: (a) Hydrogen-bonded chain of 20; (b) packing of 20 viewed down the a axis; (c) packing of 20 
viewed down [1 -2 0]. 
 
 
 
 
 
 
(a) 
(b) (c) 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4: Forming multicomponent crystals with quinazolinones 
 
98 | P a g e  
 
 
Table 4.1: Selected crystallographic details for 41, 41·MeOH, 45 and 20. 
 41 41·MeOH 45 20 
Molecular formula C8H5N3O3 C8H5N3O3·CH4O C8H7N3O C8H7IN2O 
Formula weight 191.15 223.19 161.17 272.04 
Crystal system Triclinic Monoclinic P Orthorhombic Monoclinic 
Space group P  P21/c Pca21 P21/n 
Z 2 4 8 4 
a (Å) 5.5097(2) 7.829(2) 13.3387(1) 7.9429(8) 
b (Å) 8.6412(3) 10.876(3) 4.9229(4) 7.1808(7) 
c (Å) 8.6508(3) 11.669(3) 21.4414(2) 14.3395(1) 
α (°) 105.456(1) 90 90 90 
 (°) 90.777(2) 94.037(3) 90 91.833(1) 
 (°) 99.774(2) 90 90 90 
Volume (Å3) 390.46(2) 991.2(4) 1407.95(2) 817.45 
Temperature (K) 100(2) 100(2) 100(2) 100(2) 
Rint 0.024 0.046 0.035 0.013 
R1 [I>2(I)] 0.043 0.038 0.034 0.015 
wR2 0.140 0.098 0.090 0.036 
GoF 1.11 1.04 1.06 1.10 
 
Each quinazolinone shows the same amide-amide hydrogen bond motif, however these motifs pack in 
different ways to form the solid state structure. In addition, π-π interactions between the quinazolinone 
molecules also play an important role in the stabilisation and packing of each structure. Compound 45 
and 20 show additional interactions (through the 6-position substituent) that contribute to the overall 
packing and stability of the solid-state structure.  
Initially, each quinazolinone was dissolved in various organic solvents in an attempt to form solvates 
similarly to 41·MeOH, however, in each case, only the close-packed structures (described above) were 
obtained. While we were able to obtain the methanol solvate of 41, it does not seem to be very stable, 
and appears to convert over time to the close-packed structure. Therefore, it is not too surprising that we 
did not obtain any other solvates.  
We did, however, have more hope for the formation of multicomponent crystals with organic coformers, 
given the precedent for them on the CSD. While there were only three multicomponent forms of 40, it 
provided precedent for our pursuit for the formation of multicomponent crystals of these quinazolinone 
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derivatives. For this, we would need to select coformers in which to carry out the experimental 
screening.  
4.3 SELECTION OF COFORMERS 
 
By studying the crystal structures of 41, 45 and 20, it can be seen that the amide-amide interactions, as 
well as the π-π interactions, are central to the packing of these molecules in the solid state. In order to 
form multicomponent crystals, the interactions formed between the quinazolinone and the coformer 
would need to be more favourable than the interactions present in each individual component. While the 
crystal structure of 40 could not be obtained, it is not unreasonable to assume that similar amide-amide 
interactions to those of 41, 45 and 20 are present in the packing of these molecules in the solid state. By 
studying the three multicomponent crystals of 40 that were found in the CSD, it can be seen that in each 
case, a hydrogen bond between the quinazolinone nitrogen atom and the OH moiety of the coformer 
links the two molecules in the multicomponent crystal.  
Therefore, the use of carboxylic acid coformers, as well as aromatic acids or phenols, would be a good 
choice in coformer in the formation of multicomponent crystals with this series of quinazolinones. We 
decided to make use of the same MEPS approach that was used in Chapter 2 to choose coformers for 
this study. In this way we could further validate the usefulness of this approach for the appropriate choice 
of coformers. This method proves especially useful in this study over other computational methods as 
the crystal structure of 40 is not known.  
The same 32 coformers were used for this study as described in Chapter 2. The advantage of this is that 
the geometry optimisation and identification of the local minima and maxima on the electrostatic 
potential map for each coformer has already been performed (Chapter 2). This allowed for a substantially 
faster processing time, as only the quinazolinone compounds needed to be optimised (and local minima 
and maxima identified) before the change in energy for each system could be calculated. The ten 
coformers with the highest ∆E values for 40, 41 and 45 are given in Table 4.2. The full list for each 
compound and the corresponding ∆E values for each coformer is tabulated in Chapter 6, page 164.  
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One of the disadvantages of the MEPS approach is that the same basis set must be used in the geometry 
optimisations for both components (both the quinazolinone and the coformer) for the calculations to be 
sufficiently accurate. Up until now, this has not been problematic as the B3LYP/6-31+G* basis set was 
used for all components. This basis set, however, does not allow for the geometry optimisation of 20, 
due to the presence of the iodine atom in the molecule. Instead, the LanL2DZ basis set needed to be 
used for this compound to accommodate the heavy atom.6 This unfortunately meant that the calculations 
for 20 could not be carried out unless all coformers were re-optimised using this basis set. As we were 
merely trying to narrow down our list of coformers, we simply opted to only perform the liquid-assisted 
grinding with the coformers that were present in the top ten list for the other quinazolinone compounds. 
As each quinazolinone’s top ten list was similar, this would not yield an unreasonable list of coformers 
for 20.  
For this study, we also investigated different stoichiometry between the quinazolinones and coformer in 
these calculations. The values for a 2:1 or 1:2 ratio (quinazolinone to coformer) were comparable to the 
1:1 ratio and the ranking of the coformers remained mostly the same. Similar conclusions were made 
by Musumeci et al. in their study.7,8 We therefore proceeded with a 1:1 ratio for the experimental 
screening.  
 
 
Table 4.2: Ranked list of the top ten coformers for 40, 41 and 45.  
40 41 45 
Coformer* 
-∆E 
(kJ mol-1) 
Coformer* 
-∆E 
(kJ mol-1) 
Coformer* 
-∆E 
(kJ mol-1) 
OXA 10.4 OXA 9.6 OXA 12.1 
DHBA 6.2 p-ABA 9.5 TRIM 7.1 
MGAL 6.1 EDA 9.0 PAM 7.0 
FUM 5.4 DHBA 8.1 EDA 6.5 
TRIM 5.4 MGAL 7.3 DHBA 6.2 
PAM 5.0 RES 6.6 FUM 5.9 
p-ABA 4.9 TRIM 6.5 RES 5.5 
RES 4.4 BENZ 6.4 PIP 5.5 
IND 4.2 PIP 6.2 PYZ 4.9 
BENZ 3.1 PAM 5.3 BIPY 4.4 
*Coformer codes: OXA – oxalic acid, DHBA – 3,5-dihydroxybenzoic acid, MGAL – methyl gallate, 
FUM – fumaric acid, TRIM – trimesic acid, PAM – pamoic acid, p-ABA – p-aminobenzoic acid, 
RES – resorcinol, IND – indole, BENZ – benzamide, EDA – 1,3-ethylenediamine, PIP – piperazine, 
PYZ – pyrazine, BIPY – 4,4-bipyridine 
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4.4 FORMATION OF MULTICOMPONENT CRYSTALS 
 
The formation of multicomponent crystals for these compounds followed a similar procedure as for 
those in Chapter 2. Initially, each quinazolinone was ground individually in a mortar and pestle for 
5 minutes with a few drops of MeOH to determine whether a new product (solvate, hydrate, polymorph 
etc.) could be formed simply from these conditions, without a coformer present. In the case of 20, 40, 
and 45, the PXRD pattern obtained after grinding the compound matched that of the pre-ground material, 
indicating that no new product is obtained from grinding the compound under these conditions. The 
PXRD of 41, however, showed that after grinding, the material becomes partially amorphous. Extending 
the grinding time to 10 minutes resulted in a completely amorphous product. 
For the purpose of this study, the top ten coformers were chosen to perform the experimental screening. 
Stoichiometric amounts (1:1 ratio) of each compound (10 mg) and coformer were ground together in a 
mortar and pestle for 5 minutes with a few drops of methanol. PXRD was used to determine whether a 
new product was obtained, or if merely a mixture of starting materials was present.  
 
4.4.1 Outcome of liquid-assisted grinding experiments 
For each grinding experiment, the PXRD pattern of the product was compared to those of the individual 
components to determine whether or not a new product had been obtained. The PXRD patterns of the 
successful attempts can be found in Chapter 6 (page 165 to 167). The remaining combinations only 
yielded starting material after liquid-assisted grinding, even after grinding for an additional 5 minutes.   
As an example, the formation of 40·SAL is discussed here in more detail. In Figure 4.8, the powder 
patterns of 40 (shown in blue), salicylic acid (shown in green) and the product obtained after LAG 
(maroon) is shown. It is clear that the product after LAG is not simply a mixture of the two starting 
components. Single crystals of 40·SAL were obtained (discussed later in this chapter) and the calculated 
pattern obtained from the single crystal data (shown in black in Figure 4.8) matches the experimentally 
obtained pattern for 40·SAL. 
Analysis of the PXRD patterns of 40·OXA and 40·FUM after grinding for 5 minutes in a 1:1 ratio 
(40:coformer) showed that a new product had formed, however there were still peaks corresponding to 
40 present. As no coformer peaks were present, it indicated that the ratio of 1:1 was likely incorrect. 
Repeating the grinding experiment in a 2:1 ratio (40:coformer) resulted in a seemingly pure product (see 
Figure 6.48 and Figure 6.49 on page 165).  
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4: Forming multicomponent crystals with quinazolinones 
 
102 | P a g e  
 
 
 
 
 
 
 
 
 
Figure 4.8. Comparison of the PXRD patterns of 40·SAL (maroon), 40 (blue), salicylic acid (SAL, green) and 
the predicted PXRD pattern of 40·SAL obtained from single crystal data (black). 
 
Out of the top ten coformers, only oxalic acid, fumaric acid and resorcinol formed multicomponent 
crystals with 40, while, surprisingly, no new multicomponent crystals were obtained when any of the 
other quinazolinones were ground together with the various coformers. For grinding experiments with 
41 and each coformer, a powder pattern corresponding to the same amorphous material obtained when 
grinding 41 individually, was obtained. It was therefore concluded that a new multicomponent product 
was not obtained. We extended the experimental screening to all 32 coformers for 40 to see whether we 
could obtain any other multicomponent crystals. To our delight, we were able to obtain an additional 
four multicomponent crystals (with salicylic acid, succinic acid, glutaric acid and benzoic acid). 
We then extended the experimental screening of the other three quinazolinones to include the coformers 
that were successful in forming multicomponent crystals with 40, but this did not yield a fruitful 
outcome. 
In addition, we also tried grinding the four quinazolinones with each other (for example grinding 40 
with 41). All of the possible combinations were tried; however, in each case, only a physical mixture of 
the two components was obtained, even after extended grinding times. 
 
 
 
 
 
40·SAL_predicted 
40·SAL_experimental 
40 
SAL 
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The products obtained after LAG were then dissolved in MeOH (with gentle heating and stirring) in an 
attempt to form single crystals of the multicomponent product. The vials were placed on a shelf, away 
from movement and vibration, and the solution was left to slowly evaporate. If crystals or powder 
formed in the vial, PXRD was used to ascertain whether or not this product matched that of the outcome 
of LAG. Single crystals of new products were used to obtain crystal structure data to study the packing 
and association of these molecules in the solid state. 
 
4.4.2 Obtaining crystal structures of the multicomponent crystals 
We were able to obtain crystal structures of three of the multicomponent crystals formed with 40 – those 
formed with oxalic acid, fumaric acid and salicylic acid as coformers. Selected crystallographic 
parameters for each crystal structure are given in Table 4.4. The PXRD pattern obtained from single 
Table 4.3: Ranked list of the 32 coformers and corresponding outcome after LAG with 40 
Coformer* 
-(∆E) 
(kJ mol-1) 
LAG 
outcome** 
Coformer* 
-(∆E) 
(kJ mol-1) 
LAG 
outcome** 
OXA 10.4 MCC PIP 2.1 SM 
DHBA 6.2 SM HYD 1.9 SM 
MGAL 6.1 SM SUC 1.5 MCC 
FUM 5.4 MCC SAC 1.2 SM 
TRIM 5.4 SM MOR 1.0 SM 
PAM 5.0 SM BIPY 0.7 SM 
p-ABA 4.9 SM GLU 0.7 MCC 
RES 4.4 MCC THEO 0.6 SM 
IND 4.2 SM CAF 0.6 SM 
BENZ 3.1 SM VAN 0.5 SM 
TERE 3.1 MCC NAPH 0.4 SM 
EDA 3.1 SM NIC 0.3 SM 
MAL 2.7 SM PYZ 0.3 SM 
SAL 2.6 MCC BEN 0.2 MCC 
TAR 2.5 SM MEN 0.1 SM 
THY 2.3 SM NICO 0.1 SM 
*Coformer code: OXA – oxalic acid, DHBA – 3,5-dihydroxybenzoic acid, MGAL – methyl gallate, 
FUM – fumaric acid, TRIM – trimesic acid, PAM – pamoic acid, p-ABA – p-aminobenzoic acid, 
RES – resorcinol, IND – indole, BENZ – benzamide, TERE – terephthalic acid, EDA – 1,3-ethylenediamine, 
MAL – malonic acid, SAL – salicylic acid, TAR – tartaric acid, THY – thymine, PIP – piperazine, 
HYD – hydroquinone, SUC – succinic acid, SAC – saccharin, MOR – morpholine, BIPY – 4,4-bipyridine, 
GLU – glutaric acid, THEO – theophylline, CAF – caffeine, VAN – vanillin, NAPH – naphthalene, 
NIC – nicotinic acid, PYZ – pyrazine, BEN – benzoic acid, MEN – menthol, NICO – nicotinic acid. 
**LAG outcome: MCC = multicomponent crystal; SM = starting material 
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crystal data matched that of the bulk sample obtained from solution as well as the product obtained from 
the LAG experiments. This confirmed that in each case, the same multicomponent product was obtained 
from grinding and solution methods. 
Compound 40 forms a 2:1 salt with oxalic acid (40·OXA) that crystallises in the monoclinic space group 
C2/c. There is one molecule of 40 and half an oxalic acid molecule per asymmetric unit. The amide-
amide hydrogen bond is no longer seen between two molecules of 40. An N–H⋯O hydrogen bond 
(2.877 ) between the quinazolinone NH atoms and the carbonyl oxygen atom of oxalic acid and an N–
H⋯O (2.583 ) between the tertiary nitrogen atom of the quinazolinone and one of the oxygen atoms 
of oxalic acid is observed. These two hydrogen bonds link molecules of 40 together into columns down 
the c axis. Additionally, π-π interactions between pairs of molecules of 40 (centroid to centroid distance 
of 3.753 ) are observed. The hydrogen atom of the carboxylic acid was located in the electron density 
difference map. The C=O and C–O bond lengths (1.227  and 1.287 , respectively) of the carboxylic 
acid moiety indicate that only partial proton transfer has taken place. After several refinements, the 
hydrogen atom appears slightly closer to the nitrogen atom of the quinazolinone than to the oxygen atom 
of the coformer (1.228  versus 1.338) and therefore is depicted as a salt in Figure 4.9.  
 
 
 
 
 
Figure 4.9: (a) Asymmetric unit of 40·OXA with the symmetry-generated half of the oxalic acid molecule 
shown in green for clarity; (b) π-π interactions between molecules of 40 and N–H⋯O hydrogen bond between 
40 and oxalic acid and (c) packing of 40·OXA viewed down the b axis.  
 
Compound 40 also forms a 2:1 cocrystal with fumaric acid (40·FUM) that packs in the monoclinic space 
group P21/n with one molecule of 40 and half a molecule of fumaric acid per asymmetric unit. Similarly 
to 40·OXA, the amide-amide hydrogen bond is not seen in 40·FUM, but rather the O–H⋯N hydrogen 
bond (2.619 ) between the OH moiety of fumaric acid and one of the quinazolinone nitrogen atoms. 
An additional N–H⋯O hydrogen bond (2.838 ) is observed between the secondary nitrogen atom of 
the quinazolinone molecule and the carbonyl oxygen atom of neighbouring molecules of 40.  
 
 
(a) (c) (b) 
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Figure 4.10: (a) Asymmetric unit of 40·FUM with the symmetry-generated half of fumaric acid shown in green 
for clarity and (b) packing of 40·FUM viewed down the b axis. 
 
Compound 40 forms a 1:1 cocrystal with salicylic acid (40·SAL) that packs in the triclinic space group 
P, with two molecules of each component present in the asymmetric unit. While it appears that there 
could be additional symmetry present in this structure, the molecules are slightly offset and this disrupts 
the symmetry that would result in a different space group. The structure was analysed in Platon9 using 
the “addsym” function, which did not detect additional symmetry. Interestingly, in this multicomponent 
crystal, the amide-amide hydrogen bonding motif between the 40 molecules is observed with a 
hydrogen-bond distance of 2.784  and 2.784 . A second hydrogen bond (2.633 ) between the 
carboxylic acid moiety and the tertiary quinazolinone nitrogen atom links the molecules into tetramers. 
These tetramers pack in sheets perpendicular to the a axis. 
 
 
 
 
 
Figure 4.11: (a) Asymmetric unit of 40·SAL and (b) hydrogen-bonded sheet of 40·SAL viewed down the 
a axis. 
 
 
 
 
(a) (b) 
(a) (b) 
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Table 4.4: Selected crystallographic details for the multicomponent crystals obtained with 40 
 40·OXA 40·FUM 40·SAL 
Molecular formula C8H6N2O·0.5(C2H4O4) C8H6N2O·0.5(C4H4O4) C8H6N2O·C7H6O3 
Formula weight 190.16 204.18 284.27 
Crystal system Monoclinic Monoclinic Triclinic 
Space group C2/c P21/n P 
Z 8 4 4 
a (Å) 30.794(1) 12.5466(4) 8.1396(6) 
b (Å) 3.7535(1) 5.6384(2) 12.9286(1) 
c (Å) 13.872(5) 14.1431(5) 13.4391(1) 
α (°) 90 90 109.609(1) 
 (°) 104.263(7) 111.521(2) 102.898(1) 
 (°) 90 90 93.278(1) 
Volume (Å3) 1553.9(1) 932.08(6) 1285.10(1) 
Temperature (K) 100(2) 100(2) 100(2) 
Rint 0.085 0.045 0.028 
R1 [I>2(I)] 0.062 0.034 0.038 
wR2 0.155 0.091 0.107 
GoF 1.14 1.07 1.04 
 
Unfortunately, we were unable to form single crystals of the remaining multicomponent products, 
despite numerous attempts. The use of various solvents, including solvent mixtures and layering 
techniques, were tried, but resulted either in no product forming or the powdered multicomponent 
product. Both the pre-formed multicomponent product as well as the individual components were used 
in these attempts but no single crystals were obtained. In addition to solution methods, sublimation 
techniques were also tried, using either the pre-formed product or the two individual components, 
however this resulted only in the formation of two bands of powder/crystals, which PXRD analysis 
confirmed to be the two individual components.   
Unfortunately, using infrared spectroscopy to identify whether proton transfer has taken place during 
the formation of these multicomponent crystals was not feasible, because the amide stretch of the 
quinazolinone overlaps with the carbonyl stretching peak of the carboxylic acid/carboxylate moiety. 
One of the methods used to assist in the prediction of whether a coformer is likely to produce a cocrystal 
or a salt if a multicomponent product is obtained is the ∆pKa rule. This method has been used extensively 
in the literature and is based on the difference in the pKa values of the two components.10–13 If ∆pKa is 
greater than 3, then a salt is expected to form, while if ∆pKa is less than 0, then a cocrystal is expected. 
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There is uncertainty in whether a salt or cocrystal will form (or even if a product in which partial proton 
transfer occurs) when the ∆pKa value lies between 0 and 3.  
Because the majority of the multicomponent products obtained in this work contained carboxylic acid 
coformers, we decided to make use of this tool to see whether the predicted outcomes matched that of 
the experimental outcomes for the multicomponent products for which crystal structures are available. 
The results of this are summarised in Table 4.5. The pKa values for the quinazolinones and coformers 
were calculated using Advanced Chemistry Development (ACD/Labs) Software (V11.02). 
 
 
 
 
 
 
 
 
 
 
 
 
From the table above, it is clear that the prediction was accurate for each crystal structure obtained in 
this study (oxalic acid, fumaric acid and salicylic acid), as well as for the three multicomponent crystals 
obtained from the CSD (terephthalic acid, picric acid and 5-aminoisophthalic acid). Therefore, it is likely 
that the prediction would be correct for the remaining four multicomponent products for which we could 
not obtain single crystals. However, without single crystal data, this cannot be confirmed.  
 
4.5 WHY DOES ONLY COMPOUND 40 FORM MULTICOMPONENT CRYSTALS? 
 
It is surprising that only the unsubstituted quinazolinone (40) forms multicomponent crystals with these 
coformers. While we did expect that the substituent may have some influence, we did not expect it to 
Table 4.5: Using the ∆pKa rule to assess whether the multicomponent products of 40 are likely 
to be salts or cocrystals. 
Coformer* ∆pKa Predicted outcome Experimental outcome 
OXA 1.31 Salt/cocrystal Partial proton transfer 
FUM -0.46 Cocrystal Cocrystal 
SAL -0.32 Cocrystal Cocrystal 
GLU  -1.64 Cocrystal N/A 
SUC -1.55 Cocrystal N/A 
BEN -1.51 Cocrystal N/A 
RES -6.63 Cocrystal  N/A 
TERE  -0.8 Cocrystal Cocrystal** 
PIC 2.39 Salt/cocrystal Salt** 
AISO -6.17 Cocrystal Cocrystal** 
*Coformer codes: OXA – oxalic acid, FUM – fumaric acid, SAL – salicylic acid, GLU – glutaric 
acid, SUC – succinic acid, BEN – benzoic acid, RES – resorcinol, TERE – terephthalic acid, 
PIC – picric acid, AISO – 5-aminoisophthalic acid.  
**Crystal structures available on the CSD (described at the beginning of this chapter); N/A = no 
crystal structure obtained. 
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completely hinder the compounds’ ability to form multicomponent crystals with these coformers. By 
studying the crystal structures and the MEPS of these compounds in more detail we could perhaps find 
a possible explanation. 
Etter’s rule, which has been used extensively in crystal engineering and prediction studies in the 
literature, states that the strongest hydrogen-bond donor will interact with the strongest hydrogen-bond 
acceptor site.14,15 We therefore studied the MEPS of each compound and some of the coformers in more 
detail to determine whether the strongest donor-acceptor interaction would be between two different 
components or two of the same components. Shown in Figure 4.12 is the MEPS for 40, 41 and 45, as 
well as for the coformer, salicylic acid (SAL). This example was chosen as salicylic acid forms a 
multicomponent crystal with 40, and the crystal structure had been obtained and therefore we were able 
to study the interactions that result in its formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.12: MEPS of (a) salicylic acid, (b) 40, (c) 41 and (d) 45 mapped onto the 0.002 Bohr A-3 isosurface 
(blue +315 kJ mol-1 to red -225 kJ mol-1).  
When looking at the combination of 40 and SAL, the strongest hydrogen-bond donor site between both 
molecules is +308 kJ mol-1 (carboxylic acid OH group on SAL), while the strongest hydrogen-bond 
acceptor site is -172 kJ mol-1 (carbonyl oxygen atom of 40). Following Etter’s rules, it is predicted that 
–112 kJ mol-1 
+308 kJ mol-1 
+193 kJ mol-1 
–138 kJ mol-1 
(a) 
–142 kJ mol-1 
–172 kJ mol-1 
+263 kJ mol-1 
(b) 
–156 kJ mol-1 
–181 kJ mol-1 
+249 kJ mol-1 
(d) 
–103 kJ mol-1 
–143 kJ mol-1 
+302 kJ mol-1 
(c) 
–152 kJ mol-1 +211 kJ mol-1 
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this combination would likely form a multicomponent crystal through that interaction. While we did 
indeed form a multicomponent crystal with this combination, the main hydrogen-bonding interaction 
between 40 and SAL in the crystal structure is between the strongest donor on the coformer and the 
second strongest acceptor (tertiary nitrogen atom) on 40. In addition, a second hydrogen bond is 
observed between the second strongest donor (NH moiety of 40) and the strongest acceptor (carbonyl 
oxygen atom of 40). These interactions are both found on the same molecule and therefore result in an 
amide-amide dimeric interaction between two molecules of 40. 
If these are the interactions observed in the formation of 40·SAL, then one might expect these to be the 
favoured interactions should a multicomponent product form between 41 and SAL. Looking at the 
combination of 41 and SAL, the strongest hydrogen-bond donor site on 41 (NH moiety, 302 kJ mol-1) 
has very similar strength to that of the strongest hydrogen-bond donor site on SAL (carboxylic acid OH 
moiety, 308 kJ mol-1). As these are of comparable strength and the tertiary quinazolinone nitrogen atom 
acceptor is a weaker acceptor than in 40, this may result in the favoured formation of only the amide-
amide dimer between two molecules of 41, rather than the O–H⋯N interaction between 41 and SAL, 
resulting in no multicomponent product being obtained. Although the nitro group is the strongest 
acceptor, this does not seem to be favoured as a hydrogen-bond acceptor as it is not involved in hydrogen 
bonding in either of the crystal structures of 41 obtained (41 and 41·MeOH).  
For the combination of 45 and SAL, there is now the presence of another relatively strong hydrogen-
bond donor on the quinazolinone. In the crystal structure of 45, the strongest hydrogen-bond donor (NH 
moiety of the amide) and the strongest hydrogen-bond acceptor (carbonyl oxygen atom) interact, 
forming the amide-amide dimer. The second strongest donor (NH2 moiety) interacts with the second 
strongest acceptor (tertiary nitrogen atom). It seems that these two interactions are more favourable than 
an interaction between 45 and a coformer and therefore no multicomponent products are obtained.  
In the other multicomponent products obtained with 40, 40·FUM and 40·OXA, a different packing 
arrangement is observed to that in 40·SAL, in which the amide-amide interaction is not present. Despite 
this, in these combinations of hydrogen-bond donors and acceptors, a similar trend is still observed as 
in 40·SAL, with the strongest hydrogen-bond donor on the coformer interacting with the second 
strongest hydrogen-bond acceptor (tertiary nitrogen atom on 40).  
The difference in the arrangement of these combinations lies not with this O–H⋯N hydrogen-bonding 
interaction, but rather in the additional hydrogen bond present. The second hydrogen bond between the 
second strongest donor (NH moiety on 40) and strongest acceptor (carbonyl oxygen atom on 40) no 
longer occurs as an amide-amide hydrogen bond between two molecules of 40 (forming the amide-
amide dimer). In the case of 40-FUM, this N–H⋯O hydrogen bond now links three molecules of 40 
together, rather than just two (each with separate N–H⋯O hydrogen bonds). In the case of 40·OXA, 
this N–H⋯O hydrogen bond no longer occurs, but rather a different N–H⋯O hydrogen bond linking 
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two 40·OXA dimers together, again in the pattern of strongest hydrogen bond donor (NH moiety of 40) 
interacting with the second strongest hydrogen-bond acceptor (oxygen atom of the OH moiety on the 
coformer). 
So far, the focus has been directed toward hydrogen-bonding interactions. To test whether this applies 
to other intermolecular interactions such as halogen bonding, we carried out LAG experiments in which 
each of the quinazolinones were ground with 1,4-diiodotetrafluorobenzene and a few drops of MeOH. 
This compound is known to form halogen bonds with other molecules and has the potential to form 
halogen bonds with our quinazolinone series.11,16,17 Once again, only the unsubstituted quinazolinone 
(40) formed a multicomponent product (as analysed by PXRD), while the remaining three 
quinazolinones (41, 45 and 20) yielded only a physical mixture of starting materials after grinding. 
The most plausible interaction occurring in this multicomponent product would be a halogen bond 
between the tertiary nitrogen atom of 40 and one of the iodine atoms on the coformer as this seemed to 
be most favourable for the hydrogen bond linking 40 and the other coformers, however, without single 
crystal data, this cannot be confirmed. This indicates that it is most likely that both hydrogen- and 
halogen-bonding interactions are influenced by the substituents at the 6-position of these quinazolinone 
molecules. While we have explored a number of commonly-accepted explanations for interactions in 
crystal engineering (“rule of thumb” type ideas), none of them provide a satisfactory explanation for the 
variation that is observed here.  
 
4.6 CONCLUDING REMARKS 
 
This study began with the serendipitous discovery of two forms of 6-nitroquinazolinone (41) that grew 
concomitantly from MeOH. Other 6-subsituted derivatives of quinazolin-4-(3H)-one had been 
synthesised in our pursuit for novel lapatinib analogues (Chapter 3) including the amino- and 
iodo-derivatives (45 and 20), as well as the unsubstituted derivative (40). While the antiplasmodial 
efficacy of these compounds has not been established, some quinazolinones have been shown to display 
adequate efficacies. Studying these simpler systems could provide insight into what effect that small 
changes on the molecule have on its ability to form multicomponent crystals and the types of interactions 
that occur in such structures.  
The formation of multicomponent crystals with a series of four 6-substituted quinazolinones and small 
organic coformers was investigated. Once again, the MEPS approach was used to select coformers by 
studying their surface-site interaction pairing energies. After simple calculations, a ranked list of the 
coformers was obtained that gave an indication of which coformers were more likely to form 
multicomponent crystals with each quinazolinone. This study highlighted one of the complications of 
the MEPS approach, in that heavy atoms such as iodine influences the choice of basis set to use during 
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the geometry optimisation step. Calculations could therefore not be performed with 20 and its list of top 
coformers. It was also evident that while the MEPS approach did provided a ranked list, it did not seem 
to be accurate for these systems, since the coformers that resulted in multicomponent products of 40 
were scattered across the entire list of 32 coformers.  
Eight novel multicomponent crystalline products of 40 and one methanol solvate of 41 were obtained 
by liquid-assisted grinding of each quinazolinone with selected coformers. Of these nine forms, four 
were obtained as single crystals (after use of solvent evaporation methods) and therefore their crystal 
structures could be studied, giving insight into the packing and association of these molecules in the 
solid state. In all except one case, cocrystals were obtained (no proton transfer between the 
quinazolinone and coformer).  
Unexpectedly, the other quinazolinones did not form multicomponent products with any of these 
coformers. Instead, only starting material was obtained after grinding. We studied the molecular 
electrostatic potential surfaces of each quinazolinone and coformer more closely to see if we could 
pinpoint a reason for this; however, no conclusive information was obtained. Van der Waals forces and 
other weaker interactions may be playing a more significant role than initially suspected and a more 
extensive computational study would be needed to provide more information on the interactions present 
between the quinazolinone and coformer. It appears that small changes, at least in these molecules, seem 
to have a profound effect on the compound’s ability to form multicomponent products.  
It would be interesting to synthesise other 6-substituted quinazolinones that, for example, contain a 
hydroxyl or methyl moiety at that position, to determine whether these would form multicomponent 
crystals. Unfortunately these compounds would be slightly more challenging to synthesise. Perhaps 
moving the substituent to other positions on the quinazolinone ring (for example, to the 7-position) 
would alter the electrostatics of the molecule to an extent where multicomponent formation is possible 
with a range of substituents.  
This study supports the current knowledge that the formation of multicomponent crystals is controlled 
by many factors, including sterics, ‘best donor…best acceptor’ guidelines and other weaker interactions, 
and a delicate balance between them dictates the self-assembly of these molecules. It is evident from 
this study that these systems are not as simple as initially thought and that there is still a great deal of 
information that needs to be obtained in order to fully understand the balance between these factors and 
to be able to predict combinations of molecules that are likely to result in multicomponent crystal 
formation.  
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CHAPTER 5 
Conclusions and future work 
 
 
The aim of this project was to investigate the formation of multicomponent crystals of known and novel 
antiplasmodial agents. By doing so, we aimed to contribute to the current knowledge in the crystal 
engineering field that would ultimately allow for accurate predictions of multicomponent crystals with 
tailor-made properties. Studying the intermolecular interactions formed between particular 
combinations of antiplasmodials and coformers, gives us insight into the relationship between the 
structure of the antiplasmodial agent and the types of multicomponent products that would form.  
The objectives of this project were, therefore, to investigate a series of known antiplasmodial agents to 
determine what effect various moieties have on the formation of intra- and inter-molecular interactions, 
how these molecules pack in the solid state and what types of multicomponent crystals form, if any. 
Using this knowledge, we could then expand this strategy to novel systems. 
Our initial strategy was to select, from the literature, five 4-aminoquinoline antiplasmodial agents that 
have similar features, but with sufficient difference to ensure difference in three dimensional crystalline 
structures. This allowed us to study what effect these differences have on the ability of the compounds 
to form multicomponent crystals and what types of intermolecular interactions are formed. We made 
use of molecular electrostatic potential surfaces (MEPS) to calculate the pairing energies of the 
multicomponent product. This provided a list of coformers, ranked according to their likelihood of 
forming multicomponent crystals, which narrowed down our choice of coformers for each 
antiplasmodial agent. 
The top ten coformers were then chosen to carry out liquid-assisted grinding experiments to form 
multicomponent products. A total of 19 novel multicomponent products were obtained, 6 of which were 
amorphous and 13 of which were crystalline. This resulted in a 38% success rate of the MEPS method 
for choosing coformers. While this value is lower than hoped, this method still proved useful in 
narrowing down the list of coformers. It is likely that a larger pool of coformers may have yielded an 
alternative top ten list. This could be facilitated by the development of a computational high throughput 
screen. It is likely that these kinds of resources will become more widely available in the next decade.  
Comparing the outcomes of the experimental study, it was found that compounds 2 and 5 form only 
amorphous products, while compounds 3 and 4 yield only crystalline multicomponent products with the 
chosen coformers. Compound 1 forms mostly crystalline products; however, one amorphous product 
was also obtained. It was noted that the racemic nature of 2, as well as the likelihood of more favourable 
intramolecular hydrogen-bonding of 2, could be as least partially contributing to the outcome of 
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amorphous products. It is also likely that the bulky ferrocene moiety is playing a role in the packing of 
molecules, more so than the phenyl group of 3, and could be influencing the outcome of 
cocrystallisation. The additional carbon atom in the side chain of 5 (in comparison to the side chain of 
4) leads to increased rotational freedom that could be resulting in the amorphous nature of the 
multicomponent forms of 5.  
One of the assumptions made by the MEPS method is that the shape and long-range packing of the 
molecules in the solid state are of secondary importance (with intermolecular interactions being most 
important) when analysing whether these molecules are likely to form multicomponent crystals. This 
study indicates that, while intermolecular interactions do play a primary role in the formation of 
multicomponent crystals, the shape and long-range packing have a larger role than initially thought. This 
warrants further attention and a more detailed study on similar compounds, where the shape 
complementarity is taken into consideration, should be carried out.  
Developing an in silico high throughput screening tool for coformer selection would certainly be useful 
for the formation of multicomponent products of drug molecules. Currently, there is insufficient 
knowledge in predictions, such that the formation of multicomponent crystals is still deemed non-
obvious in patent terminology. Having said this, it is likely that in the upcoming years such predictions 
may be possible and in silico screening may become a viable method of predicting the formation of 
multicomponent crystals. 
Being able to study the types of intermolecular interactions taking place in these multicomponent 
products would be useful. Unfortunately, single crystals of these multicomponent crystals were not 
obtained, despite considerable effort. Solving the crystal structures of some of these products by PXRD 
data could be helpful in this regard.1 For the amorphous products, pair distribution function (PDF) 
analysis could also be investigated to gain more detailed knowledge of these products.2 The use of cryo-
electron microscopy (cryoEM) technology would also be advantageous.3  
Having successfully formed a range of multicomponent products with these known antiplasmodial 
agents, our next strategy was to apply similar techniques to form multicomponent crystals with a series 
of novel compounds. To this end, a target repurposing strategy was employed to design aminoferrocene-
containing lapatinib analogues as potential antiplasmodial agents. A series of five compounds (15a-e), 
differing in the amino moiety on the ferrocene ring, were designed to study what effect that group has 
on the antiplasmodial efficacy, as well as on its ability to form multicomponent crystals. The use of a 
Suzuki-Miyaura reaction to carry out a carbon-carbon coupling reaction between an aminoferrocene 
boronic acid fragment and the 6-iodoquinazoline scaffold was investigated; however, the desired 
products could not be formed, despite extensively modifying reaction conditions. Instead, only a mixture 
of starting materials or the dehalogenated quinazoline by-product was obtained in each case.  
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Our next approach involved switching the coupling partners (i.e. using an iodoferrocene fragment and 
a boronate quinazoline scaffold). After numerous attempts, we were able to synthesis the desired product 
(as detected by LC-MS); however, we were unable to isolate it, most likely because only trace quantities 
were formed. It is suspected that there are various factors that influence this lack of reactivity and 
investigating this further through computational studies to ascertain which factor contributes most would 
be valuable. Owing to the complexity of these molecules, this would be challenging and would require 
substantial effort, but could provide the necessary information that will allow us to redesign our synthetic 
pathway or reaction conditions to form the desired product in higher yields. 
As the direct carbon-carbon coupling reaction did not give a favourable outcome, we turned to 
synthesising amine-linked analogues where reductive amination was used to couple the aminoferrocene 
carboxaldehyde and 6-aminoquinazoline fragments. Unfortunately, problems in the synthesis of the 
aminoquinazoline scaffold forced us to abandon this strategy too. While other methods are reported in 
the literature for coupling similar fragments, many of them make use of palladium chemistry in a similar 
coupling-type reaction and therefore they were not investigated further.  
During the synthesis of the abovementioned compounds, a series of quinazolinones were also 
synthesised that provided an opportunity to study the formation of multicomponent crystals of simpler 
systems in more detail. While the antiplasmodial efficacy of these compounds has not been established, 
there are quinazolinone derivatives in the literature that have been shown to have moderate to good 
efficacy. By studying these simpler systems we expected to obtain detailed information on what effect 
the substituent has when forming multicomponent products with small organic coformers.  
Four 6-substituted quinazolin-4-(3H)-ones were synthesised and the crystal structures of three of them 
were obtained and compared. We once again made use of the MEPS approach to select coformers that 
would be most likely to form multicomponent crystals with each quinazolinone. After liquid-assisted 
grinding experiments were performed, it was discovered that only the unsubstituted quinazolinone (40) 
formed multicomponent crystals with the selected coformers. Solution cocrystallisation methods were 
employed to obtain single crystals of each multicomponent product. This was successful for three of the 
products, and their structures were compared. We investigated possible reasons for why only the 
unsubstituted quinazolinone forms multicomponent crystals, but no clear reason was identified. This led 
to the conclusion that these systems are more intricate than initially thought and that there is a delicate 
balance between various factors that ultimately drive the formation of multicomponent crystals.  
It is evident from this work that the use of MEPS to select coformers, while robust and straight forward 
to carry out, may not be as simple as initially thought and that additional experimental factors are playing 
a large role in the outcome of multicomponent forms, which are not taken into account in the 
calculations. It is likely that the shape and packing of the molecules in the solid state play a more 
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significant role than described by Hunter and coworkers4–6 in the use of MEPS to identify appropriate 
coformers, at least in the systems described in this work.  
The work discussed in this thesis provides evidence that both quinoline- and quinazolinone-based 
antiplasmodial compounds have potential to form multicomponent crystals and warrants further 
investigation. This study has given insight into the types of intermolecular interactions that can be 
formed with a variety of small organic coformers and provides additional information that is useful for 
selecting coformers for similar systems.  
While this project focused on the formation of multicomponent crystals, studying the physicochemical 
properties of these new products would provide insight into how cocrystallisation effects the in vitro 
properties and the pharmacokinetic profile of these compounds. The compounds discussed in Chapter 2 
have the potential to be studied further in this regard, provided that more detail can be provided by single 
crystal structure determination. Being able to determine what effect various coformers have on the 
pharmacokinetic profile of the drug molecule would provide further insight into the viability of this 
method to improve physicochemical properties.  
Recently, the use of Cryo-electron microscopy (cryoEM) and microcrystal electron diffraction 
(microED) has been shown to provide one-ngstrom and even sub-ngstrom resolution structural data 
from powdered samples, with minimum sample preparation and experiment time.3,7 This technique, 
while still in its infancy for small molecule applications, will most likely radically change the manner 
in which we analyse powered samples in the future. It should be noted that there are certainly limitations 
with this technique and single crystal data is still more powerful in studying intermolecular interactions. 
However, for samples where single crystals cannot be obtained, such as those in this thesis, this method 
is certainly an option to study those products further.  
The formation of multicomponent forms of drug molecules is receiving increased attention and has the 
potential to solve at least some of the current problems that cause many compounds to be discarded from 
the drug discovery pipeline. Perhaps once sufficient knowledge is available in the field, we could see a 
revival of drug candidates that were previously discarded due to poor physicochemical properties. This 
study contributes to this knowledge pool that can be used, ideally in combination with other studies, to 
provide a more complete understanding of how these types of molecules interact in the solid state. This 
could potentially aid in a faster drug discovery process that could allow for more drug molecules to 
reach the market place.  
Being able to eradicate malaria is a challenging endeavour and it is evident that no strategy will be 
successful alone. Rather, a combined effort between the chemistry, biology and education sectors (both 
in industry and academia) will be necessary to one day eliminate this debilitating disease.  
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CHAPTER 6 
Experimental Information 
 
 
Note to the reader: 
The experimental details pertaining to the work carried out in chapters 2, 3 and 4 are described here. 
Addendum A (starting on page 173 of this thesis) contains work carried out as part of a research visit to 
Prof Pollastri’s research laboratory in Boston, USA. The experimental details for that work are included 
in the addendum, and not as part of this chapter. Addendum B (electronic supplementary information) 
contains the input files, wavefunction files and log files for the MEPS work. It also contains the CIFs 
and RES files for all crystal structures obtained in this study as well as the FT-IR spectra described in 
Chapter 2.  
 
6.1 GENERAL INFORMATION 
6.1.1 Chemicals 
All chemicals used in this project were obtained from Sigma Aldrich / Merck South Africa. Chemicals 
were used without further purification in most cases, unless otherwise stated, in which case they were 
purified according to standard literature procedures.1 Solvents that were required to be free from water 
were dried using the techniques listed in Table 6.1 below. 
Table 6.1: Purification and drying methods for various solvents 
Solvent Purification technique 
Methanol (MeOH) Distilled under nitrogen from I2/Mg turnings 
Ethanol (EtOH) Distilled under nitrogen from I2/Mg turnings 
Tetrahydrofuran (THF) Distilled under nitrogen from sodium ribbons and benzophenone 
as indicator 
1,4-Dioxane Distilled under nitrogen from CaH 
Diethyl ether 3 molecular sieves for three days prior to use 
N,N-Dimethylformamide (DMF) 3 molecular sieves for three days prior to use 
 
Ethyl acetate (EtOAc), hexane and dichloromethane (DCM) that were used for silica gel 
chromatography were purchased from Protea Chemicals and bulk distilled in air prior to use. All solvents 
used for crystallisation experiments were purchased from Sigma Aldrich South Africa and were of 
HPLC grade and stored on 3 molecular sieves for two days prior to use.  
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Alkyl lithium reagents were titrated prior to use using the following procedure:2  
An oven-dried Schlenk tube was evaculated and filled with nitrogen three times, following which freshly 
distilled THF (8.0 mL), menthol (0.100 g, 0.640 mmol, 1.00 equivalent) and 2,2-bipyridine (4 – 5 mg 
as indicator) were added. The reaction mixture was cooled to -78 °C (dry ice/acetone bath) and the alkyl 
lithium reagent was added dropwise via an oven-dried glass syringe until the colour changed to a 
persistent deep red within one drop. The volume of alkyl lithium used was recorded and used to calculate 
the molar concentration. The experiment was repeated in triplicate for accuracy.  
  
6.1.2 Instrumentation and related software 
Microwave reactions were performed using a CEM Focused Microwave Synthesis System, Discover 
SP, using either 10 mL or 35 mL microwave vials and Teflon coated stir bars.  
Flash column chromatography was performed using a CombiFlash Rf+ 150 Teledyne ISCO automated 
purification instrument fitted with a UV detector (200 – 400 nm). All chromatography was performed 
using 230 – 400 mesch Merck silica gel. Thin layer chromatography was carried out using Macherey-
Nagel Alugram® Xtra SIL G/UV254 TLC sheets pre-coated with silica gel 60. Spots were visualised 
using a UV lamp or stains (ninhydrin, 2,6-dinitrophenyl hydrazine or bromocresol green) 
LC-MS analysis was performed using a Waters Alliance reverse phase HPLC (columns Waters SunFire 
C18 4.6 × 50 mm) with single-wavelength UV−visible detector and Waters Micromass ZQ detector 
(electrospray ionisation). 
Mechanochemistry was performed either manually in a mortar and pestle or with a FTS1000 Shaker 
Mill with stainless steel jars and stainless steel milling balls (size: 6 mm). 
Nuclear Magnetic Resonance (NMR) spectroscopy was carried out to confirm the structure and purity 
of synthesised compounds. Samples were prepared by dissolving 10 – 20 mg of the sample in an 
appropriate deuterated solvent. In all cases CDCl3 was used, except when samples were not soluble. 
DMSO-d6 or CD3OD were used in these cases. All solvents were stored on 3  molecular sieves to 
eliminate the presence of water peaks in the spectrum. 1H and 13C spectra were obtained using a 300 
MHz Varian VNMRS (75.5 MHz for 13C), 400 MHz (100 MHz for 13C) or 600 MHz (150 MHz for 13C). 
Chemical shifts are reported using the residual peaks of deuterated solvents as reference. Spectra were 
analysed using ACD Labs NMR spectroscopic processing software.3  
Fourier Transform Infrared Spectroscopy (FTIR) was carried out using a Bruker Alpha spectrometer 
with platinum ATR attachment. OPUS v7.5 software4 was use to record spectra, and processing was 
carried out using KnowItAll freeware.5 A background scan was acquired before each sample scan. 
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Powder X-ray diffraction (PXRD) was carried out on a Bruker D2 Phaser powder X-ray diffractometer 
with 1.54183  CuKα radiation, operated at 30 kV and 10 mA. Data were collected from 2θ = 4 to 40° 
with a scan step of 0.5 seconds per step and a step size of 0.0201 (for multicomponent crystals) or a step 
size of 0.0161 (for individual components). Data analysis was performed using X’Pert HighScore Plus 
(v 2.2e).6  
Single crystal X-ray diffraction (SC-XRD) was used to obtain the solid-state structure of compounds 
from diffraction-quality single crystals. Crystals were placed in paratone oil on a slide and a suitable 
crystal was mounted on a MiTeGen mount, which was then placed on the goniometer head of the 
instrument. A Bruker Apex II DUO CCD area-detector diffractometer was used for 41, 41·MeOH, 20, 
45, 40·OXA and 40·SAL, operating with MoKα radiation of wavelength 0.71073  produced by an 
Incoatec IµS microsource coupled with a multilayer mirror optics monochromator. An Oxford 
Crysosystems cryostat (Cryostream Plus 700 Controller) was used for all data collections (100 K). For 
3 and 40·FUM, a Bruker D8 Venture Photon II four-circle diffractometer was used operating with 
MoKα radiation of wavelength 0.71073  produced by an Incoatec IµS microsource coupled with a 
multilayer mirror optics monochromator. Low temperature (100 K) data collections were performed for 
all structures, making use of an Oxford Cryosystems Cryostream 800 series cryostat. Data were collected 
and reduced using Bruker SAINT7 in the ApexIII interface and absorption corrections were carried out 
with SADABS8,9 The structures were solved using SHELXT-13 and SHELXT-1610 using direct methods 
and refined using SHELXL-1610 in the Xseed graphical user interface.11,12 Hydrogen atoms were placed 
in calculated positions using riding models, except for OH and NH hydrogen atoms, which were placed 
on maxima found in the electron density difference maps. Images were generated using POV-Ray.13 
CIFs were generated within Xseed and edited with EnCiFer.14 All CIFs were checked using CheckCIF 
prior to submission.15 The CIFs and CIFCheck files are included in this thesis as part of the electronic 
supplementary information.  
Thermogravimetric analysis (TGA) was performed under nitrogen (flow rate: 40 mL/min) using a TA 
Q500 instrument. Samples (2 – 5 mg) were placed in open aluminium pans and the traces were obtained 
by heating at 10 °C/min under a N2 gas purge. 
Differential Scanning Calorimetry (DSC): was performed using a TA Q20 instrument coupled to an 
RSC cooling unit. Samples (2 – 5 mg) were placed in non-hermetically sealed aluminium pans with a 
pinhole in the lid and heated at a rate of 10 °C/min. Analysis of the traces obtained from the TGA and 
DSC measurements were carried out using the TA Instruments Universal Analysis program. 
ConQuest 1.18,16 as part of the Cambridge Structural Database, was used to search for published crystal 
structures and hydrogen-bonding motifs.  
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Mercury CSD 3.9,16–18 was used to generate the channel mapping image for 41·MeOH as well as for 
analysis of intermolecular interactions in the crystal structures described in this these. In addition, it was 
used to generate the calculated PXRD patterns from single crystal data.  
For the molecular electrostatic potential surface calculations, molecules were draw in ChemCraft and 
geometry optimisations carried out with Gaussian 09.19 AIMAll and AIMQB were used to map the MEPS 
onto the 0.002 Bohr -3 isodensity surface and to generate the MEPS images.20  
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6.2 EXPERIMENTAL DATA PERTAINING TO CHAPTER 2 
Amodiaquine free base (1) 
 
 
 
Amodiaquine dihydrochloride dihydrate was purchased from Sigma Aldrich South Africa. The free base 
was obtained by stirring the salt (0.350 g) in ammonia solution (25%) for 2 hours and then extracting 
into EtOAc (3 × 30 mL). The organic layers were combined, dried over anhydrous K2CO3, filtered and 
the filtrate concentrated under reduced pressure. The resulting pale yellow powder was recrystallised 
from hot methanol (87% yield).  
1H NMR (300 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.42 (d, J = 8.8 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.84 
(d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.8, 2.1 Hz, 1H), 7.08 (s, 1H), 7.07 – 7.03 (m, 1H), 6.81 – 6.75 (m, 
1H), 6.57 (d, J = 5.6 Hz, 1H), 3.74 (s, 2H), 2.57 (q, J = 7.0 Hz, 4H), 1.04 (t, J = 7.0 Hz, 6H). 
 
 
 
 
 
 
Figure 6.1: Experimental PXRD pattern of 1 (blue) and of commercially available amodiaquine dihydrochloride 
dihydrate (black). 
 
 
 
 
 
 
1_free base 
1_dihydrochloride dihydrate 
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Figure 6.2: TGA trace of 1 (blue) and of commercially available amodiaquine dihydrochloride dihydrate 
(black). 
 
 
 
 
 
 
 
Figure 6.3: DSC trace of 1 (blue) and of commercially available amodiaquine dihydrochloride dihydrate (black). 
 
[(N, N-Dimethylamino)methyl]ferrocenecarboxaldehyde (7) 
 
To a dry Schlenk tube that has been evacuated and filled with nitrogen three times was added 
commercially available N,N-dimethylaminomethyl ferrocene (0.3 mL, 1 mmol, 1 equivalent) and 
anhydrous diethyl ether (6.0 mL). This solution was then cooled to 0 °C and t-BuLi (1.5 mL, 1.0 M, 
1.1 equivalents) was added dropwise. The ice bath was removed and the bright orange reaction mixture 
was stirred for a further 2 hours at room temperature. The reaction mixture was then once again cooled 
to 0 °C and anhydrous DMF (0.1 mL, 1 mmol, 1 equivalent) was added dropwise. The ice bath was once 
again removed and the reaction stirred at room temperature for a further 2 hours, after which 1.0 mL 
distilled water was added dropwise to quench the reaction. Additional distilled water (5 mL) was added 
161.0 °C 
210.4 °C 
Exo up 
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and the product was extracted with DCM (3 × 30 mL). The organic fractions were combined, dried over 
anhydrous MgSO4 and concentrated under reduced pressure. A quantitative yield of the dark red oil was 
obtained and used directly in the next reaction without further purification.  
TLC (EtOAc/Et3N/MeOH = 95:3:2): Rf = 0.33; DNP (2,4-dinitrophenyl hydrazine) solution stains the 
aldehyde product an orange colour on the TLC plate. 1H NMR (300 MHz, CDCl3) δ 10.10 (s, 1H), 
4.78 – 4.76 (m, 1H), 4.64 – 4.61 (m, 1H), 4.56 – 4.55 (m, 1H), 4.23 (s, 5H), 3.84 (d, J = 12.9 Hz, 1H), 
3.38 (d, J = 12.9 Hz, 1H), 2.23 (s, 6H). The data compared well with the literature.21,22  
 
2-[(N,N-Dimethylamino)methyl]ferrocenecarboxaldehyde oxime (8) 
 
To a 50 mL round-bottomed flask containing [(N,N-dimethylamino)methyl]ferrocenecarboxaldehyde 
(7) (0.383 g, 1.48 mmol, 1.00 equivalent) was added absolute EtOH (15 mL) and hydroxylamine 
hydrochloride (0.281 g, 4.00 mmol, 2.70 equivalents). To this mixture was added 2.5 M NaOH solution 
(4 mL, 6 mmol, 3 equivalents). The reaction was heated under reflux for 3 hours before cooling back to 
room temperature and neutralising with dry ice until a pH of 7 was obtained. The mixture was diluted 
with DCM (40 mL) and the product extracted with a further DCM (3 × 20 mL). The combined organic 
fractions were washed with brine (30 mL), then dried over anhydrous MgSO4, filtered and the filtrate 
concentrated under reduced pressure. The product was used directly in the next step without further 
purification.  
TLC (EtOAc/Et3N/MeOH = 95:3:2): Rf = 0.25. 
 
2-[(N,N-Dimethylamino)methyl]ferrocenemethylamine (9) 
 
To a two-neck round-bottomed flask containing the crude 
2-[(N,N-dimethylamino)methyl]ferrocenecarboxaldehyde oxime product (8) described above (0.420 g, 
1.48 mmol, 1.00 equivalent) was added anhydrous THF (8.0 mL) and the mixture stirred under nitrogen 
until dissolved. LiAlH4 (0.114 g, 3.00 mmol, 2.00 equivalents) was added portion-wise under a positive 
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pressure of nitrogen. The reaction mixture was then heated under reflux under a nitrogen atmosphere 
for 18 hours. Once cooled, the reaction mixture was diluted with diethyl ether (40 mL) and excess 
LiAlH4 was quenched by the slow addition of brine (5 mL). The reaction mixture was transferred to a 
separatory funnel and additional brine added (10 mL). The product was extracted with diethyl ether (3 × 
30 mL), then dried over anhydrous K2CO3, filtered and the filtrate concentrated under reduced pressure 
to afford the crude product as a dark red oil that was used directly in the next step without further 
purification.  
TLC (DCM/Et3N/EtOH = 80:10:10): Rf = 0.31; Ninhydrin stains amine product an orange colour on 
TLC. 1H NMR (300 MHz, CDCl3) δ 4.19 (m, 1H), 4.11 (m, 1H), 4.04 (s, 5H), 4.03 – 4.01 (m, 1H), 
3.78 (d, J = 13.5 Hz, 1H), 3.59 – 3.61 (m, 1H), 3.65 – 3.64 (m, 1H), 3.50 (br s, 2H), 2.86 (d, J = 12.3 
Hz, 1H), 2.14 (s, 6H). The data compared well with the literature.21,22 
 
Ferroquine (2) 
 
 
 
To a 25 mL round-bottomed flask was added crude 
2-[(N,N-dimethylamino)methyl]ferrocenemethylamine (9) (0.475 g, 1.75 mmol, 1.00 equivalent) and 
anhydrous N-methylpyrolidinone (NMP, 8.0 mL) under a positive flow of nitrogen. To this was added 
anhydrous triethylamine (0.3 mL, 2 mmol, 1 equivalents) and K2CO3 (0.393 g, 3.25 mmol, 1.50 
equivalents). 4,7-Dichloroquinoline (1.82 g, 9.19 mmol, 5.00 equivalents) was added portion wise to 
the reaction mixture after which the reaction mixture was stirred at 135 °C for 4 hours. The reaction 
mixture was cooled to room temperature, diluted with EtOAc (150 mL) and transferred to a separatory 
funnel where the NMP was extracted with brine (10 × 50 mL). The organic layer was dried over 
anhydrous MgSO4, filtered and the filtrate concentrated under reduced pressure. Purification by column 
chromatography (EtOAC/Hexane/Et3N = 45:50:5) afforded the desired product, which was then 
recrystallised from DCM/Hexane to give orange rod-shaped crystals of diffraction quality in 54% yield.  
TLC (EtOAC/Hex/Et3N = 45:50:5): Rf = 0.33. 1H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 5.3 Hz, 1H), 
7.92 (d, J = 2.4 Hz, 1H), 7.67 (br s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.29 – 7.28. (m, 1H), 6.46 (d, J = 5.3 
Hz, 1H), 4.42 – 4.36 (m, 1H), 4.29 – 4.27 (m, 1H), 4.21 – 4.16 (m, 1H), 4.15 (s, 5H), 4.14 – 4.12 (m, 
1H), 4.09 – 4.08 (m, 1H), 3.80 (d, J = 12.3 Hz, 1H), 2.89 (d, J = 12.3 Hz, 1H), 2.23 (s, 6H). IR (ATR, 
cm-1) 3170 (br. w, NH), 1574 (s, C=N of quinoline), 797 (C–Cl). Mp 201.0 °C (DSC peak). The data 
compared well with the literature.23  
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Figure 6.4: Experimental PXRD pattern of 2 (blue) and the calculated PXRD pattern obtained from single 
crystal data (black, CSD refcode: LEZNIO). 
 
 
 
 
 
 
Figure 6.5: TGA trace (black) and DSC trace (blue) of 2.  
 
2-[(Dimethylamino)methyl]benzaldehyde (12) 
 
To a dry Schlenk tube that has been evacuated and filled with nitrogen three times was added 
commercially available N,N-dimethyl-1-phenylmethanamine (0.2 mL 2 mmol, 1 equivalent) and 
anhydrous diethyl ether (8 mL). This solution was then cooled to -78 °C and n-BuLi (1.0 mL, 2.0 M, 
1.1 equivalents) was added dropwise. The reaction mixture was stirred without the dry ice/acetone bath 
for a further 18 hours, during which the yellow solution becomes milky. The reaction mixture was cooled 
to 0 °C and anhydrous DMF (0.1 mL, 2 mmol, 1 equivalents) added dropwise. The ice bath was removed 
and the reaction stirred at room temperature for a further 2 hours after which distilled water (5 mL) was 
added dropwise to quench the reaction. The product was extracted with diethyl ether (3 × 30 mL) and 
2_experimental 
2_calculated 
201.0 °C 
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the organic fractions combined, dried over anhydrous MgSO4 and concentrated under reduced pressure. 
The product was obtained as a colourless oil in quantitative yield (0.302 g). 
TLC (Ether/Hexane/Et3N = 70:20:10): Rf = 0.75; DNP stains aldehyde product an orange colour on the 
TLC plate. 1H NMR (300 MHz, CDCl3) δ 10.28 (s, 1H), 7.91 (dd, J = 8.2, 1.3, 1H), 7.49 – 7.48 (m, 
1H) 7.36 – 7.31 (m, overlapping peaks, 2H) 3.61 (s, 2H), 2.19 (s, 6H). The data compared well with the 
literature.21,24 
 
2-[(Dimethylamino)methyl]benzaldehyde oxime (13) 
 
To a 50 mL round-bottomed flask containing 2-((dimethylamino)methyl)benzaldehyde (12) (0.302 g, 
1.85 mmol, 1.00 equivalent) was added to absolute EtOH (8.0 mL) and hydroxylamine hydrochloride 
(0.319 g, 2.77 mmol, 1.50 equivalents). To this mixture was added NaOH solution (3.7 mL, 2.5 M, 
3.0 equivalents). The reaction was heated under reflux for 18 hours before cooling back to room 
temperature and neutralising with dry ice until a pH of 7 was obtained. The mixture was diluted with 
DCM (40 mL) and the product extracted with a further DCM (3 × 20 mL). The combined organic 
fractions were washed with brine (1 × 30 mL), then dried over anhydrous MgSO4, filtered and the filtrate 
concentrated under reduced pressure. The product was used directly in the next step without further 
purification.  
TLC (Ether/Hexane/Et3N = 70:20:10): Rf = 0.75; DNP stain on the TLC plate confirms that aldehyde 
starting material was consumed and that the reaction was complete.  
 
1-[2-(Aminomethyl)phenyl]-N,N-dimethylmethanamine (14) 
 
To a 2-neck round-bottomed flask containing the crude oxime product 12 described above (0.328 g, 
1.85 mmol, 1.00 equivalent) was added anhydrous THF (6.0 mL) and the mixture stirred under nitrogen 
until dissolved. LiAlH4 (0.140 g, 3.69 mmol, 2.00 equivalents) was added portion wise under a positive 
pressure of nitrogen. The reaction mixture was then heated under reflux under a nitrogen atmosphere 
for 18 hours. Once cooled, the reaction mixture was diluted with diethyl ether (40 mL) and excess 
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LiAlH4 was quenched by the slow addition of brine (5 mL). The reaction mixture was transferred to a 
separatory funnel and additional brine (10 mL) added. The product was extracted with diethyl ether 
(3 × 30 mL), then dried over anhydrous K2CO3, filtered and the filtrate concentrated under reduced 
pressure to give a pale yellow oil. The product was used directly in the next step without further 
purification.  
TLC (Ether/Hexane/Et3N = 70:20:10): Rf = 0.68. Ninhydrin was used to visualise the amine product, 
which stains an orange colour on the TLC plate. 
 
Phenylequine (3) 
 
 
 
To a 25 mL round-bottomed flask was added 1-[2-(aminomethyl)phenyl]-N,N-dimethylmethanamine 
(13) (0.302 g, 1.85 mmol, 1.00 equivalent) and anhydrous NMP (5.0 mL) under a positive flow of 
nitrogen. To this was added anhydrous triethylamine (0.3 mL, 2 mmol, 1 equivalent) and K2CO3 
(0.228 g, 1.65 mmol, 1.50 equivalents). 4,7-Dichloroquinoline (1.09 g, 5.50 mmol, 5.00 equivalents) 
was added portion-wise to the reaction mixture after which the reaction mixture was stirred at 135 °C 
for 4 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc (80 mL) and 
transferred to a separatory funnel where the NMP was extracted with brine (10 × 30 mL). The organic 
layer was dried over anhydrous MgSO4, filtered and the filtrate concentrated under reduced pressure. 
Purification by column chromatography and subsequent recrystallisation from DCM/Hexane afforded 
the desired product in a 48% yield (0.108 g) as an off-white solid. 
TLC (EtOAc/Hexane/Et3N = 45:50:5): Rf = 0.56. 1H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 5.5 Hz, 
1H), 8.50 (br s, 1H), 7.96 (d, J = 1.8 Hz, 1H), 7.63 (d, J = 9.4 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.37 – 7.28 
(m, 4H), 6.56 (d, J = 5.5 Hz, 1H), 4.47 (s, 2H), 3.51 (s, 2H), 2.29 (s, 6H). IR (ATR, cm-1) 3228 (br. m, 
NH), 1561 (s, C=N of quinoline), 1489 (m, NCH3). Mp 139 – 143 °C. The data compared well with the 
literature.25  
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Figure 6.6: Experimental PXRD pattern of 3 (blue) and the calculated PXRD pattern obtained from single 
crystal data (black). 
 
 
 
 
 
 
Table 6.2: Hydrogen-bond geometries for 3 from single crystal X-ray diffraction data. 
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C11–H11A···N3 0.97 2.68 3.191 (2) 113 
N2–H1···N1i 0.85 (3) 2.09 (3) 2.900 (2) 158 (2) 
Symmetry code: (i) y-1/2, x+1/2, z-1/2. 
 
N-(7-Chloroquinolin-4-yl)ethane-1,2-diamine (4) 
 
 
 
Commercially available 4,7-dichloroquinoline (1.04 g, 5.00 mmol, 1.00 equivalent) and 1,2-
diaminoethane (1.3 mL, 20 mmol, 4.0 equivalents) was added to a 50 mL round-bottomed flask and 
stirred at 80 °C for one hour after which the temperature was increased to 135 °C for a further 5 hours. 
3_calculated 
3_experimental 
N3 
H11A 
N2 
N1 
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The reaction mixture was then cooled to room temperature and diluted with DCM (80 mL). A saturated 
solution of sodium bicarbonate (20 mL) was added until a pH of 7 was obtained. The organic layer was 
separated from the aqueous layer and the latter washed with DCM (4 × 30 mL). The organic layers were 
combined and washed once with brine (30 mL). The organic layer was dried over anhydrous MgSO4, 
filtered and the filtrate concentrated under reduced pressure to yield a pale yellow powder (0.623 g, 
56%). 
TLC (EtOAc/Hexane/MeOH/Et3N = 50:30:10:10): Rf = 0.32. 1H NMR (300 MHz, DMSO-d6) δ 8.39 
(d, J = 5.3 Hz, 1H), 8.24 (d, J = 9.6 Hz, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.45 (dd, J = 9.6, 2.0 Hz, 1H), 
6.47 (d, J = 5.3 Hz, 1H), 3.31 (t, J = 6.6 Hz, 2H), 2.69 (t, J = 6.6 Hz, 2H). IR (ATR, cm-1) 3264 (m, 
NH), 1610 (m, NH2). Mp 137 – 139 °C. The data compared well with the literature.26,27 
 
N1-(7-chloroquinolin-4-yl)propane-1,2-diamine (5) 
 
 
 
Compound 5 was prepared using the same procedure described above for compound 4 with the same 
equivalents of 4,7-dichloroquinine and 1,3-diaminopropane to yield a pale yellow powder (0.856 g, 
73%). 
TLC (EtOAc/Hexane/MeOH/Et3N = 50:30:10:10): Rf = 35. 1H NMR (300 MHz, DMSO-d6) δ 8.39 (d, 
J = 5.4 Hz, 1H), 8.23 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.52 (br s, 1H), 7.45 (dd, J = 9.0, 
6.7 Hz, 1H), 6.46 (d, J = 5.4 Hz, 1H), 3.32 (t, J = 6.5 Hz, 2H), 2.68 (t, 6.5 Hz, 2H), 1.73 (m, 2H). IR 
(ATR, cm-1) 3285 (m, NH), 1610 (m, NH2). Mp 89–92 °C. The data compared well with the 
literature.26,27 
 
Molecular Electrostatic Potential Surfaces (MEPS) 
All input and wavefunction files, as well as log files for each compound can be found in Appendix B 
(electronic data). The coformers used in this study can all be found on either the GRAS or EAFUS lists 
and were available in the laboratory at the time. Table 6.3 shows the change in energy for each coformer 
and antiplasmodial agent in descending order of the energy value. 
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Table 6.3: ∆E values for each antiplasmodial agent and coformer combination. 
1 2 3 4 5 
Coformer -∆E 
(kJ mol-1) 
Coformer -∆E 
(kJ mol-1) 
Coformer -∆E 
(kJ mol-1) 
Coformer -∆E 
(kJ mol-1) 
Coformer -∆E 
(kJ mol-1) 
oxalic acid 12.1 oxalic acid 24.5 oxalic acid 14.6 oxalic acid 15.5 fumaric acid 22.5 
3,5-dihydroxy 
benzoic acid 9.0 
3,5-dihydroxy 
benzoic acid 19.0 
3,5-dihydroxy 
benzoic acid 10.7 pamoic acid 10.3 oxalic acid 18.4 
trimesic acid 8.4 fumaric acid 18.4 fumaric acid 9.1 trimesic acid 10.0 trimesic acid 13.5 
fumaric acid 7.6 trimesic acid 17.0 indole 8.5 4,4-bipyridine 9.0 
3.5-dihydroxy 
benzoic acid 13.2 
pamoic acid 6.9 malonic acid 16.8 pamoic acid 8.2 pyrazine 8.2 pamoic acid 12.9 
resorcinol 6.7 pamoic acid 16.8 trimesic acid 8.1 
3,5-dihydroxy 
benzoic acid 8.1 resorcinol 10.9 
indole 6.4 indole 16.2 resorcinol 7.7 fumaric acid 7.7 indole 9.9 
malonic acid 4.9 resorcinol 16.1 malonic acid 7.3 indole 7.5 malonic acid 9.2 
teraphthalic acid 4.9 teraphthalic acid 15.7 teraphthalic acid 6.6 resorcinol 7.2 teraphthalic acid 8.7 
salicylic acid 4.3 succinic acid 15.2 
p-aminobenzoic 
acid 6.1 vanillin 6.8 succinic acid 7.7 
hydroquinone 4.1 salicylic acid 14.6 succinic acid 6.0 piperazine 6.2 salicylic acid 7.6 
p-aminobenzoic 
acid 4.0 saccharin 13.7 salicylic acid 5.9 ethylenediamine 6.1 hydroquinone 7.2 
ethylenediamine 3.8 thymine 13.0 saccharin 5.2 teraphthalic acid 6.0 glutaric acid 6.5 
benzamide 3.8 hydroquinone 13.0 hydroquinone 4.7 malonic acid 5.5 
p-aminobenzoic 
acid 6.1 
succinic acid 3.6 
p-aminobenzoic 
acid 13.0 thymine 4.6 saccharin 5.1 saccharin 5.5 
saccharin 3.0 methyl gallate 11.6 glutaric acid 4.0 succinic acid 5.0 methyl gallate 5.3 
thymine 2.6 glutaric acid 11.2 methyl gallate 3.7 theophylline 4.9 vanillin 5.2 
vanillin 2.5 benzamide 10.7 benzamide 3.4 glutaric acid 4.5 tartaric acid 5.0 
glutaric acid 2.2 tartaric acid 10.6 vanillin 3.3 salicylic acid 4.5 nicotinic acid 4.8 
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piperazine 1.7 vanillin 10.4 tartaric acid 2.6 nicotinic acid 4.4 theophylline 4.6 
4,4-bipyridine 1.2 nicotinic acid 8.9 benzoic acid 2.6 hydroquinone 4.0 thymine 4.2 
methyl gallate 1.2 benzoic acid 8.9 nicotinic acid 2.5 
p-aminobenzoic 
acid 3.2 benzamide 3.8 
tartaric acid 1.0 theophylline 8.6 theophylline 2.1 morpholine 3.1 benzoic acid 3.8 
morpholine 0.9 nicotinamide 7.1 ethylenediamine 1.5 tartaric acid 3.1 pyrazine 3.1 
caffeine 0.9 morpholine 6.0 morpholine 1.3 methyl gallate 2.2 44-bipyridine 2.3 
benzoic acid 0.6 ethylenediamine 5.9 nicotinamide 1.2 benzoic acid 2.2 nicotinamide 2.0 
nicotinic acid 0.5 caffeine 4.9 naphthalene 0.9 naphthalene 2.0 morpholine 1.8 
theophylline 0.4 menthol 4.6 menthol 0.4 benzamide 1.6 piperazine 1.6 
naphthalene 0.3 4,4-bipyridine 2.7 pyrazine 0.3 caffeine 1.5 naphthalene 1.1 
pyrazine 0.2 piperazine 2.6 piperazine 0.2 thymine 0.9 ethylenediamine 1.0 
nicotinamide 0.1 naphthalene 2.5 4,4-bipyridine 0.1 nicotinamide 0.6 menthol 0.8 
menthol 0.0 pyrazine 1.9 caffeine 0.1 menthol 0.0 caffeine 0.4 
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Obtaining multicomponent crystals of 1 – 5 with organic coformers: 
Liquid-assisted grinding (with a few drops of MeOH) was used as a screening tool to determine whether 
multicomponent crystals would form between the respective antiplasmodial agent and the top ten 
coformers in the list obtained from the virtual screening method. Stoichiometric amounts (1:1) of the 
antiplasmodial agent (10 mg) and coformer were added to a mortar and pestle and 3 drops of solvent 
were added. The components were ground together for 5 minutes, occasionally adding an extra drop of 
MeOH when necessary. PXRD was used to determine whether a mixture of starting components was 
still present or whether a new product had formed. In cases where starting material was still present, an 
additional 10 minutes of grinding was carried out and PXRD was once again performed.  
PXRD patterns of the individual components and that of the product obtained after 5 minutes of 
grinding: 
 
 
 
 
 
 
 
Figure 6.7: Experimental PXRD pattern of amodiaquine (1, navy blue), oxalic acid (OXA, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (1·OXA, maroon). 
 
 
 
 
 
 
 
Figure 6.8: Experimental PXRD pattern of amodiaquine (1, navy blue), trimesic acid (TRIM, green) and the 
new product obtained after grinding for 5 min with a few drops of MeOH (1·TRIM, maroon). 
1·OXA 
1 
OXA 
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Figure 6.9: Experimental PXRD pattern of amodiaquine (1, navy blue), fumaric acid (FUM, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (1·FUM, maroon). 
 
 
 
 
 
 
 
 
Figure 6.10: Experimental PXRD pattern of amodiaquine (1, navy blue), terephthalic acid (TERE, green) and 
the new product obtained after grinding for 5 min with a few drops of MeOH (1·TERE, maroon). 
 
 
 
 
 
 
 
Figure 6.11: Experimental PXRD pattern of ferroquine (2, navy blue), oxalic acid (OXA, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (2·OXA, maroon). 
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Figure 6.12: Experimental PXRD pattern of ferroquine (2, navy blue), trimesic acid (TRIM, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (2·TRIM, maroon). 
 
 
 
 
 
 
 
Figure 6.13: Experimental PXRD pattern of phenylequine (3, navy blue), oxalic acid (OXA, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (3·OXA, maroon). 
 
 
 
 
 
 
 
Figure 6.14: Experimental PXRD pattern of phenylequine (3, navy blue), 3,5-dihydroxybenzoic acid (DHBA, 
green) and the new product obtained after grinding for 5 min with a few drops of MeOH (3·DHBA, maroon). 
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Figure 6.15: Experimental PXRD pattern of phenylequine (3, navy blue), indole (IND, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (3·IND, maroon). 
 
 
 
 
 
 
 
Figure 6.16: Experimental PXRD pattern of phenylequine (3, navy blue), resorcinol (RES, green) and the new 
product obtained after grinding for 5 min with a few drops of MeOH (3·RES, maroon). 
 
 
 
 
 
 
 
Figure 6.17: Experimental PXRD pattern of phenylequine (3, navy blue), malonic acid (MAL, green) and the 
new product obtained after grinding for 5 min with a few drops of MeOH (3·MAL, maroon). 
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Figure 6.18: Experimental PXRD pattern of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4, navy blue), oxalic 
acid (OXA, green) and the new product obtained after grinding for 5 min with a few drops of MeOH (4·OXA, 
maroon). 
 
 
 
 
 
 
 
Figure 6.19: Experimental PXRD pattern of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4, navy blue), 
pamoic acid (PAM, green) and the new product obtained after grinding for 5 min with a few drops of MeOH 
(4·SUC, maroon). 
 
 
 
 
 
 
 
Figure 6.20: Experimental PXRD pattern of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4, navy blue), 
trimesic acid (TRIM, green) and the new product obtained after grinding for 5 min with a few drops of MeOH 
(4·TRIM, maroon). 
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Figure 6.21: Experimental PXRD pattern of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4, navy blue), 
fumaric acid (FUM, green) and the new product obtained after grinding for 5 min with a few drops of MeOH 
(4·FUM, maroon). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.22: Experimental PXRD pattern of N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (4, navy blue), indole 
(IND, green) and the new product obtained after grinding for 5 min with a few drops of MeOH (4·IND, 
maroon). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.23: Experimental PXRD pattern of N1-(7-chloroquinolin-4-yl)propane-1,2-diamine (5, navy blue), 
oxalic acid (OXA, green) and the new product obtained after grinding for 5 min with a few drops of MeOH 
(5·OXA, maroon). 
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Figure 6.24: Experimental PXRD pattern of N-(7-chloroquinolin-4-yl)propane-1,2-diamine (5, navy blue), 
malonic acid (MAL, green) and the new product obtained after grinding for 5 min with a few drops of MeOH 
(5·MAL, maroon). 
 
 
 
 
 
 
 
 
 
Figure 6.25: Experimental PXRD pattern of N-(7-chloroquinolin-4-yl)propane-1,2-diamine (5, navy blue), 
succinic acid (SUC, green) and the new product obtained after grinding for 5 min with a few drops of MeOH 
(5·SUC, maroon). 
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Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) traces: 
 
 
 
 
 
 
 
Figure 6.26: Thermal analysis of 1·OXA in comparison to its individual components. The TGA trace of 1·OXA 
is shown in black, the DSC trace of 1·OXA is shown in maroon, the DSC trace of 1 is shown in blue and the 
DSC trace of oxalic acid (OXA) is shown in green. The initial mass loss on the TGA trace (5.6%) most likely 
corresponds to the loss of one MeOH molecule (calculated loss: 6.2%) from 1:OXA:MeOH in a 1:1:1 ratio.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.27: Thermal analysis of 1·TRIM in comparison to its individual components. The TGA trace of 
1·TRIM is shown in black, the DSC trace of 1·TRIM is shown in maroon, the DSC trace of 1 is shown in blue 
and the DSC trace of trimesic acid (TRIM) is shown in green. The initial mass loss on the TGA trace (2.1%) 
most likely corresponds to the loss of one H2O molecule (calculated loss: 3.1%) from 1:TRIM:H2O in a 1:1:1 
ratio. 
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Figure 6.28: Thermal analysis of 1·FUM in comparison to its individual components. The TGA trace of 1·FUM 
is shown in black, the DSC trace of 1·FUM is shown in maroon, the DSC trace of 1 is shown in blue and the 
DSC trace of fumaric acid (FUM) is shown in green. The initial mass loss on the TGA (8.7%) most likely 
corresponds to the loss of two H2O molecules (calculated loss: 7.1%) from 1:FUM:2H2O in a 1:1:3 ratio, or the 
loss of one H2O and one MeOH molecule (calculated loss: 9.6%) from 1:FUM:MeOH:H2O in a 1:1:1:1 ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.29: Thermal analysis of 1·TERE in comparison to its individual components. The TGA trace of 
1·TERE is shown in black, the DSC trace of 1·TERE is shown in maroon, the DSC trace of 1 is shown in blue 
and the DSC trace of terephthalic acid (TERE) is shown in green. The initial mass loss on the TGA (4.1%) most 
likely corresponds to the loss of one H2O molecule (calculated loss: 3.3%) from 1:TERE:H2O in a 1:1:1 ratio. 
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 Figure 6.30: Thermal analysis of 2·OXA in comparison to its individual components. The TGA trace of 
2·OXA is shown in black, the DSC trace of 2·OXA is shown in maroon, the DSC trace of 2 is shown in blue and 
the DSC trace of oxalic acid (OXA) is shown in green. The initial mass loss on the TGA (6.3%) most likely 
corresponds to the loss of one MeOH molecule (calculated loss: 5.5%) from 2:OXA:MeOH in a 1:1:1 ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.31: Thermal analysis of 2·TRIM in comparison to its individual components. The TGA trace of 
2·TRIM is shown in black, the DSC trace of 2·TRIM is shown in maroon, the DSC trace of 2 is shown in blue 
and the DSC trace of trimesic acid (TRIM) is shown in green. The initial mass loss on the TGA (5.1%) most 
likely corresponds to the loss of one MeOH molecule (calculated loss: 4.8%) from 2:TRIM:MeOH in a 1:1:1 
ratio. 
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Figure 6.32: Thermal analysis of 3·OXA in comparison to its individual components. The TGA trace of 3·OXA 
is shown in black, the DSC trace of 3·OXA is shown in maroon, the DSC trace of 3 is shown in blue and the 
DSC trace of oxalic acid (OXA) is shown in green. The initial mass loss on the TGA (2.9%) most likely 
corresponds to the loss of one H2O molecule (calculated loss: 3.8%) from 3:OXA:H2O in a 1:1:1 ratio. 
 
 
 
 
 
 
 
 
 
 
Figure 6.33: Thermal analysis of 3·DHBA in comparison to its individual components. The TGA trace of 
3·DHBA is shown in black, the DSC trace of 3·DHBA is shown in maroon, the DSC trace of 3 is shown in blue 
and the DSC trace of dihydroxybenzoic acid (DHBA) is shown in green. 
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Figure 6.34: Thermal analysis of 3·IND in comparison to its individual components. The TGA trace of 3·IND is 
shown in black, the DSC trace of 3·IND is shown in maroon, the DSC trace of 3 is shown in blue and the DSC 
trace of indole (IND) is shown in green. The initial mass loss on the TGA (10.4%) most likely corresponds to the 
loss of one MeOH and one H2O molecule (calculated loss: 10.2%) from 3:IND:MeOH:H2O in a 1:1:1:1 ratip. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.35: Thermal analysis of 3·RES in comparison to its individual components. The TGA trace of 3·RES 
is shown in black, the DSC trace of 3·RES is shown in maroon, the DSC trace of 3 is shown in blue and the 
DSC trace of resorcinol (RES) is shown in green. 
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Figure 6.36: Thermal analysis of 3·MAL in comparison to its individual components. The TGA trace of 3·MAL 
is shown in black, the DSC trace of 3·MAL is shown in maroon, the DSC trace of 3 is shown in blue and the 
DSC trace of malonic acid (MAL) is shown in green. 
 
 
 
 
 
 
 
 
 
Figure 6.37: Thermal analysis of 4·OXA in comparison to its individual components. The TGA trace of 4·OXA 
is shown in black, the DSC trace of 4·OXA is shown in maroon, the DSC trace of 4 is shown in blue and the 
DSC trace of oxalic acid is shown in green. 
 
 
 
 
 
 
110.9 °C 138.4 °C 
144.3 °C 
143.4 °C 
78.3 °C 
97.9 °C 
135.1 °C 
102.5 °C 
138.3 °C 
162.9 °C 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 6: Experimental Information 
 
147 | P a g e  
 
 
 
 
 
 
 
 
 
Figure 6.38: Thermal analysis of 4·PAM in comparison to its individual components. The TGA trace of 4·PAM 
is shown in black, the DSC trace of 4·PAM is shown in maroon, the DSC trace of 4 is shown in blue and the 
DSC trace of pamoic acid is shown in green. The initial mass loss on the TGA (5.9%) mostly likely corresponds 
to the loss of one MeOH molecule (calculated loss: 4.9%) from 4:PAM:MeOH in a 1:1:1 ratio, or the loss of two 
H2O molecules (calculated loss: 5.6%) from 4:PAM:2H2O in a 1:1:2 ratio. 
 
 
 
 
 
 
 
 
 
Figure 6.39: Thermal analysis of 4·TRIM in comparison to its individual components. The TGA trace of 
4·TRIM is shown in black, the DSC trace of 4·TRIM is shown in maroon, the DSC trace of 4 is shown in blue 
and the DSC trace of trimesic acid is shown in green.  
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Figure 6.40: Thermal analysis of 4·FUM in comparison to its individual components. The TGA trace 
of 4·FUM is shown in black, the DSC trace of 4·FUM is shown in maroon, the DSC trace of 4 is shown in blue 
and the DSC trace of fumaric acid is shown in green. The initial mass loss on the TGA (10.6%) most likely 
corresponds to the loss of two H2O molecules (calculated loss: 9.7%) from 4:FUM:2H2O in a 1:1:2 ratio. 
 
 
 
 
 
 
 
 
Figure 6.41: Thermal analysis of 4·IND in comparison to its individual components. The TGA trace of 
4·IND is shown in black, the DSC trace of 4·IND is shown in maroon, the DSC trace of 4 is shown in blue and 
the DSC trace of indole is shown in green. 
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Figure 6.42: Thermal analysis of 5·OXA in comparison to its individual components. The TGA trace 
of 5·OXA is shown in black, the DSC trace of 5·OXA is shown in maroon, the DSC trace of 5 is shown in blue 
and the DSC trace of oxalic acid is shown in green. 
 
 
 
 
 
 
 
 
 
 
Figure 6.43: Thermal analysis of 5·SUC in comparison to its individual components. The TGA trace of 
5·OXA is shown in black, the DSC trace of 5·SUC is shown in maroon, the DSC trace of 5 is shown in blue and 
the DSC trace of succinic acid is shown in green. The initial mass loss on the TGA (7.9%) most likely 
corresponds to the loss of one MeOH molecule (8.3%) from 5:SUC:MeOH in a 1:1:1 ratio. 
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\ 
Figure 6.44: Thermal analysis of 5·MAL in comparison to its individual components. The TGA trace 
of 5·MAL is shown in black, the DSC trace of 5·MAL is shown in maroon, the DSC trace of 5 is shown in blue 
and the DSC trace of malonic acid is shown in green. The initial mass loss on the TGA (10.0%) most likely 
corresponds to the loss of one MeOH molecule (8.6%) from 5:MAL:MeOH in a 1:1:1 ratio. 
 
6.3 EXPERIMENTAL DATA PERTAINING TO CHAPTER 3 
2-Amino-5-iodobenzoic acid (19) 
 
In a 500 mL round-bottomed flask was added 0.58 M KOH solution (1.32 g KOH in 40 mL distilled 
water) and commercially available 2-aminobenzoic acid (2.01 g, 14.6 mmol, 1.00 equivalents). In a 
second flask, iodine (3.70 g, 14.6 mmol, 1.00 equivalent) was added portion wise to a 1.7 M KOH 
solution (1.91 g KOH in 20 mL distilled water) and the mixture stirred until the iodine was completely 
dissolved. This iodine mixture was then added dropwise to the 2-aminobenzoate solution over 
20 minutes, resulting in an orange-brown solution. After 1 hour, glacial acetic acid (8 mL) was added 
in one portion, followed immediately by distilled water (25 mL). The dark reaction mixture was stirred 
for 2 hours at room temperature before a saturated solution of sodium thiosulphate (50 mL) was added. 
The reaction mixture was stirred for further 1 hour, during which the mixture lightened in colour. The 
precipitate was filtered off and washed with distilled water (4 × 20 mL) and dried in air for 10 minutes 
using vacuum filtration. The resulting product was recrystallised from hot methanol to afford the title 
compound in 78% yield (3.01 g) as a brown crystalline solid.  
189.8 °C 
89.6 °C 
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TLC (50% EtOAc/Hexane): Rf = 0.42. 1H NMR (300 MHz, DMSO-d6) δ 8.80 (br. s., 3H), 
7.92 (d, J = 2.2 Hz, 1H), 7.45 (dd, J = 8.7, 2.2 Hz, 1H), 6.61 (d, J = 8.7 Hz, 1H). IR (ATR, cm-1) 3500 
(s, NH2), 3386 (s, NH2), 1662 (m, C=O), 1227 (s, C–O), 619 (C–I). Mp >230 °C (exceeded maximum 
temperature on melting point apparatus). The data compared well with the literature.28,29  
 
6-Iodoquinazolin-4(3H)-one (20) 
 
To a 25 mL round-bottomed flask was added 2-amino-5-iodobenzoic acid (19) (4.47 g, 16.9 mmol, 
1.00 equivalents), formamide (13.5 mL, 509 mmol, 30.0 equivalents) and ammonium formate (1.60 g, 
25.5 mmol, 1.50 equivalents). The reaction mixture was stirred at 140 °C for 18 hours. Once the reaction 
was complete (as indicated by TLC analysis), the mixture was cooled to room temperature and poured 
into ice cold distilled water (200 mL). The precipitate was filtered and washed with distilled water 
(4 × 20 mL) and then dried in air for 10 minutes using vacuum filtration. A brown crystalline solid was 
obtained after recrystallisation from hot methanol (2.96 g, 64% yield). 
TLC (80% EtOAc/Hexane): Rf = 0.41. 1H NMR (300 MHz, DMSO-d6) δ 12.40 (br s, 1H), 8.38 
(d, J = 2.3 Hz, 1H), 8.12 (s, 1H), 8.09 (dd, J = 8.4, 2.3 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H). IR (ATR, cm-1) 
3165 (w, NH), 1670 (s, C=O), 619 (m, C–I). Mp >230 °C (exceeded maximum temperature on melting 
point apparatus). The data compared well with the literature.30  
 
4-Chloro-6-iodoquinazoline (21) 
 
A solution of 6-iodo-quinazolin-4(3H)-one (20) (2.85 g, 7.36 mmol, 1.00 equivalent) in thionyl chloride 
(15.0 mL) and anhydrous DMF (0.1 mL) was heated under reflux (85 °C) under a nitrogen atmosphere 
for 2 hours. Upon complete consumption of the starting material (as indicated by TLC analysis), the 
pale brown translucent reaction mixture was quenched with a saturated solution of sodium bicarbonate 
(200 mL). The product was extracted into DCM (4 × 30 mL) and washed once with brine (30 mL). The 
organic fractions were dried over anhydrous MgSO4 and concentrated under reduced pressure. Flash 
column chromatography was used to purify the product, eluting with 0 – 60% EtOAc/Hexane to give 
the desired product as a pale yellow powder in a 58% yield (1.36 g).  
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TLC (50% EtOAc/Hexane): Rf = 0.79. 1H NMR (300 MHz, CDCl3) δ 9.08 (s, 1H), 8.67 (d, J = 1.9 Hz, 
1H), 8.22 (dd, J = 8.8, 1.9 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H). Mp 168 – 170 °C. The data compared well 
with the literature.30  
 
2-Chloro-1-[(3-fluorobenzyl)oxy]-4-nitrobenzene (24) 
 
To a 25 mL round-bottomed flask containing commercially available 3-fluorobenzyl bromide (0.3 mL, 
3 mmol, 1 equivalent), K2CO3 (0.486 g, 3.52 mmol, 1.50 equivalents) and acetonitrile (4 mL) was added 
a solution of commercially available 2-chloro-4-nitrophenol (0.408 g, 2.35 mmol, 1.00 equivalent) in 
acetonitrile (3 mL) in a dropwise fashion. The reaction mixture was stirred at 75 °C for 3 hours after 
which it was cooled to room temperature. The precipitate was filtered off using vacuum filtration and 
the filtrate was concentrated under reduced pressure. The product was eluted with a 0 – 30% 
EtOAc/Hexane gradient solvent system to give a pale yellow crystalline solid in 0.592 g yield (90%).  
TLC (15% EtOAc/Hexane): Rf = 0.63. 1H NMR (300 MHz, CDCl3) δ 8.34 (d, J = 2.8 Hz, 1H), 8.15 
(dd, J = 9.0, 2.8 Hz, 1H), 7.44 – 7.36 (m, 1H), 7.25 – 7.18 (m, overlapping peaks, 2H), 7.10 – 7.06 (m, 
1H), 7.02 (d, J = 9.0 Hz, 1H) 5.27 (s, 2H). IR (ATR, cm-1) 1511 (s, NO2), 1051 (s, C–O). Mp 90 – 93 
°C. The data compared well with the literature.30  
 
3-Chloro-4-[(3-fluorobenzyl)oxy]aniline (25) 
 
2-chloro-1-[(3-fluorobenzyl)oxy]-4-nitrobenzene (24) (0.718 g, 2.55 mmol, 1.00 equivalent), 
ammonium chloride (1.64 g, 30.6 mmol, 12.0 equivalents), methanol (20 mL), acetonitrile (15 mL), 
distilled water (10 mL) and zinc powder (1.05 g, 15.3 mmol, 6.00 equivalents) were added to a 100 mL 
round-bottomed flask and stirred at 30 °C for 4 hours. Once the reaction was complete (as indicated by 
TLC analysis), the precipitated was filtered off using vacuum filtration and washed well with methanol 
(4 × 20 mL). The solvent (filtrate) was removed under reduced pressure to yield a brown residue that 
was purified by recrystallisation from hot methanol to yield a pale brown crystalline solid (0.543 g, 
84%).  
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TLC (15% EtOAc/Hexane): Rf = 0.23. 1H NMR (300 MHz, CD3OD) δ 7.38 – 7.34 (m, 1H), 7.23 – 
7.20 (m, overlapping peaks, 2H), 7.02 – 7.00 (m, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 
6.60 (dd, J = 8.4, 2.3 Hz, 1H), 5.03 (s, 2H). The NH2 protons were not observed. IR (ATR, cm-1) 3405 
(m, NH2), 3318 (m, NH2) 1051 (s, C–O). Mp 69 – 71 °C. The data compared well with the literature.30  
 
N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine (17) 
 
To a 50 mL round-bottomed flask was added 4-chloro-6-iodoquinazoline (21) (0.520 g, 1.80 mmol, 
1.00 equivalent), 2-propanol (20 mL) and 3-chloro-4-[(3-fluoroylbenzyl)oxy]aniline (25) (0.500 g, 
1.98 mmol, 1.10 equivalents). The reaction mixture was stirred at 85 °C for 14 hours. The bright yellow 
precipitate was collected and dried in vacuo to yield the desired product (0.734 g, 81%). No further 
purification was carried out.  
TLC (50% EtOAc/Hexane): Rf = 0.62. 1H NMR (300 MHz, DMSO-d6) δ 11.38 (s, 1H), 9.26 (d, 1.4 Hz, 
1H), 8.95 (s, 1H), 8.37 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.67 (d, 
J = 8.8 1H), 7.40 – 7.38 (m, 1H), 7.31 – 7.30 (m, 3H), 7.23 – 7.19 (m, 1H), 5.20 (s, 2H). IR (ATR, cm-1) 
3035 (w, NH), 1059 (m, C–O). Mp 202 – 208 °C. LC-MS found [M+H]+ = 505.9 m/z (C21H14ClFIN3O); 
calculated [M+H]+ = 505.9 m/z. The data compared well with the literature.30 
 
Piperidylaminomethyl ferrocene (27d) 
 
To a 50 mL round-bottomed flask was added formaldehyde solution (34%, 1.3 mL, 20 mmol, 12.5 
equivalents) followed by phosphoric acid (85%, 0.1 mL, 2 mmol, 2 equivalents). To this solution, the 
piperidine (0.2 mL, 2 mmol, 1 equivalent) was added dropwise. Glacial acetic acid (8.0 mL) was added 
in one portion, followed by ferrocene (0.298 g, 1.60 mmol, 0.800 equivalents). The reaction mixture 
was stirred at 100 °C for 7.5 hours after which the reaction mixture was cooled and any unreacted 
ferrocene was extracted with EtOAc (3 × 10 mL). The aqueous layer was neutralised by the addition of 
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1.0 M NaOH solution (25 mL) and the product was extracted with EtOAc (3 × 30 mL). These organic 
fractions were combined, dried over anhydrous MgSO4, and concentrated under reduced pressure. 
Purification by flash column chromatography using EtOAc/Hexane/Et3N as the eluent provided the 
desired product moderate yield (0.296 g, 52%).  
TLC (EtOAc/Hexane/Et3N = 45:50:5): Rf = 0.63. 1H NMR (300 MHz, CDCl3) δ 4.17 – 4.15 (m, 2H), 
4.11 – 4.08 (m, overlapping peaks, 7H), 3.36 – 3.35 (m, 2H), 2.33 – 2.30 (m, 4H), 1.53 (quin, J = 5.6 
Hz, 4H), 1.36 – 1.34 (m, 2H). Mp 79 – 82 °C. The data compared well with the literature.31 
 
General procedure for the synthesis of di-substituted ferrocenes: 
To a dry Schlenk tube that has been evacuated and filled with nitrogen three times was added the relevant 
amino ferrocene (1.0 equivalent) and anhydrous diethyl ether (8 mL). This solution was then cooled to 
0 °C and t-BuLi (1.0 M, 1.1 equivalents) was added dropwise. The ice bath was removed and the bright 
orange reaction mixture was stirred for a further 2 hours. The reaction mixture was once again cooled 
to 0 °C and the appropriate electrophile (1.1 equivalents) added dropwise. The ice bath was removed 
and the reaction stirred at room temperature for a further 2 hours after which dilute hydrochloric acid 
(1.0 mL, 1.0 M) was added dropwise to quench the reaction. The product was extracted with DCM 
(3 × 30 mL) and the organic fractions combined, dried over anhydrous MgSO4 and concentrated under 
reduced pressure. No further purification was carried out. 
 
2-Dimethylaminomethyl-ferrocene-1-boronic acid (16a) 
 
Amino ferrocene: N,N-dimethylaminomethyl ferrocene (0.7 mL, 4 mmol, 1 equivalent). Appropriate 
electrophile: trimethyl borate (0.4 mL, 4 mmol, 1 equivalent). Product obtained as a dark red-brown 
crystalline solid in quantitative yields (1.01 g).  
TLC (EtOAc/Hexane/Et3N = 45:50:5): Rf = 0.36. 1H NMR (300 MHz, CDCl3) δ 4.47- 4.44 (m, 1H), 
4.25 – 4.21 (m, 2H), 4.12 (s, 5H), 4.07 (d, J = 12.5 Hz, 1H), 2.87 (d, J = 12.5 Hz, 1H), 2.21 (s, 6H). IR 
(ATR, cm-1) 3279 (br, m, OH), 1462 (NCH3). Mp 72 – 74 °C. The data compared well with the 
literature. 32 
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2-Piperidylaminomethyl-ferrocene-1-boronic acid (16d) 
 
Amino ferrocene: piperidylaminomethyl ferrocene (27d) (0.283 g, 0.993 mmol, 1 equivalent). 
Appropriate electrophile: trimethyl borate (0.1 mL, 1 mmol, 1 equivalent). Product obtained as a dark 
brown solid in quantitative yield. (0.320 g).  
TLC (EtOAc/Hexane/Et3N = 45:50:5): Rf = 0.32. 1H NMR (300 MHz, CDCl3) δ 4.30 – 4.28 (m, 1H), 
4.22 – 4.20 (m, 1H), 4.16 (s, 5H), 4.13 – 4.12 (m, 1H), 3.73 (br s, 2H), 2.66 (br s, 4 H), 1.81 (br s, 4H), 
1.49 (br s, 2H). The OH protons of the boronic acid are not observed. IR (ATR, cm-1) 3272 (br, m, OH), 
1465 (NCH3). Mp 91 – 94 °C. LCMS found [M+H]+ = 287.94 m/z for C16H22BFeNO2); found [M+H]+ 
= 287.14 m/z. 
 
1-Iodo-2-piperadylmethyl ferrocene (32) 
 
Amino ferrocene: piperadylaminomethyl ferrocene (27d) (0.200 g, 0.707 mmol, 1.00 equivalent). 
Appropriate electrophile: 1,2-diiodoethane (0.258 g, 0.918 mmol, 1.10 equivalents). Product obtained 
as a deliquescent dark brown solid in quantitative yield (0.288 g,). 
TLC (EtOAc/Hexane/Et3N = 45:50:5): Rf = 0.33. 1H NMR (300 MHz, CDCl3) δ 4.30 – 4.28 (m, 1H), 
4.22 – 4.19 (m, overlapping peaks, 2H), 4.15 (s, 5H), 2.66 – 2.64 (m, 4H), 1.81 – 1.79 (m, 4H), 1.49 – 
1.48 (m, 2H), 1.26 (s, 2H). LC-MS found [M+H]+ = 410.09 m/z for C16H22FeIN; calculated [M+H]+ = 
410.09 m/z. 
 
Suzuki-Miyaura coupling reaction 
General method A: solution synthesis 
To a Schlenk tube was added aryl halide (1 equivalent), boronic acid (1 – 2 equivalents), base 
(2 equivalents) and the respective solvent mixture. The reaction mixture was degassed using the freeze-
pump-thaw method (4 cycles) and backfilled with nitrogen gas. The respective palladium catalyst 
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(10 mol%) was added under a positive pressure of nitrogen. The reaction was then stirred and heated for 
18 hours after which it was cooled, filtered through Celite (washing with MeOH) and the filtrate 
concentrated onto silica gel and purified by flash column chromatography (0 – 100% EtOAc/Hexane) 
In most cases, either starting material remained, or the by-product described below formed. 
 
 
 
 
 
TLC (50% EtOAc/Hexane): Rf = 0.34. 1H NMR (300 MHz, CDCl3) δ 9.76 (s, 1H), 8.56 (s, 1H), 8.54 
(d, J = 8.2 Hz, 1H), 8.05 (d, J = 2.4 Hz, 1H), 7.91 – 7.90 (m, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.75 (dd, J 
= 8.8, 2.4 Hz, 1H), 7.59 – 7.57 (m, 1H), 7.47 – 7.46 (m, 1H), 7.32 – 7.30 (m, 2H), 7.21 (d, J = 8.8 Hz, 
1H), 7.15 – 7.13 (m, 1H), 5.26 (s, 2H). LC-MS found [M+H]+ = 380.10 m/z; calculated 
[M+H]+ = 380.09 m/z for C21H15ClFNO3. The data compared well with the literature.30 
 
General method B: microwave synthesis of 15d30 
 
 
 
 
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine (1 equivalent) was added to a 
microwave vial, followed by bis(pinacolato)diboron (1.5 equivalents) and potassium acetate 
(3.5 equivalents). Anhydrous dioxane was added followed by PdCl2(dppf)·CH2Cl2 (10 mol%). The 
reaction mixture was degassed by bubbling nitrogen gas through the mixture for 10 minutes. The vial 
was placed in the microwave and stirred at 145 °C for 1 hour 45 minutes. Once complete, the reaction 
mixture was filtered through Celite (washing with EtOAc) and concentrated under reduced pressure to 
give a crude residue that was used directly in the next reaction.  
To a second microwave vial was added 2-piperadylaminomethyl ferrocene-1-boronic acid 
(1.00 equivalent), the crude boronate product above (1.50 equivalents), barium hydroxide 
(3.00 equivalents), and EtOH/H2O (3:1, 1.3 mL). The reaction mixture was degassed for 10 minutes by 
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bubbling nitrogen gas through the mixture. The respective palladium catalyst was then added and the 
reaction mixture degassed for a further 5 minutes. The reaction was stirred in the microwave reactor at 
the conditions listed in Chapter 3. The mixture was then cooled, filtered through Celite (washing with 
MeOH) and concentrated under reduced pressure. Purification was carried out with flash column 
chromatography however the desired product was unable to be isolated. Preparative HPLC on a second 
reaction also was tried, but without success.  
LC-MS found [M+H]+ = 661.22 m/z; calculated [M+H]+ = 661.19 m/z for C37H34ClFFeN4O. 
 
Quinazolin-4(3H)-one (40) 
 
 
 
Commercially available anthranilic acid (5.00 g, 19.1 mmol, 1.00 equivalent), ammonium formate 
(13.8 g, 219 mmol, 6.00 equivalents) and formamide (20 mL) were added to a 50 mL round-bottomed 
flask and stirred at 140 °C overnight. The pale brown solution was then cooled to room temperature and 
poured into ice cold water (100 mL), upon which a precipitate was formed. This off-white precipitate 
was collected by vacuum filtration and washed with distilled water (3 × 20 mL) and dried in vacuo for 
1 hour. Purification by flash column chromatography eluting with 50 – 100% EtOAc/Hexane resulted 
in the desired compound as a white solid (3.39 g, 67%).  
TLC (15% EtOAc/Hexane): Rf = 0.43. 1H NMR (300 MHz, CDCl3) δ 8.30 (dd, J = 8.0, 1.1 Hz, 1H), 
8.23 (d, J =13.7 Hz, 1H), 8.14 (s, 1H), 7.81 – 7.80 (m, 1H), 7.78 – 7.75 (m, 1H), 7.54 – 7.51 (m, 1H). 
IR (ATR, cm-1) 3163 (m, NH), 1660 (s, C=O). Mp 142 – 145 °C. 
 
6-Nitro-quinazolin-4(3H)-one (41) 
 
 
 
To a 25 mL round-bottomed flask was added conc. H2SO4 (8.0 mL, 140 mmol, 6 equivalents), followed 
by fuming nitric acid (8.0 mL, 140 mmol, 6 equivalents). To this mixture was added quinazolin-4(3H)-
one (40) (3.28 g, 22.5 mmol, 1.00 equivalent) portion wise over 30 minutes. The resulting yellow 
solution was stirred at 95 °C for 2 hours. The solution was cooled to room temperature and neutralised 
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by slowly adding the solution to a cold, saturated solution of sodium bicarbonate (150 mL). An 
additional amount of the sodium bicarbonate solution was added until a pH of approximately 7 was 
obtained as determined by universal indicator paper (roughly 50 mL). The pale yellow precipitate was 
collected by vacuum filtration, washed with distilled water (3 × 30 mL) and dried in air overnight. The 
desired product was obtained as a pale yellow solid in 83% yield (3.56 g). No further purification was 
necessary.  
TLC (50% EtOAc/Hexane): Rf = 0.37. 1H NMR (300 MHz, DMSO-d6) δ 12.75 (br. s., 1H), 8.78 
(d, J = 2.4 Hz, 1H), 8.53 (dd, J = 8.8, 2.4 Hz, 1H), 8.30 (s, 1H), 7.85 (d, J = 8.8 Hz, 1H). 
IR (ATR cm-1) 1652 (s, C=O), 1607 (s, NO2). Mp 285 – 287 °C.  
 
4-Chloro-6-nitro-quinazoline (42) 
 
A solution of 6-nitro-quinazolin-4(3H)-one (41) (0.501 g, 2.62 mmol, 1.00 equivalent) in thionyl 
chloride (10.0 mL, 0.139 mmol, 53.0 equivalents) and anhydrous DMF (0.2 mL, 3 mmol, 1 equivalents) 
was heated under reflux at 85 °C under a nitrogen atmosphere for 2 hours. Upon complete consumption 
of the starting material (TLC), the reaction mixture was quenched with a saturated solution of sodium 
bicarbonate (15 mL). The product was extracted into DCM (4 × 30 mL) and washed once with brine 
(30 mL). The organic fractions were dried over anhydrous MgSO4 and concentrated under reduced 
pressure. Flash column chromatography was used to purify the product, eluting with 0 – 60% 
EtOAc/Hexane to give 42 as a pale yellow powder in a 70% yield (0.384 g).  
TLC (50% EtOAc/Hexane): Rf = 0.84. 1H NMR (300 MHz, CDCl3) δ 9.51 (d, J = 2.3 Hz, 1H), 8.55 
(m, 1H), 8.10 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H). Mp 168 – 170 °C. The data compared well with the 
literature.33  
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N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-nitroquinazolin-4-amine (43) 
 
To a 50 mL round-bottomed flask was added 4-chloro-6-nitroquinazoline (42) (0.351 g, 1.67 mmol, 
1.00 equivalent), 2-propanol (20 mL) and 3-chloro-4-[(3-fluoroylbenzyl)oxy]aniline (25) (0.422 g, 
1.67 mmol, 1.00 equivalent). The reaction mixture was stirred at 85 °C for 14 hours. The bright yellow 
precipitate was collected and dried in vacuo to yield the desired product (0.726 g, 86%). No further 
purification was necessary.  
TLC (20% MeOH/DCM): Rf = 0.73. 1H NMR (300 MHz, CDCl3) δ 9.75 (d, J = 2.4 Hz, 1H), 8.92 (s, 
1H), 8.70 (dd, J = 9.4, 2.4 Hz, 1H), 8.05 (d, J = 9.4 Hz, 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 8.8, 
2.4 Hz, 1H), 7.41 – 7.37 (overlapping peaks, 2H), 7.29 – 7.(overlapping peaks, 4H), 7.15 – 7.13 (m, 
1H), 5.30 (s, 2H).  
 
6-Amino-quinazolin-4-(3H)-one (45) 
 
Method A: zinc and mildly acidic conditions  
6-Nitro-quinazolin-4(3H)-one (0.251 g, 1.31 mmol, 1 equivalent), ammonium chloride (0.839 g, 
15.7 mmol, 12.0 equivalents), methanol (10 mL), acetonitrile (8 mL), distilled water (5 mL) and zinc 
powder (0.513 g, 7.85 mmol, 6 equivalents) were added to a 50 mL round-bottomed flask and stirred at 
60 °C overnight. Once the reaction was complete, the precipitate was filtered off using vacuum filtration 
and washed well with methanol (4 × 20 mL). The solvent (filtrate) was removed under reduced pressure 
to yield a brown residue that was purified by recrystallisation from hot methanol to yield a pale brown 
crystalline solid (0.0358 g, 17%). 
Method B: Hydrazine hydrate and Pd/C34 
6-Nitro-quinazolin-4(3H)-one (0.199 g, 1.04 mmol, 1.0 equivalent) and anhydrous methanol (10 mL) 
were added to a 50 mL round-bottomed flask, that had been previously dried and flushed with nitrogen. 
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To this solution was added hydrazine hydrate (0.5 mL, 3 mmol, 3 equivalents) and palladium on carbon 
(10 mol%). This mixture was heated under reflux under a nitrogen atmosphere for 24 hours, after which 
the reaction was cooled. The mixture was filtered through Celite and the filtrate concentrated under 
reduced pressure to give a brown residue that was purified by recrystallisation from hot methanol to 
give a pale brown crystalline solid (0.0396 g, 23%)  
TLC (EtOAc/Hexane/MeOH/Et3N = 50:30:10:10): Rf = 0.28. Ninhydrin was used to visualise the amine 
product on the TLC plate. 1H NMR (300 MHz, CDCl3) δ 11.81 (br. s., 1H), 7.76 (s, 1H), 7.38 (d, 
J = 8.2 Hz, 1H), 7.18 (d, J = 2.4 Hz, 1H), 7.07 (dd, J = 8.2, 2.4 Hz, 1H), 5.61 (br. s., 2H). IR (ATR, cm-1) 
3426 (w, NH), 3333 (w, NH), 1657 (s, C=O), 1603 (s, NH2).  
 
6.4 EXPERIMENTAL DATA PERTAINING TO CHAPTER 4 
Obtaining single crystals of the quinazolinone derivatives: 
To a 20 mL glass vial was added 20 mg of the respective quinazolinone. Methanol was added to dissolve 
the sample, using gentle heating and stirring to assist with dissolution. The solution was filtered through 
a microfilter into a clean, labelled vial and the cap replaced. After three days, if no crystals had formed, 
2 – 3 holes were poked into the vial cap to aid slow evaporation of the solvent. Diffraction-quality 
crystals were obtained within 1 week for 41, 45 and 20. 
In addition to methanol, DMSO, DMF and DMA could also be used to obtain diffraction-quality crystals 
of each of the quinazolinone derivatives, with the exception of 40.  
 
Hydrogen-bonding geometry tables 
 
 
 
Table 6.4: Hydrogen-bonding geometries of 41 
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C13—H13···N1i 0.95 2.48 3.420 (2) 171 
C2—H2···O11ii 0.95 2.50 3.416 (2) 162 
C12—H12···O11iii 0.95 2.49 3.388 (2) 157 
N3—H3···O5iv 0.87 (2) 1.92 (2) 2.790 (1) 176 (2) 
Symmetry codes: (i) −x+2, −y, −z+1; (ii) x+1, y, z+1; (iii) −x+1, −y, −z; (iv) −x+1, −y+1, −z+2. 
 
 
N1 
N3 
O5 
C12 
O11 
O10 
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Table 6.5: Hydrogen-bonding geometries for 20  
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C10—H10···I9i 0.95 3.24 4.013 (2) 140 
N3—H3···O5ii 0.88 (3) 1.90 (3) 2.778 (2) 175 (2) 
Symmetry codes: (i) −x+1, −y, −z+1; (ii) −x+2, −y+2, −z+1. 
 
 
 
 
 
 
Table 6.6: Hydrogen-bonding geometries for 45 
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C2—H2···O5i 0.93 2.50 3.211 (3) 133 
C12—H12···O15ii 0.93 2.48 3.214 (3) 136 
N13—H1···O5iii 0.90 (3) 1.92 (3) 2.814 (2) 174 (2) 
N3—H7···O15iv 0.92 (3) 1.91 (3) 2.828 (2) 174 (3) 
N19—H5···N8v 0.91 (3) 2.53 (3) 3.389 (3) 158 (3) 
N8—H3···N1ii 0.92 (3) 2.15 (3) 3.065 (3) 173 (3) 
N19—H4···N11i 0.89 (4) 2.24 (4) 3.112 (3) 169 (3) 
Symmetry codes: (i) x+1/2, −y, z; (ii) x−1/2, −y+1, z; (iii) x, y+1, z; (iv) x, y−1, z; (v) −x+1, −y, z−1/2. 
 
 
 
 
 
 
 
 
 
I9 
N3 
O5 
C10 
N13 
N11 
N3 
N1 
O5 
O15 
N8 
N19 
C12 
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Powder X-ray Diffraction: 
 
 
 
 
 
 
 
Figure 6.45: Comparison of the experimental (blue) and calculated (black) PXRD patterns of 41. The 
experimental pattern was recorded at room temperature and the calculated pattern was obtained from crystal 
structure data collected at 100 K.  
Figure 6.46: Comparison of the experimental (blue) and calculated (black) PXRD patterns of 45. The 
experimental pattern was recorded at room temperature and the calculated pattern was obtained from crystal 
structure data collected at 100 K. 
 
 
 
 
 
 
 
 
45_experimental 
45_calculated 
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Figure 6.47: Comparison of the experimental (blue) and calculated (black) PXRD patterns of 20. The 
experimental pattern was recorded at oom temperature and the calculated pattern was obtained from crystal 
structure data collected at 100 K. 
 
 Molecular Electrostatic Potential Surface (MEPS) calculation results 
All input and wavefunction files as well as log files for each compound can be found in Appendix B 
(electronic data). Table 6.7 lists the 32 coformers and the ∆E value associated with each combination.  
 
 
 
 
 
 
 
 
 
 
 
 
20_experimental 
20_calculated 
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Table 6.7: ∆E values for the 1:1 combinations of 40, 41 and 45 with each coformer. 
40 41 45 
Coformer -∆E 
(kJ mol-1) 
Coformer -∆E 
(kJ mol-1) 
Coformer -∆E 
(kJ mol-1) 
Oxalic acid 10.4 Oxalic acid 9.6 Oxalic acid 12.1 
3,5-Dihydroxy 
benzoic acid 
6.2 
p-Aminobenzoic 
acid 
9.5 Trimesic acid 7.1 
Methyl gallate 6.1 Ethylenediamine 9.0 Pamoic acid 7.0 
Fumaric acid 5.4 
3,5-Dihydroxy 
benzoic acid 
8.1 Ethylenediamine 6.5 
Trimesic acid 5.4 Methyl gallate 7.3 
3,5-Dihydroxy 
benzoic acid 
6.2 
Pamoic acid 5.0 Resorcinol 6.6 Fumaric acid 5.9 
p-Aminobenzoic 
acid 
4.9 Trimesic acid 6.5 Resorcinol 5.5 
Resorcinol 4.4 Benzamide 6.4 Piperazine 5.5 
Indole 4.2 Piperazine 6.2 Pyrazine 4.9 
Benzamide 3.1 Pamoic acid 5.3 4,4-Bipyridine 4.4 
Teraphthalic acid 3.1 Indole 5.3 Tartaric acid 4.3 
Ethylenediamine 3.1 Fumaric acid 4.9 Teraphthalic acid 4.2 
Malonic acid 2.7 Thymine 4.3 Theophylline 4.0 
Salicylic acid 2.6 Tartaric acid 4.2 Malonic acid 3.7 
Tartaric acid 2.5 Caffeine 3.5 Salicylic acid 3.3 
Thymine 2.3 4,4-Bipyridine 3.2 Succinic acid 3.2 
Piperazine 2.1 Hydroquinone 3.0 Hydroquinone 3.0 
Hydroquinone 1.9 Teraphthalic acid 2.9 Nicotinic acid 3.0 
Succinic acid 1.5 Theophylline 2.6 Indole 2.7 
Saccharin 1.2 Malonic acid 2.6 Glutaric acid 2.5 
Morpholine 1.0 Salicylic acid 2.5 Saccharin 2.5 
4,4-Bipyridine 0.7 Saccharin 2.2 Caffeine 2.3 
Glutaric acid 0.7 Morpholine 2.1 Methyl gallate 2.0 
Theophylline 0.6 Succinic acid 1.7 Morpholine 1.8 
Caffeine 0.6 Pyrazine 1.6 
p-Aminobenzoic 
acid 
1.4 
Vanillin 0.5 Menthol 1.6 Benzoic acid 1.3 
Naphthalene 0.4 Vanillin 1.5 Naphthalene 1.1 
Nicotinic acid 0.3 Nicotinamide 1.5 Thymine 0.7 
Pyrazine 0.3 Glutaric acid 1.1 Vanillin 0.4 
Benzoic acid 0.2 Naphthalene 0.6 Benzamide 0.2 
Menthol 0.1 Benzoic acid 0.4 Nicotinamide 0.2 
Nicotinamide 0.1 Nicotinic acid 0.4 Menthol 0.2 
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Obtaining multicomponent crystals of 40, 41 and 45 with organic coformers: 
Mechanochemistry: 
Liquid-assisted grinding (using a few drops of MeOH) was used as a screening tool to determine whether 
multicomponent crystals would form between the respective quinazolinone and various coformers. 
Stoichiometric amounts of the quinazolinone (10 mg) and coformer were added to a mortar and pestle 
and 3 drops of MeOH were added. The components were ground together for 5 minutes. PXRD was 
used to determine whether a mixture of starting components was still present or whether a new product 
had formed. In cases where starting material was still observed (by PXRD), an additional 10 minutes of 
grinding was carried out and PXRD was once again carried out.  
PXRD patterns of successful attempts 
 
 
 
 
 
 
Figure 6.48: Comparison of the PXRD patterns of the product obtained from MeOH (40·OXA – black), product 
obtained from LAG (40·OXA – maroon), and the two individual components (40 – blue and oxalic acid – 
green).  
 
 
 
 
 
 
Figure 6.49: Comparison of the PXRD patterns of the product obtained from MeOH (40·FUM – black), product 
obtained from LAG (40·FUM – maroon), and the two individual components (40 – blue and fumaric acid – 
green). 
Fumaric acid 
40 
40·FUM from LAG (2:1) 
40·FUM from MeOH (2:1) 
Oxalic acid 
40 
40·OXA from MeOH (2:1) 
40·OXA from LAG (2:1) 
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Figure 6.50: Comparison of the experimental PXRD pattern obtained from LAG (40·SAL – maroon) and 
calculated (black) PXRD patterns of 40·SAL, as well as the two starting components – 40 (blue) and salicylic 
acid (green). 
 
 
 
 
 
 
 
Figure 6.51: Comparison of the PXRD patterns of the product obtained from LAG (40·TERE – maroon) and 
the two individual components (40 – blue and terephthalic acid – green).  
 
 
 
 
 
 
 
Figure 6.52: Comparison of the PXRD patterns of the product obtained from LAG (40·BEN – maroon), product 
obtained from MeOH (40·BEN – black), and the two individual components (40 – blue and benzoic acid – 
green). 
Salicylic acid 
40 
40·SAL from LAG 
40·SAL_calculated 
Benzoic acid 
40 
40·BEN from solution 
40·BEN from LAG 
Terephthalic acid 
40 
40·TERE 
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Figure 6.53: Comparison of the PXRD patterns of the product obtained from LAG (40·SUC – maroon) and the 
two individual components (40 – blue and succinic acid – green).  
 
 
 
 
 
 
 
Figure 6.54: Comparison of the PXRD patterns of the product obtained from LAG (40·GLU – maroon) and the 
two individual components (40 – blue and glutaric acid – green).  
 
 
 
 
 
 
 
Figure 6.55: Comparison of the PXRD patterns of the product obtained from LAG (40·DIFB – maroon) and the 
two individual components (40 – blue and 1,4-diiodotetrafluorobenzene (DIFB) – green).  
40 
40·SUC 
Succinic acid 
Glutaric acid 
40 
40·GLU 
DIFB 
40 
40·DIFB 
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Solution cocrystallisation: 
Stoichiometric amounts of the quinazolinone (10 mg) and coformer were added to a vial and the 
appropriate solvent (MeOH or DMSO) was added. Gentle heating and stirring ensured that the minimum 
amount of solvent needed was used to dissolve the components. Vials were then placed on a shelf and 
the solvent allowed to slowly evaporate. Crystals/solid material was obtained after 1 – 18 days. If 
diffraction-quality crystals were obtained, single-crystal X-ray diffraction was used to determine the 
unit cell (and therefore whether the crystal was one of either starting component or something new). If 
only poor quality crystals or powders were obtained from solution, PXRD was used to identify the solid 
material.  
Hydrogen-bonding geometry tables 
 
 
 
 
Table 6.8: Hydrogen-bonding geometries for 41·MeOH  
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C2—H2···O5i 0.95 2.21 3.136 (2) 166 
C12—H12···O10ii 0.95 2.34 3.213 (2) 152 
N3—H1···O16 0.91 (2) 1.87 (2) 2.773 (2) 175.1 (2) 
O16—H3···N1iii 0.88 (2) 1.97 (2) 2.839 (2) 170.4 (2) 
Symmetry codes: (i) −x+1, y+1/2, −z+3/2; (ii) −x+2, y+1/2, −z+1/2; (iii) −x+1, y−1/2, −z+3/2. 
 
 
 
 
 
Table 6.9: Hydrogen-bonding geometries for 40·OXA 
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C2—H2···O13i 0.93 2.44 3.013 (4) 120 
C8—H8···O11ii 0.93 2.43 3.130 (4) 132 
N3—H1···O12iii 0.92 (5) 1.98 (5) 2.877 (4) 164 (5) 
N3—H1···O13i 0.92 (5) 2.38 (5) 2.949 (4) 120 (4) 
O12—H3···N1 0.91 (2) 1.69 (3) 2.583 (4) 166 (8) 
Symmetry codes: (i) −x+1, y+1, −z+1/2; (ii) x, −y+1, z−1/2; (iii) x, −y+2, z+1/2. 
 
 
N1 
N3 
O5 
O10
O11
O16 
C2 
C8 N1 
N3 
O5 
O13 
O12 
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Table 6.10: Hydrogen-bonding geometries for 40·FUM 
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C2—H2···O12 0.93 2.52 3.177 (2) 128 
N3—H1···O11i 0.912 (2) 1.99 (2) 2.833 (1) 154.3 (1) 
O13—H3···N1 1.03 (2) 1.59 (2) 2.619 (1) 175 (2) 
Symmetry code: (i) −x+3/2, y+1/2, −z+1/2. 
 
 
 
 
 
 
 
 
 
 
 
Table 6.11: Hydrogen-bonding geometries for 40·SAL 
D–H⋯A D–H () H⋯A () D⋯A () D–H⋯A (°) 
C40—H40···O11 0.93 2.59 3.470 (2) 159 
C2—H2···O32i 0.93 2.47 3.350 (2) 158 
C30—H30···O22ii 0.93 2.53 3.402 (2) 156 
C13—H13···O42 0.93 2.36 3.280 (1) 169 
N3—H1···O22 0.91 (2) 1.88 (2) 2.784 (2) 172 (2) 
N14—H9···O11 0.89 (2) 1.89 (2) 2.782 (2) 174 (2) 
O32—H3···O23 0.89 (2) 1.84 (2) 2.644 (1) 150 (2) 
O32—H3···O34iii 0.89 (2) 2.46 (2) 3.009 (2) 120 (2) 
O42—H4···O23iv 0.89 (2) 2.48 (2) 3.016 (1) 120 (2) 
O42—H4···O34 0.89 (2) 1.82 (2) 2.630 (1) 150 (2) 
O24—H10···N12iii 0.95 (2) 1.67 (3) 2.606 (2) 168 (2) 
O33—H11···N1v 0.94 (2) 1.71 (2) 2.633 (2) 166 (2) 
Symmetry codes: (i) x, y, z−1; (ii) x, y, z+1; (iii) x−1, y, z; (iv) x+1, y, z; (v) x+1, y, z+1. 
N1 
N3 
C2 
O5 
O12 
O13 
C40 
C30 
N14 
N1 
C13 
N3 
O11 
O22 
O33 
O34 
O42 
O24 
O23 
O32 
N12 
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Figure 6.56: Comparison of the TGA trace of 41·MeOH (black) and the DSC trace of 41 (blue) and 41·MeOH 
(green). The mass loss on the TGA (12.3%) corresponds to the loss of one MeOH molecule (calculated 
loss: 14.4%) 
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Addendum A 
Synthesis of quinoline derivatives as antischistosomal 
agents 
 
 
Note to the reader: 
 
This work was carried out in the Pollastri laboratory at Northeastern University, Boston, USA between August 
and October 2017. While only the work that I carried out is reported herein, additional information based on the 
larger project is given where necessary for completeness. This work forms part of a manuscript currently being 
prepared by the Pollastri group.  
 
 
A.1 INTRODUCTION 
 
Neglected tropical diseases (NTDs) are classified as a group of seventeen communicable diseases that 
affect the lives of over 1 billion people globally that live in tropical and subtropical regions, but have 
received little attention from pharmaceutical companies in terms of drug discovery, simply because of 
a lack of financial interest.1 The Pollastri research group focusses on three of these diseases, namely 
American trypanosomiasis (chagas disease), human African trypanosomiasis (African sleeping 
sickness) and leishmaniasis (black fever).2–4 As these diseases are all caused by protozoan parasites, 
many of the compounds that are screened against NTDs are potent against more than one parasite. 
While not technically classified as a NTD by the World Health Organisation, malaria is still one of the 
deadliest infectious protozoan diseases.5,6 Therefore, compounds used to treat NTDs are also tested 
against the chloroquine-susceptible and chloroquine-resistant strains of P. falciparum.7 More recently, 
the Pollastri group has included a fourth NTD, schistosomiasis (bilharzia), to their list of disease 
targets. While schistosomiasis is caused by trematodes (blood flukes or worms) and not protozoa, 
there are similar features in their life cycles and potential drug targets. For example, as for protozoa of 
the Plasmodium genus, the detoxification of heme through hemozoin formation occurs in tremadoes of 
the Schistosoma genus too. 
With over 200 million people infected worldwide in 2016, the World Health Organisation considers 
schistosomiasis to be a major public health concern.8 There are three main species of Schistosoma that 
infect humans, namely S. japonicum, S. haematobium and S. mansoni, of which S. mansoni is most 
prevalent. Similarly to malaria, the parasite requires a human as well as animal host to complete its life 
cycle (Figure A.1). Schistosome eggs hatch in water and the larvae (miracidia) penetrate freshwater 
snails (animal host) where, after several weeks of growth, cercariae are released from the snail into the 
surrounding water. These cercariae are then able to penetrate human skin and subsequently move to 
the liver where they mature into adult worms. After maturation, the worms move through the 
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bloodstream to either the abdominal cavity or urinary tract where they reproduce. Some of the eggs 
that are produced escape through the bladder or bowel, while the others are trapped in the tissue of the 
host. The eggs that are released from the human host are then once again able to infect freshwater 
snails and the cycle repeats.9,10  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1: Life cycle of Schistosoma worms. Image taken from the Centre for Disease Control (CDC) 
website.10 
 
Remarkably, we have relied on just one drug as treatment for this disease – praziquantel (Figure A.2).8 
After its discovery in the early 1970s, Bayer marketed the drug as Biltricide; however, at a cost 
beyond the affordability of developing nations. Soon after, Shin Poong (a South Korean 
pharmaceutical company) patented a new synthetic procedure for praziquantel and the cost was 
reduced dramatically to the point where mass production was feasible for the treatment of the 
disease.11 Since then, little attention has been paid to finding alternative treatment options. While 
clinically-relevant resistance has not yet emerged, the recent increased usage of the drug could change 
this.9 There is therefore a genuine concern regarding the absence of an alternative treatment option, 
should praziquantel no longer be effective. This warrants the search for novel agents to target this 
disease. 
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Figure A.2: Structure of praziquantel. 
 
S. mansoni, in its adult stage, is known to digest human host blood to obtain the required nutrients 
needed for growth and sexual development.12 In order to do this, S. mansoni degrades host 
hemeoglobin, similarly to P. falciparum, and in the process forms heme – a toxic by-product. The 
biocrystallisation of heme to hemeozoin has evolved as a method of detoxification and evidence of 
these hemeozoin crystals has been observed within the gut of the adult female worms.13,14 Initial tests 
with chloroquine and other quinoline-based antimalarial agents have shown inhibition of hemeozoin 
formation in mice livers,15 which indicates a potential drug target in S. mansoni similar to that of P. 
falciparum. However, it has been reported that for some of these antimalarial agents, the excellent 
efficacy did not in fact correlate well with their hemeozoin inhibition potencies.12 This suggests that 
there is possibly an alternative mechanism by which these drugs inhibit hemeozoin formation that is 
not adequately modelled by the assay, or even that there is an additional target. A number of 
repurposed compounds have been explored for the treatment of schistosomiasis and some are showing 
promise.16–18 These include natural products, such as artemisinin, plumbagin and sanguinarine, and 
metal-based compounds, such as ferroquine and ferrocene derivatives of praziquantel (Figure A.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.3: Structure of (a) artemisinin, (b) plumbagin, (c) sanguinarine, (d) ferroquine, (e) ferrocene derivative 
of praziquantel. 
(a) (b) (c) 
(d) (e) 
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As part of the target class repurposing strategy discussed in Chapter 3, the Pollastri group have 
synthesised a large number of compounds mainly targeting trypanosomes; however, all compounds 
that they synthesise are tested against the other four parasitic diseases mentioned above. For example, 
one project found that a quinoline analogue, shown in Figure A.4 (NEU1953), exhibited reasonable 
potency in preliminary screens against adult S. mansoni worms. Additionally, introducing a methyl 
substituent onto the 8-position of the quinoline ring further increased the potency against S. mansoni 
(currently unpublished results).  
One of the drawbacks, however, was the poor aqueous solubility of these compounds (especially 
NEU1953).7 For a drug to be orally administered, a reasonable solubility is required for acceptable 
bioavailability. For NTDs especially, any other route of delivery of the drug is simply not viable in 
terms of cost and access to treatment centres. Previous work on similar compounds has shown that the 
incorporation of a homopiperazine (1,4-diazacycloheptane) moiety, instead of a piperizine or other 
cyclic amine group substantially improved the solubility of the compound without a significant loss in 
efficacy against trypanosomes.19 In addition, preliminary unpublished work using similar analogues 
has shown that increasing the length of the side chain attached to the amino tail group leads to an 
increase in efficacy toward the adult worms. 
 
Figure A.4: The incorporation of a methyl substituent at the 8-position on the quinoline scaffold (NEU2215) 
increases potency against S. mansoni. This work investigates incorporating a homopiperazine derivative instead 
of the piperazine derivative (this work: 46a-d) to potentially improve solubility. H (46a), Me = methyl (46b), 
Et = ethyl (46c) and Pr = propyl (46d) chain. 
 
Therefore, the goal of this work was to resynthesise NEU2215 to confirm the phenotypic observation, 
as well as to synthesise compounds 46a-d (Figure A.4) to explore the effect of the homopiperazine 
and alkyl chain lengths on the Adsorption, Distribution, Metabolism and Excretion (ADME) profile 
and potency against S. mansoni. These compounds will also be compared to other analogues 
synthesised by the Pollastri group to investigate the structure-activity relationships of these 
compounds. 
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A.2 SYNTHESIS OF THE PRECURSOR FRAGMENTS 
 
The synthesis of these compounds is briefly discussed here; however, full experimental details and 
characterisation data can be found in Section A.6 (page 186). Similarly to the synthesis discussed in 
Chapter 3, the synthesis of these compounds can be divided into three parts – synthesis of the 
quinoline scaffold, synthesis of the tail group and finally the Suzuki-Miyaura reaction to couple the 
two fragments. 
 
A.2.1 Synthesis of the quinoline scaffold 
 
As shown in Scheme A.1, the synthesis begun with a condensation-type reaction where commercially 
available 2-methyl-3-bromo-aniline (47) was reacted with diethyl-2-(ethoxymethylene)malonate (48) 
to form compound 49. This reaction had been previously performed by another member of the 
Pollastri group and product 49 was received from them (roughly 5 g) when I arrived. Cyclisation of 49 
to form quinolone 50 was carried out by refluxing 49 in diphenyl ether (DPE) for 4 hours. Monitoring 
the reaction with LC-MS analysis showed that the reaction was complete after 4 hours and that the 
desired product had formed. In addition, by-products were also observed, one of which was the 
decarboxylated quinolone 52. As this was the product of a subsequent reaction, we decided not to 
separate out the products at this stage, but rather to work with the crude mixture for the following 
steps. This was also because the solubility of these compounds is rather poor and this made column 
chromatography challenging. The crude mixture of 50 was saponified, followed by decarboxylation to 
give 52, which, after chlorination using phosphorous oxychloride (POCl3) yielded quinoline scaffold 
53 in a yield of 35% over four steps. 
 
 
 
 
 
 
 
 
 
 
 
Scheme A.1: Synthesis of the core quinoline scaffold 53 starting from commercially available aniline 47. 
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 1H NMR spectroscopic analysis of 53 showed a singlet, integrating to 3H, at 2.94 ppm 
that corresponds to the methyl group at the 8-position. Four peaks are observed in the 
aromatic region, each integrating for 1H, which correspond to the remaining protons on 
the molecule. LC-MS found an [M+H]+ of 258.0 m/z, which corresponds well with the 
calculated [M+H]+ of 257.9 m/z. 
Once the quinoline scaffold had been synthesised, the head group could be introduced to the 4-position 
on the quinoline ring in a similar substitution reaction to that in Chapter 3 (page 74). The 
regioselectivity of the substitution to the 4-position and not the 7-position (i.e. at the chlorine and not 
the bromine) is due to the presence of the heteroatom in the quinoline ring, as explained in a similar 
example in Chapter 3 on page 74. This reaction was carried out as shown in Scheme A.2 and the 
bright yellow product was obtained in a moderate 61% yield.  
 
 
 
 
 
 
Scheme A.2: Substitution reaction to introduce 2-aminopyrazine (54) onto quinoline scaffold 53. 
 
Characterisation of 55 was carried out using NMR and LC-MS. Analysis of the 1H 
NMR spectrum showed a singlet integrating to 3H at 2.82 ppm that corresponds to 
the methyl group at the 8-position of the quinoline ring. The singlet at 9.79 ppm, 
integrating for 1H, corresponds to the protons at position 13 (on the pyrazine 
ring). The remaining aromatic protons were all accounted for. Analysis of the LC-
MS chromatogram showed one peak, with a corresponding m/z value of 317.1 [M+2H]2+; the 
calculated [M+2H]2+ is 317.1 m/z. 
With the quinoline scaffold in hand, we moved on to the synthesis of the various tail fragments.  
 
A.2.2 Synthesis of the tail fragments 
 
The methyl derivatives of the tail fragments (56 and 57) could be synthesised using commercially 
available starting material in a one-step reaction under microwave conditions (Scheme A.3). 5-Bromo-
2-chloro-pyrimidine (58) and either N-methylpiperidine (59) or N-methylhomopiperidine (60) were 
heated to 150 °C while stirring together with diisopropylethylamine (DIPEA) in tert-butanol. LC-MS 
analysis confirmed that the reaction had gone to completion within 30 minutes. Purification was 
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carried out using flash column chromatography (using a 1 – 10% MeOH/DCM gradient solvent 
system) and compounds were characterised by 1H NMR and LC-MS.   
 
   
 
 
 
 
Scheme A.3: Synthesis of tail compounds 56 and 57. 
 
1H NMR spectral analysis of 57 shows a singlet integrating to 3H at 2.53 ppm 
that corresponds to the methyl protons on the homopiperazine moiety, as well 
as a singlet integrating to 2H at 8.45 ppm that corresponds to the two aromatic 
protons on the pyrimidine ring. All other protons are accounted for. LC-MS 
analysis of the product shows the desired mass peak ([M+H]+ = 351.1 m/z). Similar spectroscopic data 
was obtained for 56.  
For the ethyl and propyl derivatives of 57, an additional two steps were required in the synthetic route 
(Scheme A.4). Making use of a commercially available boc-protected homopiperidine 61, the coupling 
reaction could be performed, followed by deprotection with 4 M HCl in dioxane to afford 63 in good 
yields. This product could then be reacted with the relevant alkyl iodides to give the tail fragments 64 
and 65, as shown in Table A.1.  
 
 
 
 
 
 
 
Scheme A.4: Synthesis of 62 that could then be further derivatised to give the desired ethyl and propyl 
analogues. 
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Table A.1: Yields obtained for the synthesis of 64 and 65. 
 
 Alkyl  R group Yield (%) 
64 Ethyl iodide  
76% 
65 Propyl iodide  
79% 
 
 
For compound 64, 1H NMR spectral analysis shows a triplet integrating to 
3H at 1.07 ppm and a quartet at 2.56 ppm, which confirms the incorporation 
of the ethyl chain. The singlet at 8.28 ppm integrating to 2H confirms the 
presence of the pyrimidine protons. All other protons are accounted for. LC-
MS confirms the desired product: [M+H]+ = 285.2 m/z (calculated [M+H]+: 285.1 m/z). 
With both the quinoline scaffold and the desired tail fragments in hand, the next step was to perform 
the Suzuki-Miyaura reaction to couple them together.  
 
A.3 THE SUZUKI-MIYAURA REACTION 
 
The Suzuki-Miyaura reaction was carried out under microwave conditions in a similar two-step, one-
pot procedure as described in Chapter 3 (page 82). The reaction began with the borylation of the tail 
fragment using bis(pinacolato)diboron in anhydrous dioxane under microwave reaction conditions 
(Scheme A.5). This product was used directly in the next step without purification to afford 46a-d in 
low yields.  
 
Scheme A.5: Suzuki-Miyaura reaction to couple fragments 63-65 and 53 together to form 46a-d. 
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Table A.2 shows the synthesised compounds 46a-d as well as the yields obtained for each product. 
While improving the yield would be imperative if these compounds were to move on to in vivo testing, 
it was not deemed necessary at this point to optimise the reaction until initial in vitro testing showed 
promising results. Unfortunately, compound 46c was not isolated in sufficient quantities for 
characterisation or biological testing. As this was a short research visit, time constraints did not allow 
for the compound to be resynthesised. This would be done by another member of the group at a later 
stage. Compounds 46a-d were fully characterised using NMR, LC-MS and IR spectroscopy, with the 
exception of 46c. 
 
 
 
 
 
 
 
 
 
 
 
 
In 46b, 1H NMR spectral analysis showed two singlets integrating to 
3H each at 2.81 ppm and 2.71 ppm that correspond to the two methyl 
groups on the molecule (corresponding to the protons attached to 
carbon 18 and 29). The singlet at 8.48 ppm integrating to 2H 
corresponds to the protons at positions 20 and 21. All other protons are 
accounted for. 13C NMR spectroscopy showed two methyl carbons at 
46.6 ppm and 16.2 ppm corresponding to C-29 and C-18, respectively. 
All other carbon atoms were accounted for. LC-MS found [M+H]+ to be 427.3 which compares well to 
the calculated m/z value for [M+H]+ of 427.5. Similar spectroscopic data was obtained for 46a and 
46d with differences in the spectrum for the peaks associated with the protons of the alkyl chain. 
Table A.2: Yields obtained for the synthesis of NEU2215 and 46a-d. 
 
 R group Yield (%) 
NEU2215 
 
31 
46a 
 
19 
46b 
 
26 
46c 
 
Trace* 
46d 
 
15 
* Product lost during workup; insufficient time during research visit 
to synthesise more.  
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Having confirmed that the desired products were obtained in high purity (>95% based on LC-MS), 
samples were sent to collaborators for biological testing, as well as to determine certain 
physicochemical properties. 
 
A.4 IN VITRO TESTING 
 
NEU2215 as well as 46a, 46b and 46d were sent to collaborators at the University of California, Los 
Angeles, for testing against adult worms of S. mansoni. In their assays, adult worms are subjected to 
10 µM of the drug (made up in a DMSO solution) and a combination of manual and semi-automated 
methods are used to record the phenotypic response of the worms after 1 hour, 5 hours, 24 hours and 
48 hours. Descriptors are used at each time interval to evaluate the observed worms, and based on 
these, a severity score between 0 and 4 (with 0 corresponding to no effect, and 4 being very potent) is 
assigned.20 Some of these descriptors include changes in movement, shape, ability of the worm to 
adhere to the culture dish surface, as well as tegument (“skin” of worm) damage and death. The higher 
the score and the earlier phenotypic observations are made, the more effective the drug. It should be 
noted that the assay used forms part of a high throughput screening, where the compounds are 
screened for activity without an assigned EC50 value. Should compounds display adequate severity 
scores, further in vitro tests can be carried out to more accurately determine their efficacy profiles. The 
severity scores for each compound in this work can be seen in Table A.3.  
NEU2215 was potent against S. mansoni, with a severity score of 4 after 48 hours. Compound 46b 
was inactive against the trematodes, but compound 46d – with the longer alkyl side chain – showed 
improved potency, with a severity score of 4 after 24 hours. Surprisingly, compound 46a displayed the 
highest potency in this series, with a severity score of 3 after just 5 hours and a score of 4 after 
24 hours. Although increasing the length of the side chain was expected to increase the efficacy (based 
on previous unpublished work), these results seem to contradict this hypothesis. 
Because these compounds are quinoline-based they would most likely exhibit some efficacy against 
the malaria parasite. Therefore, these compounds were also sent for testing against the chloroquine-
sensitive D6 strain of P. falciparum. In Table A.3, the EC50 value (the half maximal effective 
concentration) for each compound is given. While the values are all in the low micromolar range 
(EC50 = 0.069 – 0.374 µM), they were still at least an order of magnitude larger than the benchmark 
standard, chloroquine (EC50 = 0.005 µM).  
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The compounds were also sent to AstraZeneca to determine their ADME profile, with specific focus 
on aqueous solubility and metabolic stability. As can be seen in Table A.4, the aqueous solubility for 
the homopiperazine analogues (46a, b, d) all show substantial improvement over NEU2215. An in-
house target threshold of 100 µM is considered adequate, while a value higher than 100 µM is 
preferred. Compound 46b showed roughly a 2-fold increase in solubility in comparison to 46a and 
46d. The human protein-plasma binding (PPB) percentage of drug was also determined. This value is 
reported as the percentage of bound drug and should be as low as possible (desired range <95%) as 
only unbound drug molecules are active against the parasite. Overall, the homopiperazine analogues 
showed improved values in comparison to NEU2215, with 46a showing the lowest binding value 
(76%). Metabolic stability – intrinsic clearance from both human liver microsomes (HLM) and rat 
hepatocytes was also established. Metabolic stability refers to the susceptibility of a compound to react 
or degrade in vivo and provides an indication of the stability, elimination rate by metabolism as well as 
toxicity of the compound. The studies are carried out on both human and rat cell lines in order to 
Table A.3. In vitro biological data for NEU2215 and 1a-d. 
 
 
 
 
 
Code R group 
S. mansoni severity score* 
P. falciparum D6 
strain EC50 (µM) 1 h 5 h 24 h 48 h 
NEU2215 
 
0 1 3 4 0.069 
46a 
 
0 3 4 4 0.299 
46b 
 
0 0 0 0 0.312 
46c 
 
N/D N/D 
46d 
 
1 1 4 4 0.374 
chloroquine  - 0.005 
*Assays were performed in duplicate. Each phenotypic descriptor observed was given a 
score of 1 and the scores were added to a maximum of 4. Descriptors: no effect = 0; 
worms darken = 1; male suction impaired = 1; overactive = 1; rounded = 1; slow = 1; 
uncoordinated = 1; degenerating = 4; tegument damage = 4; dead = 4. 
Stellenbosch University  https://scholar.sun.ac.za
Addendum A: Synthesis of quinoline derivatives as antischistosomal agents  
 
184 | P a g e  
 
ensure that there is no significant difference between the two that could give misleading in vivo results 
when the compound advances to rat studies. In this study, once again, 46a outperformed NEU2215 
and the other homopiperazine analogues.  
 
Compound 46a displayed particularly favourable results against S. mansoni, with excellent severity 
scores after 5 hours. In addition, 46a had physicochemical properties that surpassed the benchmark 
minimums of appropriate ADME profiles (profile aqueous solubility and metabolic stability). 
Although 46d displayed excellent severity scores against S. mansoni, this inhibition was only achieved 
after 24 hours as compared to 5 hours for 46a. The ADME profile of 46d (aqueous solubility and 
metabolic stability) was however not as good as that of 46a.  
The compounds performed reasonably well against the chloroquine-sensitive strain (D6) of 
P. falciparum, with values in the low micromolar range. Compound 46a displayed the best EC50 value 
of the three compounds sent for testing, but was still two orders of magnitude less effective than 
chloroquine.  
 
 
 
Table A.4: ADME data obtained for NEU2215 and 46a-d. 
Code R group 
Aqueous 
solubility (µM) 
Human 
PPB (%) 
HLM Clint 
(µL/min/mg) 
Rat hepatocyte Clint 
(µL/min/106 cells) 
Desired range7 >100  <95 <90 <50 
NEU2215 
 
5 97 115 51.8 
46a 
 
465.1 76 41.1 5.31 
46b 
 
861.9 82 121 27.3 
46c 
 
N/D N/D N/D N/D 
46d 
 
445.7 94.4 300 35.7 
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A.5 CONCLUDING REMARKS 
 
This chapter describes the synthesis and biological data of a small library of quinoline-based 
compounds. The synthesis was carried out in three stages – firstly synthesis of the quinoline scaffold 
from commercially available 5-bromo-2-chloro-pyrimidine, secondly the synthesis of various amine 
tail groups and lastly the Suzuki-Miyaura coupling reaction to combine the two fragments. While 
these reactions were successful, the yields of the final compounds are poor. Having said that, there 
was sufficient material available to test these compounds against S. manoni, as well as obtain 
physicochemical data that describe the ADME profile of the compounds, excluding 46c. Some of the 
compounds were also sent for testing against P. falciparum.  
The replacement of the piperazine moiety with a homopiperazine proved to be valuable, with a 
substantial improvement to the ADME properties in comparison to NEU2215. Interestingly, the 
hypothesis of a longer alkyl chain that improves efficacy against adult worms was not validated with 
these compounds, as 46a (with no alkyl chain) displayed the greatest severity score. Compound 46a 
warrants further investigation as it displayed the greatest in vitro activity against S. mansoni as well as 
excellent ADME properties. 
Since leaving their laboratory, other derivatives have been synthesised by members of the Pollastri 
group. These include the NH-piperidine analogue of 46a (Figure A.5(a)), as well the morpholinyl 
derivative (Figure A.5b). The morpholinyl derivative, however, was found to be inactive in 
comparison to 46a. This indicates that the basic nitrogen atom of the piperidine or homopiperidine 
moiety is important in the potency of these compounds. This could hint at a pH-trapping mechanism 
similar to that of β-hematin inhibitors for P. falciparum as part of the mode of action of these 
compounds against S. mansoni,21 but this would require further studies before any conclusive 
statement can be made. They have also explored the effect of moving the methyl group from the 8-
position on the quinoline to the 5- and 6-positions (Figure A.5c). While the head group has been 
optimised for appropriate ADME profiles,22 exploring small substituents on the pyrazine ring could be 
carried out to increase potency (Figure A.5d). Lastly, replacing the quinoline scaffold with an 
isoquinoline or a quinazoline ring could also be valuable to enrich the structure-activity relationship 
study of these compounds against S. mansoni (Figure A.5e). 
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Figure A.5: Derivatives of 46b that have been synthesised by the Pollastri group based on the work in this 
chapter: (a) NH-piperazine analogue; (b) morpholinyl derivative; (c) 5-and 6-position methyl substituent 
analogues; (d) various substitutions on the pyrazine ring; (e) quinoline and isoquinoline analogues. 
 
Since some quinoline-containing antimalarials have been shown to be potent against S. mansoni and 
they have been shown to inhibit the formation of β-hematin, it is possible that compounds 46a-d could 
be targeting the biocrystallisation of hemeozoin pathway at least as part of its mode of action.15 Other 
studies on quinazolines, isoquinolines and benzamide derivatives amongst others, have shown that 
protein kinases have potential as targets for schistosomal drug development.9 Our compounds, 
originally stemming from lapatinib (a kinase inhibitor), could also be targeting certain protein kinases 
in S. mansoni.9 However, since the assays used in this study to determine potency are purely 
phenotypic, we cannot say for certain what the mode of action is of these drug molecules without 
carrying out extensive mechanistic studies.  
 
A.6 EXPERIMENTAL DETAILS 
A.6.1 General 
All starting materials were commercially obtained and were used without further purification, unless 
otherwise specified. Reaction solvents were purified by passage through alumina columns on an 
Innovative Technology (Newburyport, MA) purification system. NMR spectra were obtained on 
Varian NMR systems (500 MHz) and processed with ACDLabs software. LC-MS analysis was 
performed using a Waters Alliance reverse phase HPLC (columns Waters SunFire C18 4.6 × 50 mm) 
with single-wavelength UV−visible detector and Waters Micromass ZQ detector (electrospray 
(a) (b) (c) (d) 
(e) (f) 
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ionisation). Final compounds were purified by preparative reverse phase HPLC (columns Waters 
Symmetry RP8 30 × 50 mm, 5 μm column), with a single wavelength UV−visible detector and Waters 
Micromass ZQ (electrospray ionization) and have purities greater than 95% based upon LC-MS 
analysis.  
 
A6.2 ADME experiment protocols (carried out by AstraZeneca) 
Aqueous pH 7.4 Solubility. Compounds are dried down from 10 mM DMSO solutions using 
centrifugal evaporation technique. Phosphate buffer (0.1 M pH 7.4) added and StirStix inserted in the 
glass vials, shaking is then performed at a constant temperature of 25 °C for 20–24 h. This step is 
followed by double centrifugation with a tip wash in between, to ensure that no residues of the dried 
compound are interfering. The solutions are diluted before analysis and quantification using LC-MS-
MS is performed. 
Log D7.4. Shake-flask octanol-water distribution coefficient at pH 7.4 (Log D7.4). The aqueous solution 
used is 10 mM sodium phosphate pH 7.4 buffer. The method has been validated for Log D7.4 ranging 
from -2 to 5.0. 
Human Plasma Protein Binding (PPB). PPB is determined using equilibrium dialysis (RED device) to 
separate free from bound compound. The amount of compound in plasma (10 µM initial 
concentration) and in dialysis buffer (pH 7.4 phosphate buffer) is measured by LC-MS-MS after 
equilibration at 37°C in a dialysis chamber. The fraction unbound (fu) is reported. 
Human Liver Microsomal Clint. In vitro intrinsic clearance determined from human liver microsomes 
using a standard approach.6 Following incubation and preparation, the samples are analysed using 
LC-MS-MS. Refined data are uploaded to IBIS and are displayed as Clint (intrinsic clearance) in 
μL/min/mg. 
Rat Hepatocyte Clint. In vitro intrinsic clearance determined from rat hepatocytes using a standard 
approach. Following incubation and preparation, the samples are analysed using LC/MS/MS. Refined 
data are uploaded to IBIS and are displayed as Clint (intrinsic clearance) μL/min/1 million cells. 
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A6.3 Synthesis of compounds 
Ethyl-7-bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (50) 
 
Diethyl-2-{[(3-bromo-2-methylphenyl)amino]methylene}malonate 49 (2.02 g, 5.61 mmol) was added 
to a 25 mL round-bottomed flask containing diphenyl ether (9.0 mL). The flask was fitted with a 
condenser and the reaction mixture stirred at 250 C for 8 hours. The orange-brown solution was then 
cooled to room temperature, upon which a pale brown precipitate formed. The mixture was 
quantitatively transferred to a 100 mL beaker containing hexane (20 mL). The precipitate was 
triturated with hexane (4 × 25 mL) and then filtered and washed with a further hexane (2 × 20 mL). 
The precipitate was dried in air on a Buchner funnel for 10 minutes before drying in vacuo for a 
further 2 hours to yield a beige solid (1.32 g) that was used directly in the next step without further 
purification.  
TLC (50% EtOAc/Hexane): Rf = 0.48. LC-MS found [M+H]+= 311.1 m/z; calculated 
[M+H]+ = 311.2 m/z for C13H12BrNO3. 
 
7-Bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (51) 
 
 
 
Ethyl-7-bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (50) (1.32 g, 4.26 mmol) was 
added to a 50 mL round-bottomed flask containing a solution of sodium hydroxide (1.02 g, 25.5 
mmol, 6.00 equivalents) in distilled water (12.0 mL). The heterogenous reaction mixture was heated to 
110 C and stirred overnight. Upon completion, the reaction mixture was cooled and then poured into 
of 1.0 M HCl (15 mL). An additional of 1.0 M HCl (15 mL) was added until a pH of 3 − 4 was 
obtained. The precipitate was filtered using a Buchner funnel and washed with distilled water (3 × 30 
mL). The dried product (1.25 g) was used without further purification in the next step. 
LC-MS found [M+H]+ = 283.3 m/z; calculated [M+H]+ = 283.1 m/z for C11H8BrNO3. 
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7-Bromo-8-methylquinolin-4(1H)-one (52) 
 
To a 50 mL round-bottomed flask was added 7-bromo-8-methyl-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid (51) (1.25 g, 4.44 mmol) and diphenyl ether (22.0 mL). The heterogenous reaction 
mixture was stirred overnight at 250 C. Once the reaction was complete (LC-MS; TLC), the solution 
was cooled to room temperature and quantitatively transferred to a 250 mL beaker containing hexane 
(60 mL). The precipitate was triturated with hexane (3 × 30 mL). The precipitate was filtered using a 
Buchner funnel and washed with a further hexane (3 × 25 mL) and allowed to air dry (Buchner 
vacuum filtration) for 15 minutes before being dried in vacuo overnight. The beige solid (0.963 g) was 
used in the next step without further purification.  
TLC (10% MeOH/EtOAc): Rf = 0.62. LC-MS found [M+H]+ = 239.01 m/z; calculated 
[M+H]+ = 239.01 m/z for C10H8BrNO. 
 
7-Bromo-4-chloro-8-methylquinoline (53) 
 
To a nitrogen-purged three-neck flask fitted with a reflux condenser was added 7-bromo-8-
methylquinolin-4(1H)-one (52) (0.963 g, 4.05 mmol) and phosphorous oxychloride (7.0 mL, 81 mmol, 
20 equivalents). The reaction was heated under reflux at 110 C for 6 hours, during which the reaction 
mixture turned a dark brown colour. Upon reaction completion (LC-MS, TLC analysis), the reaction 
mixture was cooled to room temperature. Excess phosphorous oxychloride was quenched by the slow 
addition of the reaction mixture to a saturated solution of sodium bicarbonate (200 mL) on ice. The pH 
was adjusted by adding more sodium bicarbonate solution (approximately 250 mL) until a pH of 7 – 8 
was obtained. The yellow solution was decanted into a separatory funnel and the product extracted 
with DCM (5 × 50 mL). The organic layers were combined, washed once with brine (50 mL), dried 
over anhydrous MgSO4, filtered and the filtrate concentrated under reduced pressure. The product was 
purified by flash column chromatography, eluting with a 0 – 15% EtOAc/Hexane solution. The 
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desired product was obtained as an off-white powder in 35% (0.702 g, 2.74 mmol) yield over four 
steps.  
TLC (10% EtOAc/Hexane): Rf = 0.71. 1H NMR (500 MHz, CDCl3) δ 8.80 (d, J = 4.6 Hz, 1H), 7.97 
(d, J = 9.3 Hz, 1H), 7.79 – 7.76 (m, 1H), 7.51 (d, J = 4.6 Hz, 1H), 2.94 (s, 3H). LC-MS found 
[M+H]+ = 257.9 m/z; calculated [M+H]+ = 257.9 m/z for C10H7BrNCl. 
 
7-Bromo-8-methyl-N-(pyrazine-2-yl)quinoline-4-amine (55) 
 
Anhydrous DMF (7.0 mL) was added to a 25 mL two-neck round-bottomed flask that had been purged 
with nitrogen. Commercially available 2-aminopyrazine (0.651 g, 6.86 mmol, 2.50 equivalents) was 
added to the flask, followed by sodium hydride (0.383 g, 60% dispersion in oil, 9.58 mmol, 
3.50 equivalents). This bright yellow reaction mixture was stirred at room temperature for 30 minutes 
before adding a solution of 7-bromo-4-chloro-8-methylquinoline (53) (0.702 g, 2.74 mmol, 
1.00 equivalent) in anhydrous DMF (6.0 mL) dropwise over three minutes. The reaction mixture was 
stirred at room temperature overnight before being quenched with a saturated solution of ammonium 
chloride (100 mL). The bright yellow precipitate was collected using a Buchner funnel and washed 
with distilled water (3 × 20 mL). The precipitate was dried in air for 15 minutes before being purified 
by flash column chromatography, eluting with a 1 – 10% MeOH/DCM mixture. The desired product 
was obtained as a bright yellow powder in 61% yield (0.529 g, 1.68 mmol).  
TLC (10% MeOH/DCM): Rf = 0.52. 1H NMR (500 MHz, DMSO-d6) δ 9.79 (s, 1H), 8.74 (d, 
J = 5.4 Hz, 1H), 8.69 (s, 1H), 8.35 (d, J = 5.4 Hz, 1H), 8.30 – 8.31 (m, 1H), 8.27 (d, J = 8.8 Hz, 1H), 
8.17 (d, J = 2.8 Hz, 1H), 7.78 (d, J = 9.3 Hz, 1H), 2.82 (s, 3H). LC-MS found [M+H]+ = 316.08 m/z; 
calculated [M+H]+ = 316.02 m/z for C14H11BrN4. 
 
General procedure for the synthesis of the amine tail groups: 
The relevant amine (1.55 mmol, 1.20 equivalents) and diisopropylethylamine (DIPEA) (1.68 mmol, 
1.30 equivalents) were added to a microwave vial containing tert-butanol (5 mL). To this, was added 
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5-bromo-2-chloropyrimidine (1.29 mmol, 1.00 equivalent). The microwave vial was sealed and stirred 
at 150 C for 30 minutes. The orange-brown reaction mixture was then concentrated under reduced 
pressure and purified by flash column chromatography, eluting with 0 – 7% MeOH/DCM to afford the 
desired products described below. 
 
5-Bromo-2-(4-methylpiperazin-1-yl)pyrimidine (56) 
 
Relevant amine: N-methylpiperazine (0.172 mL, 1.55 mmol, 1.20 equivalents). The desired product 
was obtained as an off-white solid in 67% yield (0.221 g, 0.859 mmol).  
TLC (5% MeOH/DCM): Rf = 0.31. 1H NMR (500 MHz, DMSO-d6) δ 8.51 (s, 2H), 3.82 (br s, 4H), 
2.78 (br s, 4H), 2.48 (br s, 3H, buried under DMSO-d6 peak). LC-MS found [M+H]2+ = 258.02; 
calculated [M+H]+ = 258.04 m/z for C9H13BrN4. 
 
1-(5-Bromopyrimidin-2-yl)-4-methyl-1,4-diazepane (57) 
 
Relevant amine: 1-(5-bromopyrimidin-2-yl)4-methyl-1,4-diazepane (0.192 mL, 1.55 mmol, 
1.20 equivalents). The desired product was obtained as an off-white solid in 50% yield (0.176 g, 
0.647 mmol).  
TLC (5% MeOH/DCM): Rf = 0.31. 1H NMR (500 MHz, DMSO-d6) δ 8.45 (s, 2H), 3.87 (br s, 2H), 
3.71 – 3.69 (m, 2H), 3.07 – 2.93 (m, 4H), 2.53 – 2.50 (m, 3H), 2.02 (br s, 2H). LC-MS found 
[M+H]+ = 272.10 m/z; calculated [M+H] + = 272.05 m/z for C10H15BrN4. 
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Tert-butyl-5-(5-bromopyrimidin-2-yl)-1,4-diazepane-1-carboxylate (62) 
 
Relevant amine: tert-butyl-1,4-diazepane-1-carboxylate (1.2 mL, 6.2 mmol, 1.2 equivalents). The 
desired product was obtained as a white powder in 84% yield (1.56 g, 4.36 mmol). 
TLC (5% MeOH/DCM): Rf = 0.62. 1H NMR (500 MHz, CDCl3) δ 8.29 (s, 2H), 3.86 – 3.81 (m, 2H), 
3.75 – 3.71 (m, 2H), 3.55 – 3.53 (m, 2H), 3.38 – 3.36 (m, 2H), 3.28 – 3.26 (m, 2H), 1.42 (s, 9H). LC-
MS found [M+H]+ = 358.11 m/z; calculated [M+H] + = 358.08 m/z for C14H21BrN4O2. 
 
1-(5-Bromopyrimidin-2-yl)-1,4-diazepane (63) 
 
Tert-butyl-5-(5-bromopyrimidin-2-yl)-1,4-diazepane-1-carboxylate (62) (1.50 g, 4.20 mmol) was 
dissolved in a 4.0 M HCl solution in dioxane (11.0 mL) and stirred at room temperature overnight. 
The milky-white precipitate was filtered off using a Buchner funnel and washed with dioxane 
(2 × 20 mL). The sticky solid was then dissolved in a minimum amount of distilled water (10 –
 15 mL) and basified using a saturated solution of sodium bicarbonate until a pH of 7 – 8 was obtained 
(about 20 mL). The product was extracted with DCM (5 × 20 mL). The organic layers were combined, 
washed once with brine (20 mL), dried over anhydrous MgSO4, filtered, and the filtrate concentrated 
under reduced pressure to yield the desired product as a pale yellow powder in 76% yield (0.824 g, 
3.20 mmol). No further purification was necessary. 
TLC (5% MeOH/DCM): Rf = 0.16. 1H NMR (500 MHz, CDCl3) δ 8.28 (s, 2H), 3.83 – 3.90 (m, 4H), 
3.03 – 3.01 (m, 2H), 2.88 – 2.86 (m, 2H), 2.16 (br. s., 1H), 1.91 – 1.86 (m, 2H). LC-MS found 
[M+H]+ = 257.10 m/z; calculated [M+H] + = 257.03 m/z for C9H13BrN4. 
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General procedure for alkylation of the amino group: 
The appropriate secondary amine was dissolved in MeOH (5 mL). To this was added DIPEA 
(8.0 equivalents) and alkyl halide (5.0 equivalents). The reaction was allowed to stir at room 
temperature for 48 hours. Upon reaction completion, the mixture was concentrated under reduced 
pressure and then diluted with DCM (50 mL). The solution was washed with a saturated solution of 
sodium bicarbonate (1 × 50 mL) and the product was extracted with DCM (2 × 30 mL). The organic 
layers were combined, dried over anhydrous MgSO4, filtered and the filtrate concentrated under 
reduced pressure to give the desired product. No further purification was necessary.  
 
1-(5-Bromopyrimidin-2-yl)-4-ethyl-1,4-diazepane (64) 
 
Appropriate secondary amine: 1-(5-bromopyrimidin-2-yl)-1,4-diazepane (63) (0.248 g, 0.964 mmol, 
1.00 equivalent). Alkyl halide: iodoethane (0.4 mL, 5 mmol, 5 equivalents). Desired product was 
obtained as a pale yellow powder in 76% yield (0.210 g, 0.738 mmol). 
TLC (5% MeOH/DCM): Rf = 0.21. 1H NMR (500 MHz, CDCl3) δ 8.28 (s, 2H), 3.87 – 3.85 (m, 2H), 
3.77 (t, J = 6.4 Hz, 2H), 2.75 – 2.73 (m, 2H), 2.61 – 2.60 (m, 2H), 2.56 (q, J = 7.2 Hz, 2H), 1.98 – 
1.94 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H). LC-MS found [M+H]+ = 286.17 m/z; calculated [M+H]+ = 
286.06 m/z for C11H17BrN4. 
 
1-(5-Bromopyrimidin-2-yl)-4-propyl-1,4-diazepane (65) 
 
Appropriate secondary amine: 1-(5-bromopyrimidin-2-yl)-1,4-diazepane (0.300 g, 1.17 mmol, 1.00 
equivalent). Alkyl halide: iodopropane (0.6 mL, 6 mmol, 5 equivalents). Desired product was obtained 
as a pale yellow powder in 79% yield (0.278 g). 
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TLC (5% MeOH/DCM): Rf = 0.31. 1H NMR (500 MHz, CDCl3) δ 8.27 (s, 2H), 3.90 – 3.88 (m, 2H), 
3.77 (t, J = 6.4 Hz, 2H), 2.81 – 2.80 (m, 2H), 2.70 – 2.67 (m, 2H), 2.51 – 2.48 (m, 2H), 2.02 (td, J = 
11.1, 5.9 Hz, 2H), 1.58 – 1.51 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H). LC-MS found [M+H]+ = 299.11 m/z; 
calculated [M+H]+ = 299.08 m/z for C12H19BrN4. 
 
General procedure for the Suzuki-Miyaura reaction between 7-bromo-8-methyl-N-(pyrazine-
2-yl)quinoline-4-amine and the relevant tail compound: 
The relevant bromopyrimidine derivative (1.0 equivalent) was added to a microwave vial that had 
been evacuated and filled with nitrogen three times. Anhydrous dioxane (2.8 mL) was then added, 
followed by bis(pinacolato)diboron (1.5 equivalents), KOAc (3.5 equivalents) and 
PdCl2(dppf)·CH2Cl2 (5 mol%). The reaction mixture was degassed with nitrogen for 10 minutes, after 
which the vial was placed in the microwave for 1 hour at 145 C. LC-MS confirmed the completion of 
the reaction as well as the formation of the desired product. The dark brown reaction mixture was then 
filtered through Celite, concentrated under reduced pressure and used directly in the next reaction 
without further purification.  
The crude boronate compound was then dissolved in 3:1 dioxane/water (3.1 mL) in a microwave vial. 
K2CO3 (3.00 equivalents) and 7-bromo-8-methyl-N-(pyrazine-2-yl)quinoline-4-amine (55) 
(1.00 equivalent) were then added and the reaction mixture degassed for 10 minutes with nitrogen gas. 
PdCl2(dppf)·CH2Cl2 (10 mol%) was then added and the mixture stirred in the microwave for 40 
minutes at 130 C. LC-MS confirmed the completion of the reaction and that the desired product had 
formed. The reaction mixture was then filtered through Celite, concentrated under reduced pressure 
and purified by flash column chromatography, eluting with 1 – 50% (MeOH + 5% NH4OH)/EtOAc. A 
second purification using preparative HPLC was performed, eluting with 5 – 70% MeCN/H2O.  
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 8-Methyl-7-[2-(4-methylpiperazine-1-yl)pyrimidin-5-yl]-N-(pyrazine-2-yl)quinoline-4-
amine (NEU2215) 
  
Tail compound used: 5-bromo-2-(piperazin-1-yl)pyrimidine (56) (0.070 g, 0.27 mmol, 1.0 equivalent). 
Desired product was obtained as a pale yellow powder in 31% yield (0.028 g, 0.067 mmol). 
TLC (10% (MeOH + 5% NH4OH)/EtOAc): Rf = 0.47. 1H NMR (500 MHz, CD3OD) δ 8.71 (d, 
J = 5.6 Hz, 1H), 8.61 (s, 1H), 8.50 (s, 2H), 8.47 (d, J = 5.6 Hz, 1H), 8.34 – 8.33 (m, 2H), 8.17 (s, 1H), 
7.51 (d, J = 8.8 Hz, 1H), 4.14 – 4.09 (m, 4H), 3.14 (t, J = 5.0 Hz, 4H), 2.78 (s, 3H), 2.69 (s, 3H). 
13C NMR (150 MHz, CD3OD) δ 161.6, 159.3, 153.4, 150.6, 148.3, 146.7, 142.9, 137.8, 137.5, 137.4, 
134.9, 128.8, 125.7, 121.4, 120.6, 108.8, 55.1, 44.9, 43.4, 15.9 LC-MS found [M+H]+ = 413.81 m/z; 
calculated [M+H]+ = 413.21 m/z for C23H24N8. 
 
8-Methyl-7-[2-(4-methyl-1,4-diazepan-1yl)pyrimidin-5-yl]-N-(pyrazine-2-yl)quinoline-4-
amine (46a) 
 
Tail compound used: 1-(5-bromopyrimidin-2-yl)-1,4-diazepane (63) (0.085 g, 0.33 mmol, 
1.0 equivalent). Desired product was obtained as a pale yellow-brown powder in 19% yield (0.020 g, 
0.051 mmol).  
TLC (30% (MeOH + 5% NH4OH)/EtOAc): Rf = 0.65. 1H NMR (500 MHz, DMSO-d6) δ 8.75 – 8.74 
(m, 1H), 8.67 – 8.66 (m, 1H), 8.49 (s, 2H), 8.37 – 8.36 (m, 2H), 8.28 – 8.25 (m, 1H), 8.13 – 8.10 (m, 
1H), 7.50 – 7.47 (m, 1H), 3.95 – 3.91 (m, 2H), 3.91 – 3.86 (m, 2H), 3.71 (s, 4H), 3.10 – 3.06 (m, 2H), 
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2.97 – 3.92 (m, 2H), 2.69 (s, 3H), 1.96 – 1.90 (m, 2H). 13C NMR (150 MHz, CD3OD) δ 161.5, 159.5, 
153.7, 151.1, 149.1, 146.2, 143.0, 137.6, 137.48, 137.3, 135.4, 128.8, 125.7, 121.6, 120.7, 109.1, 47.1, 
46.7, 46.7, 44.8, 27.2, 16.2. LC-MS found [M+H]+ = 413.20 m/z; calculated [M+H] + = 413.21 m/z for 
C23H24N8. 
 
8-Methyl-7-[2-(4-methyl-1,4-diazepan-1yl)pyrimidin-5-yl]-N-(pyrazine-2-yl)quinoline-4-
amine (46b) 
 
 
 
 
 
Tail compound used: 1-(5-bromopyrimidin-2-yl)-4-methyl-1,4-diazepane (57) (0.070 g, 0.26 mmol, 
1.0 equivalent). Desired product was obtained as a pale yellow-brown powder in 25% yield (0.023 g, 
0.052 mmol).  
TLC (10% (MeOH + 5% NH4OH)/EtOAc): Rf = 0.34. 1H NMR (500 MHz, CD3OD) δ 8.72 (d, 
J = 5.4 Hz, 1H), 8.58 (s, 1H), 8.48 (s, 2H), 8.42 (d, J = 5.4 Hz, 1H), 8.32 (s, 1H), 8.29 (d, J = 8.8 Hz, 
1H), 8.12 (s, 1H), 7.48 (d, J = 8.8 Hz, 1H), 4.15 – 4.13 (m, 2H), 3.98 (t, J = 6.2 Hz, 2H), 2.81 (s, 3H), 
2.71 (s, 3H), 2.24 (br. s., 2H), 1.19 (s, 3H). 13C NMR (150 MHz, CD3OD) δ 161.7, 159.4, 153.8, 
151.2, 149.2, 146.2, 143.0, 137.63, 137.4, 137.3, 135.5, 128.8, 125.3, 121.6, 120.7, 109.2, 58.6, 57.8, 
46.6, 45.9, 44.71, 27.0, 16.2. LC-MS found [M+H]+ = 427.20 m/z; calculated [M+H]+ = 427.23 m/z 
for C24H26N8. 
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8-Methyl-7-[2-(4-propyl-1,4-diazepan-1yl)pyrimidin-5-yl]-N-(pyrazine-2-yl)quinoline-4-
amine (46d) 
 
Tail compound used: 1-(5-bromopyrimidin-2-yl)-4-propyl-1,4-diazepane (65) (0.090 g, 0.30 mmol, 
1.0 equivalent). Desired product was obtained as a pale yellow powder in 7% yield (0.008 g, 
0.002 mmol).  
TLC (20% (MeOH + 5% NH4OH)/EtOAc): Rf = 0.58. 1H NMR (500 MHz, CD3OD) δ 8.69 (d, 
J = 5.4 Hz, 1H), 8.56 (s, 1H), 8.44 (s, 2H), 8.39 (d, J = 4.9 Hz, 1H), 8.31 – 8.29 (m, 1H), 8.25 (d, J = 
8.8 Hz, 1H), 8.11 (d, J = 2.9 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 4.14 – 4.10 (m, 2H), 3.95 (t, J = 6.4 
Hz, 2H), 3.26 (d, J = 3.9 Hz, 2H), 3.20 – 3.15 (m, 2H), 2.93 – 2.88 (m, 2H), 2.68 (s, 3H), 2.66 (s, 5H), 
2.22 – 2.16 (m, 2H), 1.75 – 1.67 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). Insufficient material was obtained 
to carry out the 13C NMR analysis. LC-MS found [M+H]+ = 455.23 m/z; calculated 
[M+H]+ = 455.26 m/z for C26H30N8. 
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